[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CN1649855A - Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 - Google Patents

Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 Download PDF

Info

Publication number
CN1649855A
CN1649855A CNA028202805A CN02820280A CN1649855A CN 1649855 A CN1649855 A CN 1649855A CN A028202805 A CNA028202805 A CN A028202805A CN 02820280 A CN02820280 A CN 02820280A CN 1649855 A CN1649855 A CN 1649855A
Authority
CN
China
Prior art keywords
thiadiazoles
chloro
methyl
phenyl
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028202805A
Other languages
Chinese (zh)
Inventor
M·威廉斯
G·柯兹
M·尼尔森
J·瓦尔加达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AB
Original Assignee
Biovitrum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum AB filed Critical Biovitrum AB
Publication of CN1649855A publication Critical patent/CN1649855A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

The present invention relates to compounds with the formula (I) and also to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on the human 11-beta-hydroxysteroid dehydrogenase type 1 enzyme.

Description

11-beta-hydroxysteroid dehydrogenase 1 type inhibitor
Related application
The application requires the Sweden application 0103913-0 that submits to November 22 calendar year 2001, the Sweden application 0104051-8 that submit to November 30 calendar year 2001 and the U.S. Provisional Application of submitting on January 14th, 2,002 60/348,468 right of priority is incorporated herein by reference the content of these documents.
Technical field
The present invention relates to new compound, comprise the pharmaceutical composition of these compounds and relate to these compounds medicine and the preparation to people 11-beta-hydroxysteroid dehydrogenase 1 type enzyme (11 β HSD 1) application in the medicine that works.
Background technology
1. glucocorticosteroid (Glucorticoids), diabetes and glycogen produce
The known sugars cortin plays an important role in diabetes since over half a century, promptly extract in the diabetes type animal body most of serious symptoms that hypophysis or suprarenal gland can diabetes-alleviating and lowering blood glucose concentration (Long, C.D. and F.D.W.Leukins (1936) " experiment medicine magazine " be 63:465-490 (J.Exp.Med.); Houssay, B.A. (1942) " incretology " is 30:884-892 (Endocrinology)).Glucocorticosteroid makes hyperglycemic-glycogenolytic factor also obtain fully determining to liver generation effect.
The effect of the important conditioning agent that 11 β HSD1 produce as local glucocorticosteroid effect and glycogen has thus obtained abundant confirmation (for example, referring to (2000) such as Jamieson " incretology magazine " (J.Endocrinol.) 165:p.685-692).Liver insulin sensitivity in healthy people volunteer, improve (Walker, B.R. etc. (1995) " clinical internal secretion and metabolism magazine " are 80:3155-3159 (J.Clin.Endocrinol.Metab.)) with the treatment of non-specific 11 beta hsd 1 inhibitors carbenoxolone.In addition, established the mechanism of estimating by the different experiments of using mouse and rat to carry out.These studies show that mRNA level and active reduction the, that is: the rate-limiting enzyme phosphoenolpyruvate carboxykinase (PEPCK) in the gluconeogenesis of catalysis gluconeogenesis and the final common step of glycogenolysis and the glucose-6-phosphatase (G6Pase) of two kinds of key enzymes in the glycogen production process.Finally, glucose level and glycogen are created in the mouse body with 11 β HSD1 gene knockouts and are reduced.The data that obtain from this model also confirm to suppress 11 β HSD1 Can notCause hypoglycemia, as being regulated according to PEPCK and G6Pase basal level with irrelevant (Kotelevtsev, Y. etc. (1997) " NAS's journal " are 94:14924-14929 (Proc.Natl.Acad.Sci.USA)) that is estimated of glucocorticosteroid.
Arzneim.-Forsch./" drug research " (Drug Res); 44 (II), No.7,821-826 discloses hypoglycemic compound 4-(3-methyl-5-oxygen-2-pyrazoline-1-yl) phenylformic acid and 1-(2-alkylsulfonyl)-1H-1 in 1994, and 2, the 4-triazole.The remarkable difference of the structure of these compounds and the structure of The compounds of this invention is that the latter has the substituent thiadiazole of (mixing) aromatic yl sodium sulfonamido.
Merck ﹠amp; Co, Merck Index; In the number of the edition 4488 antidiabetic compound N-(the 5-tertiary butyl-1,3,4-thiadiazoles-2-yl) benzsulfamide is disclosed specially.The difference of the structure of this compound and the structure of The compounds of this invention is that the latter does not contain and the direct-connected tertiary butyl of thiadiazoles ring.
FR 2,384, disclose the compound with height hypoglycemic activity in 498.Therefore, use these compounds for treating hyperglycemias can cause hypoglycemia.
2. obesity may reduce with the cardiovascular hazard factor relevant with obesity
Obesity is that the important factor in the diabetes B of X syndrome and major part (＞80%) is just looked at nethike embrane fat and had crucial importance.The other factors of abdominal obesity and glucose intolerance, hyperinsulinemia, hypertriglyceridemia and so-called X syndrome (for example elevation of blood pressure, HDL level descend and the VLDL level raises) is closely related (Montague ﹠amp; O ' Rahilly, " diabetes " are 49:883-888 (Diabetes), and 2000).Confirmed that the enzyme that suppresses in the preceding adipocyte (stroma cell) can reduce the ratio that is divided into adipocyte.Estimate that this can cause the nethike embrane depot fat expand to descend (may reduce), promptly central obesity reduces (Buja1Ska, I.J., S.Kumar, and (Lancet) 349:1210-1213 of P.M.Stewart (1997) " lancet ").
Estimate that 11 β HSD1 in the inhibition mature fat cell can reduce the secretion (Halleux, C.M. etc. (1999) " clinical internal secretion and metabolism magazine " are 84:4097-4105 (J.Clin.Endocrinol.Metab.)) of Type 1 plasminogen activator inhibitor 1 (PAI-1)-a kind of independently cardiovascular harm factor.In addition, at glucocorticosteroid " activity " and have tangible dependency between the cardiovascular hazard factor, thereby prompting reduce the effect of glucocorticosteroid may be favourable (Walker, B.R. etc. (1998) " hypertension " are 31:891-895 (Hypertension); Fraser, R. etc. (1999) " hypertension " are 33:1364-1368 (Hypertension)).
Doing adrenalectomizes has weakened the fasting effect, thereby has not only increased ingestion of food, but also increased the expression of hypothalamic neuropeptide Y.This result has supported the effect of glucocorticosteroid in promoting ingestion of food, the 11 β HSD1 that prompting suppresses in the brain can increase satiety and reduce ingestion of food (Woods thus, S.C. etc. (1998) " science " (Science), 280:1378-1383).
3. the beneficial effect possible to pancreas
Suppressing 11 β HSD1 in the isolating mouse pancreas beta cell has improved the insulin secretion that glucose stimulates (Davani, B. etc. (2000) " journal of biological chemistry " be on November 10th, 2000 (J.Biol.Chem.); 275 (45): 34841-4).The known sugars cortin can reduce the Regular Insulin release (Billaudel, B. and B.C.J.Sutter (1979) " hormone metabolism research " be 11:555-560 (Horm.Metab.Res.)) of pancreas in the body in advance.Therefore, estimating to suppress 11 β HSD1 can produce other beneficial effect to treatment of diabetes, comprises the effect to liver and fat.
4. to cognitive and dull-witted possible beneficial effect
Stress influence cognitive function (de Quervain, D.J.-F., B.Roozendaal, and (Nature) 394:787-790 of J.L.McGaugh (1998) " nature ") with glucocorticosteroid.In the 11 β HSD1 enzymes control brain level of glucocorticosteroid and produce thus neurotoxicity (Rajan, V., C.R.W.Edwards, and J.R.Seckl, J. (1996) " neuroscience " is 16:65-70 (Neuroscience); Seckl, J.R., Front. (2000) " neuroendocrinology " is 18:49-99 (Neuroendocrinol.)).Undocumented result shows with the rat memory of non-specific 11 beta hsd 1 inhibitors treatment and significantly improves (J.Seckl, person-to-person communication).Based on The above results and glucocorticosteroid known action, can also point out the 11 β HSD1 that suppress in the brain can make anxiety alleviate (Tronche, F. etc. (1999) " natural genetics " (Nature Genetics) 23:99-103) at brain.Therefore, The above results is inferred the 11 β HSD1 that suppress in the human brain jointly and can be prevented that the cortisone reactivate from becoming hydrocortisone and preventing the deleterious effect of the glucocorticosteroid mediation of the others of neuronal survival and neuronal function is comprised that cognitive impairment, dysthymia disorders and appetite increase (above-mentioned part).
The 5HT6 receptor antagonist that is used for the treatment of the CNS disease is disclosed among WO 98/027081 and the WO 99/02502.There is not a kind of general formula of the present invention (I) that falls in these compounds.In addition, without any relevant they 11 β HSD1 are had active report.
5. use 11 beta hsd 1 inhibitors to carry out immunoregulatory may the application
General idea is that glucocorticosteroid suppresses immunity system.And in fact between immunity system and HPA (hypothalamic-pituitary-adrenal) axle, have dynamic interaction (Rook, G.A.W. (1999) " clinical internal secretion of BaillerShi and metabolism " (Bailler ' s Clin.Endocrinol.Metab.) 13:576-581).Balance between cell-mediated reaction and the body fluid reaction is regulated by glucocorticosteroid.Such as under the stress reaction state, high glucocorticoid activity is relevant with humoral response.Therefore, pointed out inhibition 11 β HSD1 enzymes can be used as and made the mode that is transformed into based on the reaction of cell of reacting.
Comprising that humoral response generally is partial in immune response under some morbid state of tuberculosis, leprosy and psoriasis, this moment in fact suitable reaction may be based on cell.The of short duration inhibition 11 β HSD1 of part or whole body can be used to promote immune response and change into suitable reaction (Mason, D. (1991) " immunology today " (Immunology Today) 12:57-60; Rook etc., document is the same).
In this of short duration situation, the similar application of 11 β HSD1 can be strengthened the immune response relevant with immunization to guarantee to obtain when needed the reaction based on cell.
6. the reduction of intraocular pressure
The level decision of recent Notes of Key Data glucocorticosteroid target acceptor and 11 β HSD enzymes is to glaucomatous susceptibility (Stokes, J. etc. (2000) " ophthalmology research " are 41:1629-1638 (Invest.Ophthalmol.)).In addition, will suppress the new tool (Walker E.A. etc., the propaganda material P3-698 in June, the 1999 12-15 day internal secretion society conference, San Diego) that 11 β HSD1 classify intraocular pressure lowering as recently.The non-specific 11 beta hsd 1 inhibitors carbenoxolone of verified picked-up have reduced by 20% with intraocular pressure in common experimenter.In eye, the expression of 11 β HSD1 be limited to corneal epithelium and conjunctiva nonpigmented epithelium basal cell (position of water generates), be limited to the sphincter muscle and the dilator muscles of ciliary muscle and iris.On the contrary, edge isoazyne 11 β HSD2 far away expresses at non-pigmented ciliary epithelium and corneal endothelium camber.On the trabecular network of drainage position, do not find a kind of enzyme.Therefore, point out 11 β HSD1 to have the water of generation but not the effect of drainage, whether do not take place by disturbing the activation of glucocorticosteroid or mineralcorticoid receptor or both to have both at the same time but still do not understand this process at present.
7. osteoporosis reduces
Glucocorticosteroid has requisite effect on skeleton development and function, excessive then harmful.The bone loss that glucocorticosteroid brings out to small part takes place by suppressing bone forming, comprise and suppress osteoblastic proliferation and collagen protein synthesis (Kim, C.H., (J.Endocrinol.) 162:371-379 of S.L.Cheng and G.S.Kim (1999) " incretology magazine ").The nonspecific inhibitor carbenoxolone can be blocked the negative effect that the bone knot is formed, this results suggest 11 β HSD1 at the active critical function of glucocorticosteroid (Bellows, C.G., A.Ciaccia, and J.N.M.Heersche, (1998) " bone " be 23:119-125 (Bone)).Other Notes of Key Data 11 β HSD1 enough high-caliber active glucocorticosteroid is provided in osteoclast and increases effect (Cooper, M.S. etc. (2000) " bone " are 27:375-381 (Bone)) in the bone resorption thus.These different data point out inhibition 11 β HSD1 to produce advantageous effect by more than one mechanism that work simultaneously antagonism osteoporosis jointly.
8. antihypertensive
Bile acide suppresses 11beta-Hydroxysteroid dehydrogenase 2 type enzymes.This result causes population equilibrium to move to helping the direction of hydrocortisone above cortisone, as (the Quattropani C that ratio confirmed by research urine metabolite, Vogt B, Odermatt A, Dick B, FreyBM, Frey FJ.2001. " Journal of Clinical Investigation " (J Clin Invest.) Nov; 108 (9): 1299-305." 11beta-Hydroxysteroid dehydrogenase is intravital active reduction of cholestasis patient " (" Reduced activity of 11beta-hydroxysteroid dehydrogenase inpatients with cholestasis ").Expectation reduces the activity of 11 β HSD1 in liver with selective depressant can make this unbalance reverse also acutely resist such as the such symptom of hypertension, waits for that simultaneously operative treatment is to remove biliary obstruction.
The aminothiazole inhibitors of the kinase whose carbon replacement of cyclin dependent is disclosed among the WO 99/65884.These compounds for example can be used for cancer, inflammation and sacroiliitis.US5 discloses antibiotic preparation or the sterilant that comprises thiazolamine derivative and/or its salt in 856,347.In addition, US 5,403, disclose in 857 to have the 5-lipoxidase and suppress active benzenesulfonamide derivatives.In addition, thiazolidine also [5,4-c] pyridines be disclosed in the following document: the anodyne thiazolidine is [5,4-c] pyridines also, Fr.Addn. (1969), 18 pp, Addn.-Fr.1498465.CODEN:FAXXA3; FR 94,123 19690704 CAN 72:100685 AN1970:100685 CAPLUS; With 4,5,6, the 7-thiazolidine is [5,4-c] pyridines also, Neth.Appl. (1967), 39 pp.CODEN:NAXXAN NL, 6,610,324 19670124 CAN68:49593, AN1968:49593 CAPLUS.Yet, do not have one piece to disclose compound of the present invention or its application in treatment diabetes, obesity, glaucoma, osteoporosis, cognitive disorder, immunological disease, dysthymia disorders and hypertension in the above-mentioned open source literature.
The compound of inhibition matrix metalloproteinase (MMPs) and TNF-α saccharase (TACE) is disclosed among the WO 98/16520.Disclose among EP 0 749 964 A1 and the US 5,962,490 and had the active compound of endothelin receptor antagonists.There is not a kind of general formula of the present invention (I) that falls in these compounds.In addition, without any relevant they 11 β HSD1 are had active report.
US 5,783, disclose as PGE in 597 2And LTB 4The thiophene derivant of inhibitor.In addition, without any relevant they to 11 β HSD 1Has active report.
Therefore, there is demand to being used for the treatment of diabetes, obesity, glaucoma, osteoporosis, cognitive disorder, immunological disease, dysthymia disorders and hypertensive new compound.
Summary of the invention
Compound of the present invention has solved the problems referred to above and has comprised that having researched and developed the described compound of a class new compound can suppress people 11-beta-hydroxysteroid dehydrogenase 1 type enzyme (11-β-HSD1) and thus can be used for the treatment of such as the such disease of diabetes, obesity, glaucoma, osteoporosis, cognitive disorder, immunological disease, dysthymia disorders and hypertension.
An object of the present invention is compound or its salt, hydrate or the solvate of general formula (I):
Wherein:
T is optional independently by [R] nThe aromatic ring or the hetero-aromatic ring that replace, wherein n is that integer and the R of 0-5 are hydrogen, aryl, heteroaryl, heterocycle, optional halogenated C 1-6-alkyl, optional halogenated C 1-6-alkoxyl group, C 1-6-alkyl sulphonyl, carboxyl, cyano group, nitro, halogen, single replacement or dibasic amine, optional single replacement or disubstituded amide, aryloxy, aryl sulfonyl, virtue amino, wherein aryl, heteroaryl and aryloxy residue and heterocycle are further optional independently of one another by C on one or more positions 1-6-acyl group, C 1-6-alkylthio, cyano group, nitro, hydrogen, halogen, optional halogenated C 1-6-alkyl, optional halogenated C 1-6-alkoxyl group, optional single replacement or disubstituded amide, (benzamido) methyl, carboxyl, 2-thienyl methylamino-or ({ [4-(2-oxyethyl group-2-oxoethyl)-1,3-thiazoles-2-yl] amino } carbonyl) replacement;
R 1Be hydrogen or C 1-6-alkyl;
A 1And A 2Be nitrogen-atoms or C-Z, condition is A 1And A 2Have different implications, wherein:
Z is selected from can be further optional independently of one another by hydrogen, C on one or more positions 1-6-alkyl, halo C 1-6-alkyl, halogen, C 1-6-alkoxyl group, nitro, C 1-6-alkoxy carbonyl, C 1-6Aromatic ring or hetero-aromatic ring that-alkyl sulphonyl, kharophen or aryloxy replace, wherein aryloxy is further optional on one or more positions is replaced by hydrogen and halogen independently of one another; Or Z is X-Y-R 2, wherein:
X is CH 2Or CO;
Y is CH 2, CO or singly-bound;
R 2Be selected from:
C 1-6-alkyl, azido-, arylthio, heteroarylthio, halogen, methylol, 2-hydroxyethylamino methyl, mesyloxy methyl, 3-oxo-4-morpholinyl methylene radical (morpholinolinylmethylene), C 1-6-alkoxy carbonyl, 5-methyl isophthalic acid, 3,4-oxadiazole-2-base;
NR 3R 4, R wherein 3And R 4Be selected from hydrogen, C independently of one another 1-6-alkyl, optional halo C 1-6-alkyl sulphonyl, C 1-6-alkoxyl group, 2-methoxy ethyl, 2-hydroxyethyl, 1-methylimidazolyl alkylsulfonyl, C 1-6-acyl group, cyclohexyl methyl, cyclopropane carbonyl, aryl, optional halogenated aryl alkylsulfonyl, furyl carbonyl, tetrahydrochysene-2-furyl methyl, N-ethoxycarbonyl piperidyl or the C that is replaced by one or more aryl, heterocycle or heteroaryl 1-6-alkyl; Or
NR 3R 4Common expression heterocycle is, they can be imidazoles, piperidines, tetramethyleneimine, piperazine, morpholine, oxygen azatropylidene (oxazepine), oxazole, thiomorpholine, 1,1-dioxy thiomorpholine, 2-(3,4-dihydro-2 (1H) isoquinolyl) or (1S, 4S)-and 2-oxa--5-azabicyclo [2.2-1] heptan-5-base, these heterocycles systems can choose wantonly by C 1-6-alkyl, C 1-6-acyl group, hydroxyl, oxygen, tert-butoxycarbonyl replace;
OCONR 3R 4, R wherein 3And R 4Be selected from hydrogen, C independently of one another 1-6-alkyl or form morpholinyl with the N-atom that they connected;
R 5O, wherein R 5Be hydrogen, optional halogenated C 1-6-alkyl, aryl, heteroaryl, C 1-6-acyl group, C 1-6-alkyl sulphonyl, aryl carbonyl, heteroaryl carbonyl, 2-methoxycarbonyl phenyl;
Condition is to work as:
A 1Be C-Z and A 2When being nitrogen-atoms, then T be not the phenyl that only on 4, replaced near the nitrogenous substituting group of phenyl ring by nitrogen-atoms, not be only on 2 by methyl substituted phenyl, not be only on 4 by methyl substituted phenyl and be not the phenyl that only on 4, is replaced by ethyl;
A 1Be nitrogen-atoms and A 2When being C-Z, then Z is not 2-furyl, 5-nitro-2-furyl, 2-thienyl, the optional phenyl that replaces, the benzyl of para-orientation;
A 1Be nitrogen-atoms and A 2Be that C-Z, X are CH 2, when Y is singly-bound, R then 2Not C 1-6-alkyl, methoxyl group, oxyethyl group, benzothiazole-2-base sulfenyl and NR 3R 4, R wherein 3And R 4Be selected from methyl, ethyl, n-propyl, normal-butyl;
A 1Be nitrogen-atoms and A 2Be that C-Z, X are CH 2, Y is CH 2The time, R then 2Not C 1-6-alkyl and NR 3R 4, R wherein 3And R 4Be selected from methyl, ethyl, n-propyl, normal-butyl.
Preferably:
T is selected from:
5-chloro-1,3-dimethyl-1H-pyrazoles-4-base; 4-chloro-2,3,1-Ben Bing oxadiazole base; 5-(dimethylamino)-1-naphthyl; 1-Methylimidazole-4-base; The 1-naphthyl; The 2-naphthyl; The 8-quinolyl;
By the thienyl of the one or more replacements in the following groups: (benzamido) methyl, bromine, chlorine, 3-isoxazolyl, 2-(methyl sulfane base)-4-pyrimidyl, 1-methyl-5-(trifluoromethyl) pyrazole-3-yl, phenyl sulfonyl, pyridyl;
By the phenyl of the one or more replacements in the following groups: kharophen, the 3-acetylamino phenyl, the 3-acetylphenyl, phenylamino, 1,3-benzo dioxole-5-base, the 2-benzofuryl, benzyl amino, 3, two (trifluoromethyl) phenyl of 5-, bromine, butoxy, carboxyl, chlorine, the 4-carboxyl phenyl, 3-chloro-2-cyano-benzene oxygen, the 4-chloro-phenyl-, 5-chloro-2-thienyl, cyano group, 3, the 4-dichlorophenyl, ({ [4-(2-oxyethyl group-2-oxoethyl)-1,3-thiazoles-2-yl] amino } carbonyl), fluorine, 5-fluoro-2-p-methoxy-phenyl, the 2-furyl, hydrogen, iodine, sec.-propyl, methylsulfonyl, methoxyl group, methyl, 4-methyl isophthalic acid-piperazinyl, 4-methyl isophthalic acid-piperidyl, 4-methyl sulfane base phenyl, 5-methyl-2-thienyl, the 4-morpholinyl, nitro, the 3-nitrophenyl, phenoxy group, phenyl, n-propyl, the 4-pyridyl, 3-pyridyl methylamino-, the 1-pyrrolidyl, the 2-thienyl, the 3-thienyl, 2-thienyl methylamino-, trifluoromethoxy, the 4-Trifluoromethoxyphen-l, trifluoromethyl; Or
R 1Be hydrogen or methyl;
A 1And A 2Be nitrogen-atoms or C-Z, condition is A 1And A 2Have different implications, wherein:
Z is selected from:
1-thionaphthene-3-base, 3-(2,5-dimethyl furan base), pyridyl;
The optional thienyl that is replaced by one or more chlorine, methyl sulphonyl;
Optional by the phenyl of the one or more replacements in ethoxy carbonyl, nitro, fluorine, methyl, methoxyl group, kharophen, chlorine, 4-chlorophenoxy, the trifluoromethyl;
Or Z is X-Y-R 2, wherein
X is CH 2Or CO;
Y is CH 2, CO or singly-bound;
R 2Be selected from:
N-propyl, azido-, bromine, chlorine, 2-pyridyl sulfane base, 3-oxo-4-morpholinyl methylene radical (morpholinolinylmethylene), ethoxy carbonyl, 5-methyl isophthalic acid, 3,4-oxadiazole-2-base, methylol, 2-hydroxyethylamino methyl, mesyloxy methyl;
NR 3R 4, R wherein 3And R 4Be selected from ethanoyl, diphenyl-methyl, 1 independently of one another, 3-benzo dioxole-5-ylmethyl, benzyl, 3-chloro-2-aminomethyl phenyl alkylsulfonyl, cyclohexyl, cyclohexyl methyl, cyclopropane carbonyl, ethyl, 2-furyl carbonyl, 2-furyl methyl, hydrogen, 2-hydroxyethyl, 2-(1H-indol-3-yl) ethyl, sec.-propyl, methoxyl group, 2-methoxy ethyl, methyl, 4-(1-methylimidazolyl) alkylsulfonyl, methyl sulphonyl, phenyl, (1S)-styroyl, n-propyl, tetrahydrochysene-2-furyl methyl, trifluoromethyl sulfonyl, N-ethoxycarbonyl piperidyl; Or
NR 3R 4Common expression 4-ethanoyl piperazinyl, 4-tert-butoxycarbonyl piperazinyl, 2-(3,4-dihydro-2 (1H) isoquinolyl), (2R, 6S)-2, the 6-dimethylated morpholinyl, (2R)-2,4-dimethyl-1-piperazinyl, 2-hydroxyl-3-oxo morpholinyl, imidazolyl, 2-methyl-3-oxo morpholinyl, 4-methyl-2-oxo piperazinyl, 4-methylpiperazine base, morpholinyl, (1S, 4S)-2-oxa--5-aza-bicyclo [2.2.1] heptan-5-base, 2-oxoimidazolinium base, 3-oxo morpholinyl, 3-oxo-1,4-oxygen azatropylidene base (oxazepinyl), 2-Yang oxazolines base, piperazinyl, piperidyl, pyrrolidyl, pyrrolidone-base, thio-morpholinyl, 1,1-dioxy-thio-morpholinyl;
OCONR 3R 4, R wherein 3And R 4Be selected from ethyl, hydrogen independently of one another or form morpholinyl with the N-atom that they connected;
R 5O, wherein R 5Be ethanoyl, benzoyl, benzyl, ethyl, 2-fluoro ethyl, 2-furyl carbonyl, hydrogen, isobutyryl, sec.-propyl, methyl, 2-methoxycarbonyl benzyl, methyl sulphonyl, phenyl, positive propionyl, 3-pyridyl, 2,2, the 2-trifluoroethyl;
Condition is to work as;
A 1Be C-Z and A 2When being nitrogen-atoms, then T be not only at the phenyl that is replaced by nitro, 4-morpholinyl, 1-pyrrolidyl, kharophen, phenylamino, benzyl amino, 3-pyridyl methylamino-, 4-methyl isophthalic acid-piperazinyl, 4-methyl isophthalic acid-piperidyl or 2-thienyl methylamino-on 4, not be only on 2 by methyl substituted phenyl and be not only on 4 by methyl substituted phenyl;
A 1Be nitrogen-atoms and A 2When being C-Z, then Z is not a 2-thienyl and optional by the phenyl of the one or more replacements in ethoxy carbonyl, nitro, fluorine, methyl, methoxyl group, kharophen, chlorine, 4-chlorophenoxy, the trifluoromethyl;
A 1Be nitrogen-atoms and A 2Be that C-Z, X are CH 2, when Y is singly-bound, R then 2Not n-propyl, methoxyl group, oxyethyl group and NR 3R 4, R wherein 3And R 4Be selected from methyl, ethyl, n-propyl;
A 1Be nitrogen-atoms and A 2Be that C-Z, X are CH 2, Y is CH 2The time, R then 2Not n-propyl and NR 3R 4, R wherein 3And R 4Be selected from methyl, ethyl, n-propyl.
Work as A 1Be C-Z and A 2When being nitrogen-atoms, then preferred:
Z is selected from: 1-thionaphthene-3-base, 3-(2,5-dimethyl furan base), pyridyl;
The optional thienyl that is replaced by one or more chlorine, methyl sulphonyl;
Optional by the phenyl of the one or more replacements in ethoxy carbonyl, nitro, fluorine, methyl, methoxyl group, kharophen, chlorine, 4-chlorophenoxy, the trifluoromethyl;
Or Z is X-Y-R 2, wherein
X is CH 2Or CO;
Y is CH 2, CO or singly-bound;
R 2Be selected from:
N-propyl, azido-, bromine, chlorine, 2-pyridyl sulfane base, 3-oxo-4-morpholinyl methylene radical (morpholinolinylmethylene), ethoxy carbonyl, 5-methyl isophthalic acid, 3,4-oxadiazole-2-base, methylol, 2-hydroxyethylamino methyl, mesyloxy methyl;
NR 3R 4, R wherein 3And R 4Be selected from ethanoyl, diphenyl-methyl, 1 independently of one another, 3-benzo dioxole-5-ylmethyl, benzyl, 3-chloro-2-aminomethyl phenyl alkylsulfonyl, cyclohexyl, cyclohexyl methyl, cyclopropane carbonyl, ethyl, 2-furyl carbonyl, 2-furyl methyl, hydrogen, 2-hydroxyethyl, 2-(1H-indol-3-yl) ethyl, sec.-propyl, methoxyl group, 2-methoxy ethyl, methyl, 4-(1-methylimidazolyl) alkylsulfonyl, methyl sulphonyl, phenyl, (1S)-styroyl, n-propyl, tetrahydrochysene-2-furyl methyl, trifluoromethyl sulfonyl, N-ethoxycarbonyl piperidyl; Or
NR 3R 4Common expression 4-ethanoyl piperazinyl, 4-tert-butoxycarbonyl piperazinyl, 2-(3,4-dihydro-2 (1H) isoquinolyl), (2R, 6S)-2, the 6-dimethylated morpholinyl, (2R)-2,4-dimethyl-1-piperazinyl, 2-hydroxyl-3-oxo morpholinyl, imidazolyl, 2-methyl-3-oxo morpholinyl, 4-methyl-2-oxo piperazinyl, 4-methylpiperazine base, morpholinyl, (1S, 4S)-2-oxa--5-aza-bicyclo [2.2.1] heptan-5-base, 2-oxoimidazolinium base, 3-oxo morpholinyl, 3-oxo-1,4-oxygen azatropylidene base (oxazepinyl), 2-Yang oxazolines base, piperazinyl, piperidyl, pyrrolidyl, pyrrolidone-base, thio-morpholinyl, 1,1-dioxy-thio-morpholinyl;
OCONR 3R 4, R wherein 3And R 4Be selected from ethyl, hydrogen independently of one another or form morpholinyl with the N-atom that they connected;
R 5O, wherein R 5Be ethanoyl, benzoyl, benzyl, ethyl, 2-fluoro ethyl, 2-furyl carbonyl, hydrogen, isobutyryl, sec.-propyl, methyl, 2-methoxycarbonyl benzyl, methyl sulphonyl, phenyl, positive propionyl, 3-pyridyl, 2,2, the 2-trifluoroethyl;
Preferably:
T is selected from 5-chloro-1,3-dimethyl-1H-pyrazoles-4-base; 4-chloro-2,3,1-Ben Bing oxadiazole base; 5-(dimethylamino)-l-naphthyl; 1-Methylimidazole-4-base; The 1-naphthyl; The 2-naphthyl; The 8-quinolyl;
By the thienyl of the one or more replacements in the following groups: (benzamido) methyl, bromine, chlorine, 3-isoxazolyl, 2-(methyl sulfane base)-4-pyrimidyl, 1-methyl-5-(trifluoromethyl) pyrazole-3-yl, phenyl sulfonyl, pyridyl;
The phenyl that one or more groups in the quilt (i)-(iii) replace:
(i) 3-acetylamino phenyl, the 3-acetylphenyl, 1,3-benzo dioxole-5-base, the 2-benzofuryl, 3, two (trifluoromethyl) phenyl of 5-, bromine, butoxy, carboxyl, chlorine, the 4-carboxyl phenyl, 3-chloro-2-cyano-benzene oxygen, the 4-chloro-phenyl-, 5-chloro-2-thienyl, cyano group, 3, the 4-dichlorophenyl, ({ [4-(2-oxyethyl group-2-oxoethyl)-1,3-thiazoles-2-yl] amino } carbonyl), fluorine, 5-fluoro-2-p-methoxy-phenyl, the 2-furyl, hydrogen, iodine, sec.-propyl, methylsulfonyl, methoxyl group, 4-methyl sulfane base phenyl, 5-methyl-2-thienyl, the 3-nitrophenyl, phenoxy group, phenyl, n-propyl, the 4-pyridyl, the 2-thienyl, the 3-thienyl, trifluoromethoxy, the 4-Trifluoromethoxyphen-l, trifluoromethyl; And can further choose wantonly by at least one substituting group that is selected from following groups and replace: kharophen, the 3-acetylamino phenyl, the 3-acetylphenyl, phenylamino, 1,3-benzo dioxole-5-base, the 2-benzofuryl, benzyl amino, 3, two (trifluoromethyl) phenyl of 5-, bromine, butoxy, carboxyl, chlorine, the 4-carboxyl phenyl, 3-chloro-2-cyano-benzene oxygen, the 4-chloro-phenyl-, 5-chloro-2-thienyl, cyano group, 3, the 4-dichlorophenyl, ({ [4-(2-oxyethyl group-2-oxoethyl)-1,3-thiazoles-2-yl] amino } carbonyl), fluorine, 5-fluoro-2-p-methoxy-phenyl, the 2-furyl, hydrogen, iodine, sec.-propyl, methylsulfonyl, methoxyl group, methyl, 4-methyl isophthalic acid-piperazinyl, 4-methyl isophthalic acid-piperidyl, 4-methyl sulfane base phenyl, 5-methyl-2-thienyl, the 4-morpholinyl, nitro, the 3-nitrophenyl, phenoxy group, phenyl, n-propyl, the 4-pyridyl, 3-pyridyl methylamino-, the 1-pyrrolidyl, the 2-thienyl, the 3-thienyl, 2-thienyl methylamino-, trifluoromethoxy, the 4-Trifluoromethoxyphen-l, trifluoromethyl;
(ii) one or more nitros, 4-morpholinyl, 1-pyrrolidyl, kharophen, phenylamino, benzyl amino, 3-pyridyl methylamino-, 4-methyl isophthalic acid-piperazinyl, 4-methyl isophthalic acid-piperidyl or the 2-thienyl methylamino-on 2 and 3; And can further choose wantonly by at least one substituting group that is selected from following groups and replace: kharophen, the 3-acetylamino phenyl, the 3-acetylphenyl, phenylamino, 1,3-benzo dioxole-5-base, the 2-benzofuryl, benzyl amino, 3, two (trifluoromethyl) phenyl of 5-, bromine, butoxy, carboxyl, chlorine, the 4-carboxyl phenyl, 3-chloro-2-cyano-benzene oxygen, the 4-chloro-phenyl-, 5-chloro-2-thienyl, cyano group, 3, the 4-dichlorophenyl, ({ [4-(2-oxyethyl group-2-oxoethyl)-1, the 3-thiazol-2-yl] amino } carbonyl), fluorine, 5-fluoro-2-p-methoxy-phenyl, the 2-furyl, hydrogen, iodine, sec.-propyl, methylsulfonyl, methoxyl group, methyl, 4-methyl isophthalic acid-piperazinyl, 4-methyl isophthalic acid-piperidyl, 4-methyl sulfane base phenyl, 5-methyl-2-thienyl, the 4-morpholinyl, nitro, the 3-nitrophenyl, phenoxy group, phenyl, n-propyl, the 4-pyridyl, 3-pyridyl methylamino-, the 1-pyrrolidyl, the 2-thienyl, the 3-thienyl, 2-thienyl methylamino-, trifluoromethoxy, the 4-Trifluoromethoxyphen-l, trifluoromethyl;
The (iii) methyl on 3; And can further choose wantonly by at least one substituting group that is selected from following groups and replace: kharophen, the 3-acetylamino phenyl, the 3-acetylphenyl, phenylamino, 1,3-benzo dioxole-5-base, the 2-benzofuryl, benzyl amino, 3, two (trifluoromethyl) phenyl of 5-, bromine, butoxy, carboxyl, chlorine, the 4-carboxyl phenyl, 3-chloro-2-cyano-benzene oxygen, the 4-chloro-phenyl-, 5-chloro-2-thienyl, cyano group, 3, the 4-dichlorophenyl, ({ [4-(2-oxyethyl group-2-oxoethyl)-1,3-thiazoles-2-yl] amino } carbonyl), fluorine, 5-fluoro-2-p-methoxy-phenyl, the 2-furyl, hydrogen, iodine, sec.-propyl, methylsulfonyl, methoxyl group, methyl, 4-methyl isophthalic acid-piperazinyl, 4-methyl isophthalic acid-piperidyl, 4-methyl sulfane base phenyl, 5-methyl-2-thienyl, the 4-morpholinyl, nitro, the 3-nitrophenyl, phenoxy group, phenyl, n-propyl, the 4-pyridyl, 3-pyridyl methylamino-, the 1-pyrrolidyl, the 2-thienyl, the 3-thienyl, 2-thienyl methylamino-, trifluoromethoxy, the 4-Trifluoromethoxyphen-l, trifluoromethyl;
Work as A 1Be nitrogen-atoms and A 2When being C-Z, then preferred:
Z is selected from: 1-thionaphthene-3-base, 3-(2,5-dimethyl furan base), pyridyl; The optional thienyl that is replaced by one or more chlorine, methyl sulphonyl; Or Z is X-Y-R 2,
Wherein
X is CH 2Or CO;
Y is CH 2, CO or singly-bound;
R 2Be selected from:
N-propyl, azido-, bromine, chlorine, 2-pyridyl sulfane base, 3-oxo-4-morpholinyl methylene radical (morpholinolinylmethylene), ethoxy carbonyl, 5-methyl isophthalic acid, 3,4-oxadiazole-2-base, methylol, 2-hydroxyethylamino methyl, mesyloxy methyl;
NR 3R 4, R wherein 3And R 4Be selected from ethanoyl, diphenyl-methyl, 1 independently of one another, 3-benzo dioxole-5-ylmethyl, benzyl, 3-chloro-2-aminomethyl phenyl alkylsulfonyl, cyclohexyl, cyclohexyl methyl, cyclopropane carbonyl, ethyl, 2-furyl carbonyl, 2-furyl methyl, hydrogen, 2-hydroxyethyl, 2-(1H-indol-3-yl) ethyl, sec.-propyl, methoxyl group, 2-methoxy ethyl, methyl, 4-(1-methylimidazolyl) alkylsulfonyl, methyl sulphonyl, phenyl, (1S)-styroyl, n-propyl, tetrahydrochysene-2-furyl methyl, trifluoromethyl sulfonyl, N-ethoxycarbonyl piperidyl; Or
NR 3R 4Common expression 4-ethanoyl piperazinyl, 4-tert-butoxycarbonyl piperazinyl, 2-(3,4-dihydro-2 (1H) isoquinolyl), (2R, 6S)-2, the 6-dimethylated morpholinyl, (2R)-2,4-dimethyl-1-piperazinyl, 2-hydroxyl-3-oxo morpholinyl, imidazolyl, 2-methyl-3-oxo morpholinyl, 4-methyl-2-oxo piperazinyl, 4-methylpiperazine base, morpholinyl, (1S, 4S)-2-oxa--5-aza-bicyclo [2.2.1] heptan-5-base, 2-oxoimidazolinium base, 3-oxo morpholinyl, 3-oxo-1,4-oxygen azatropylidene base (oxazepinyl), 2-Yang oxazolines base, piperazinyl, piperidyl, pyrrolidyl, pyrrolidone-base, thio-morpholinyl, 1,1-dioxy-thio-morpholinyl;
OCONR 3R 4, R wherein 3And R 4Be selected from ethyl, hydrogen independently of one another or form morpholinyl with the N-atom that they connected;
R 5O, wherein R 5Be ethanoyl, benzoyl, benzyl, ethyl, 2-fluoro ethyl, 2-furyl carbonyl, hydrogen, isobutyryl, sec.-propyl, methyl, 2-methoxycarbonyl benzyl, methyl sulphonyl, phenyl, positive propionyl, 3-pyridyl, 2,2, the 2-trifluoroethyl;
Work as A 1Be nitrogen-atoms and A 2Be C-Z, be C-X-Y-R 2, wherein X is CH 2And when Y is singly-bound, then preferred:
R 2Be selected from:
Azido-, bromine, chlorine, 2-pyridyl sulfane base, 3-oxo-4-morpholinyl methylene radical (morpholinolinylmethylene), ethoxy carbonyl, 5-methyl isophthalic acid, 3,4-oxadiazole-2-base, methylol, 2-hydroxyethylamino methyl, mesyloxy methyl;
NR 3R 4, R wherein 3And R 4Be selected from ethanoyl, xylyl, 1 independently of one another, 3-benzo dioxole-5-ylmethyl, benzyl, 3-chloro-2-aminomethyl phenyl alkylsulfonyl, cyclohexyl, cyclohexyl methyl, cyclopropane carbonyl, 2-furyl carbonyl, 2-furyl methyl, hydrogen, 2-hydroxyethyl, 2-(1H-indol-3-yl) ethyl, sec.-propyl, methoxyl group, 2-methoxy ethyl, 4-(1-methylimidazolyl) alkylsulfonyl, methyl sulphonyl, phenyl, (1S)-styroyl, tetrahydrochysene-2-furyl methyl, trifluoromethyl sulfonyl, N-ethoxycarbonyl piperidyl; Or
NR 3R 4The common 4-ethanoyl piperazinyl of representing, 4-tert-butoxycarbonyl piperazinyl, 2-(3,4-dihydro-2 (1H) isoquinolyl, (2R, 6S)-2, the 6-dimethylated morpholinyl, (2R)-2,4-dimethyl-1-piperazinyl, 2-hydroxyl-3-oxo morpholinyl, imidazolyl, 2-methyl-3-oxo morpholinyl, 4-methyl-2-oxo piperazinyl, 4-methylpiperazine base, morpholinyl, (1S, 4S)-2-oxa--5-aza-bicyclo [2.2.1] heptan-5-base, 2-oxoimidazolinium base, 3-oxo morpholinyl, 3-oxo-1,4-oxygen azatropylidene base (oxazepinyl), 2-Yang oxazolines base, piperazinyl, piperidyl, pyrrolidyl, pyrrolidone-base, thio-morpholinyl, 1,1-dioxy-thio-morpholinyl;
OCONR 3R 4, R wherein 3And R 4Be selected from ethyl, hydrogen independently of one another or form morpholinyl with the N-atom that they connected;
R 5O, wherein R 5Be ethanoyl, benzoyl, benzyl, 2-fluoro ethyl, 2-furyl carbonyl, hydrogen, isobutyryl, sec.-propyl, 2-methoxycarbonyl benzyl, methyl sulphonyl, phenyl, positive propionyl, 3-pyridyl, 2,2, the 2-trifluoroethyl.
Work as A 1Be nitrogen-atoms and A 2Be C-Z, be C-X-Y-R 2, wherein X is CH 2And Y is CH 2The time, then preferred:
R 2Be selected from:
Azido-, bromine, chlorine, 2-pyridyl sulfane base, 3-oxo-4-morpholinyl methylene radical (morpholinolinylmethylene), ethoxy carbonyl, 5-methyl isophthalic acid, 3,4-oxadiazole-2-base, methylol, 2-hydroxyethylamino methyl, mesyloxy methyl;
NR 3R 4, R wherein 3And R 4Be selected from ethanoyl, xylyl, 1 independently of one another, 3-benzo dioxole-5-ylmethyl, benzyl, 3-chloro-2-aminomethyl phenyl alkylsulfonyl, cyclohexyl, cyclohexyl methyl, cyclopropane carbonyl, 2-furyl carbonyl, 2-furyl methyl, hydrogen, 2-hydroxyethyl, 2-(1H-indol-3-yl) ethyl, sec.-propyl, methoxyl group, 2-methoxy ethyl, 4-(1-methylimidazolyl) alkylsulfonyl, methyl sulphonyl, phenyl, (1S)-styroyl, tetrahydrochysene-2-furyl methyl, trifluoromethyl sulfonyl, N-ethoxycarbonyl piperidyl; Or
NR 3R 4The common 4-ethanoyl piperazinyl of representing, 4-tert-butoxycarbonyl piperazinyl, 2-(3,4-dihydro-2 (1H) isoquinolyl, (2R, 6S)-2, the 6-dimethylated morpholinyl, (2R)-2,4-dimethyl-1-piperazinyl, 2-hydroxyl-3-oxo morpholinyl, imidazolyl, 2-methyl-3-oxo morpholinyl, 4-methyl-2-oxo piperazinyl, 4-methylpiperazine base, morpholinyl, (1S, 4S)-2-oxa--5-aza-bicyclo [2.2.1] heptan-5-base, 2-oxoimidazolinium base, 3-oxo morpholinyl, 3-oxo-1,4-oxygen azatropylidene base (oxazepinyl), 2-Yang oxazolines base, piperazinyl, piperidyl, pyrrolidyl, pyrrolidone-base, thio-morpholinyl, 1,1-dioxy-thio-morpholinyl;
OCONR 3R 4, R wherein 3And R 4Be selected from ethyl, hydrogen independently of one another or form morpholinyl with the N-atom that they connected;
R 5O, wherein R 5Be ethanoyl, benzoyl, benzyl, ethyl, 2-fluoro ethyl, 2-furyl carbonyl, hydrogen, isobutyryl, sec.-propyl, methyl, 2-methoxycarbonyl benzyl, methyl sulphonyl, phenyl, positive propionyl, 3-pyridyl, 2,2, the 2-trifluoroethyl.
Following table is represented particularly preferred compound.They are divided into lower class:
1) 1,3 of general formula (II), the 4-thiadiazoles derivative:
Figure A0282028000621
(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethyl acetate
(5-[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) acetate
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl)-the N-methylacetamide
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl)-the N-ethyl acetamide
2,5-two chloro-N-[5-(3-chlorothiophene-2-yl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) isopropyl acetate
3-chloro-N-[5-(2-hydroxyethyl)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
3-chloro-N-[5-(2-ethoxyethyl group)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
2-(5-{[3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl)-N, the N-diethyl acetamide
(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) methyl acetate
3-chloro-N-[5-(2-isopropoxy ethyl)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
3-chloro-N-[5-(2-methoxy ethyl)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
Methylsulfonic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethyl ester
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethanamide
3-chloro-N-{5-[2-(2-fluorine oxyethyl group) ethyl]-1,3,4-thiadiazoles-2-yl }-the 2-methyl benzenesulfonamide
3-chloro-2-methyl-N-{5-[2-(2,2, the 2-trifluoro ethoxy) ethyl]-1,3,4-thiadiazoles-2-yl } benzsulfamide
Acetate 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethyl ester
3-chloro-2-methyl-N-[5-(2-morpholine-4-base ethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-[5-(2-bromotrifluoromethane)-1,3,4-thiadiazoles-2-yl]-3-chloro-2-methyl benzenesulfonamide
Morpholine-4-formic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethyl ester
Diethylamino formic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethyl ester
Propionic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethyl ester
2 Methylpropionic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethyl ester
2-furancarboxylic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethyl ester
Phenylformic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethyl ester
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl)-N-methoxyl group-N-methylacetamide
Ethyl carbamic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethyl ester
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl)-the N-ethyl acetamide
3-chloro-2-methyl-N-[5-(2-oxo amyl group)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-{5-[2-(1,1-dioxy thiomorpholine-4-yl)-2-oxoethyl]-1,3,4-thiadiazoles-2-yl }-4-propylbenzene sulphonamide
2,4,6-three chloro-N-[5-(2-morpholine-4-base ethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
2,4-two chloro-N-[5-(2-morpholine-4-base ethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
3-chloro-2-methyl-N-{5-[2-(3-oxo morpholine-4-yl) ethyl]-1,3,4-thiadiazoles-2-yl } benzsulfamide
2,4-two chloro-6-methyl-N-[5-(2-morpholine-4-base ethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-[5-(2-morpholine-4-base ethyl)-1,3,4-thiadiazoles-2-yl]-4-propylbenzene sulphonamide
2,4-two chloro-6-methyl-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
2,4,6-three chloro-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-1,1 '-xenyl-4-sulphonamide
N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-4-propylbenzene sulphonamide N-[5-(2-oxo-2-thiomorpholine-4-base ethyl)-1,3,4-thiadiazoles-2-yl]-1,1 '-xenyl-4-sulphonamide
N-[5-(2-oxo-2-thiomorpholine-4-base ethyl)-1,3,4-thiadiazoles-2-yl]-4-propylbenzene sulphonamide
2,4-two chloro-6-methyl-N-[5-(2-oxo-2-thiomorpholine-4-base ethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-[5-(2-oxo-2-piperidines-1-base ethyl)-1,3,4-thiadiazoles-2-yl]-1,1 '-xenyl-4-sulphonamide
N-[5-(2-oxo-2-piperidines-1-base ethyl)-1,3,4-thiadiazoles-2-yl]-4-propylbenzene sulphonamide
2,4-two chloro-6-methyl-N-[5-(2-oxo-2-piperidines-1-base ethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
2,4,6-three chloro-N-[5-(2-oxo-2-piperidines-1-base ethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) (oxygen) ethyl acetate
2-{5-[(1,1 '-xenyl-4-base alkylsulfonyl) amino]-1,3,4-thiadiazoles-2-yl }-N-ethyl-N-methylacetamide
N-ethyl-N-methyl-2-(5-{[(4-propyl group phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethanamide
2-(5-{[(2,4-two chloro-6-aminomethyl phenyls) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl)-N-ethyl-N-methylacetamide
N-ethyl-N-methyl-2-(5-{[(2,4,6-trichlorophenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethanamide
2,4,6-three chloro-N-[5-(2-oxo-2-thiomorpholine-4-base ethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
2-{5-[(1,1 '-xenyl-4-base alkylsulfonyl) amino]-1,3,4-thiadiazoles-2-yl }-N-sec.-propyl-N-methylacetamide
2-{5-[(1,1 '-xenyl-4-base alkylsulfonyl) amino]-1,3,4-thiadiazoles-2-yl }-N, the N-diethyl acetamide
N, N-diethyl-2-(5-{[(4-propyl group phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethanamide
2-(5-{[(2,4-two chloro-6-aminomethyl phenyls) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl)-N, the N-diethyl acetamide
N, N-diethyl-2-(5-{[(2,4,6-trichlorophenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethanamide
2-{5-[(1,1 '-xenyl-4-base alkylsulfonyl) amino]-1,3,4-thiadiazoles-2-yl }-N, N-di-isopropyl ethanamide
N, N-di-isopropyl 2-(5-{[(4-propyl group phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethanamide
2-(5-{[(2,4-two chloro-6-aminomethyl phenyls) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl)-N, N-di-isopropyl ethanamide
N, N-di-isopropyl-2-(5-{[(2,4,6-trichlorophenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethanamide
4-propyl group-N-(5-pyridin-3-yl-1,3,4-thiadiazoles-2-yl) benzsulfamide
3-chloro-N-[5-(5-chlorothiophene-2-yl)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
2,4,6-three chloro-N-(5-pyridin-3-yl-1,3,4-thiadiazoles-2-yl) benzsulfamide
2,4,6-three chloro-N-[5-(5-chlorothiophene-2-yl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-(5-pyridin-3-yl-1,3,4-thiadiazoles-2-yl)-1,1 '-xenyl-4-sulphonamide
2,4-two chloro-6-methyl-N-(5-pyridin-3-yl-1,3,4-thiadiazoles-2-yl) benzsulfamide
2,4-two chloro-N-[5-(5-chlorothiophene-2-yl)-1,3,4-thiadiazoles-2-yl]-the 6-methyl benzenesulfonamide
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl)-N, the N-Valpromide
3-chloro-2-methyl-N-[5-(2-oxo-2-piperazine-1-base ethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
2,4-two chloro-N-[5-(2,5-dimethyl-3-furyl)-1,3,4-thiadiazoles-2-yl]-the 6-methyl benzenesulfonamide
N-[5-(3-chlorothiophene-2-yl)-1,3,4-thiadiazoles-2-yl]-4-propylbenzene sulphonamide
3-chloro-N-[5-(3-chlorothiophene-2-yl)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
2,4,6-three chloro-N-[5-(3-chlorothiophene-2-yl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
2,4-two chloro-N-[5-(3-chlorothiophene-2-yl)-1,3,4-thiadiazoles-2-yl]-the 6-methyl benzenesulfonamide
4-bromo-2-methyl-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-2, two (trifluoromethyl) benzsulfamides of 4-
2-methyl-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-4-(trifluoromethoxy) benzsulfamide
N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-4-phenoxyphenylsulfonyhalides amine
4-chloro-2,6-dimethyl-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
2,4-two chloro-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
4-[(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethanoyl] piperazine-1-t-butyl formate
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl)-N,N-dimethylacetamide
3-chloro-2-methyl-N-{5-[2-(pyridin-3-yl oxygen base) ethyl]-1,3,4-thiadiazoles-2-yl } benzsulfamide
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl)-N-sec.-propyl-N-methylacetamide
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl)-N-ethyl-N-methylacetamide
3-chloro-2-methyl-N-[5-(2-oxo-2-thiomorpholine-4-base ethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
3-chloro-2-methyl-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
2-(5-[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl)-N, N-di-isopropyl ethanamide
3-chloro-2-methyl-N-[5-(2-oxo-2-tetramethyleneimine-1-base ethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
3-chloro-2-methyl-N-[5-(2-oxo-2-piperidines-1-base ethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
3-chloro-2-methyl-N-[5-(morpholine-4-ylmethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
3-chloro-N-{5-[2-(1H-imidazoles-1-yl) ethyl]-1,3,4-thiadiazoles-2-yl }-the 2-methyl benzenesulfonamide
2,4,5-three chloro-N-[5-(3-chlorothiophene-2-yl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
2,3,4-three chloro-N-[5-(3-chlorothiophene-2-yl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
4-bromo-N-[5-(3-chlorothiophene-2-yl)-1,3,4-thiadiazoles-2-yl]-2,5-difluoro benzsulfamide
4-bromo-5-chloro-N-[5-(3-chlorothiophene-2-yl)-1,3,4-thiadiazoles-2-yl] thiophene-2-sulphonamide
2,6-two chloro-N-[5-(3-chlorothiophene-2-yl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-[2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethyl] ethanamide
3-chloro-2-methyl-N-(5-{2-[(methyl sulphonyl) amino] ethyl }-1,3,4-thiadiazoles-2-yl) benzsulfamide
3-chloro-2-methyl-N-{5-[2-(3-oxo-1,4-oxygen azatropylidene-4-yl) ethyl]-1,3,4-thiadiazoles-2-yl } benzsulfamide
3-chloro-2-methyl-N-{5-[2-(2-oxo-pyrrolidine-1-yl) ethyl]-1,3,4-thiadiazoles-2-yl } benzsulfamide
3-chloro-2-methyl-N-(5-{2-[methyl (methyl sulphonyl) amino] ethyl }-1,3,4-thiadiazoles-2-yl) benzsulfamide
N-[2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethyl]-N-methyl cyclopropane methane amide
3-chloro-2-methyl-N-{5-[2-(4-methyl-2-oxo piperazine-1-yl) ethyl]-1,3,4-thiadiazoles-2-yl } benzsulfamide
3-chloro-2-methyl-N-[5-(2-{[(trifluoromethyl) alkylsulfonyl] amino } ethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
2,4-two chloro-N-{5-[2-(3-oxo morpholine-4-yl) ethyl]-1,3,4-thiadiazoles-2-yl } benzsulfamide
2,4-two chloro-6-methyl-N-{5-[2-(3-oxo morpholine-4-yl) ethyl]-1,3,4-thiadiazoles-2-yl } benzsulfamide
2,4,6-three chloro-N-{5-[2-(3-oxo morpholine-4-yl) ethyl]-1,3,4-thiadiazoles-2-yl } benzsulfamide
4-(2-furyl)-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
5 '-fluoro-2 '-methoxyl group-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-1,1 '-xenyl-4-sulphonamide
4-(5-thiotolene-2-yl)-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
3 '-ethanoyl-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-1,1 '-xenyl-4-sulphonamide
N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-4 '-(trifluoromethoxy)-1,1 '-xenyl-4-sulphonamide
3 ', 4 '-two chloro-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-1,1 '-xenyl-4-sulphonamide
4-(1,3-benzo dioxole-5-yl)-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
4-(5-chlorothiophene-2-yl)-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-4-pyridin-4-yl benzsulfamide
N-[4 '-({ [5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl] amino } alkylsulfonyl)-1,1 '-xenyl-3-yl] ethanamide
N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-4-thiene-3-yl-benzsulfamide
N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-4-thiophene-2-base benzsulfamide
4 '-(methylthio group)-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-1,1 '-xenyl-4-sulphonamide
N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-3 ', 5 '-two (trifluoromethyl)-1,1 '-xenyl-4-sulphonamide
4 '-chloro-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-1,1 '-xenyl-4-sulphonamide
N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-3 '-nitro-1,1 '-xenyl-4-sulphonamide
3-chloro-2-methyl-N-[5-(2-{ methyl [(trifluoromethyl) alkylsulfonyl] amino } ethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-2-[(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethyl]-1-methyl isophthalic acid H-imidazoles-4-sulphonamide
3-chloro-N-{5-[2-(2-hydroxyl-3-oxo morpholine-4-yl) ethyl]-1,3,4-thiadiazoles-2-yl }-the 2-methyl benzenesulfonamide
4,5-two chloro-N-{5-[2-(3-oxo morpholine-4-yl) ethyl]-1,3,4-thiadiazoles-2-yl } thiophene-2-sulphonamide
N-{5-[2-(3-oxo morpholine-4-yl) ethyl]-1,3,4-thiadiazoles-2-yl }-4-phenoxyphenylsulfonyhalides amine
3-fluoro-N-{5-[2-(3-oxo morpholine-4-yl) ethyl]-1,3,4-thiadiazoles-2-yl } benzsulfamide
N-{5-[2-(3-oxo morpholine-4-yl) ethyl]-1,3,4-thiadiazoles-2-yl }-5-pyridine-2-base thiophene-2-sulphonamide
N-{2-chloro-4-[({5-[2-(3-oxo morpholine-4-yl) ethyl]-1,3,4-thiadiazoles-2-yl } amino) alkylsulfonyl] phenyl } ethanamide
2) 1,2 of general formula (III), the 4-thiadiazoles derivative:
Figure A0282028000701
(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethyl acetate
(5-[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) acetate
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl)-the N-methylacetamide
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl)-the N-ethyl acetamide
2,5-two chloro-N-[3-(3-chlorothiophene-2-yl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) isopropyl acetate
3-chloro-N-[3-(2-hydroxyethyl)-1,2,4-thiadiazoles-5-yl]-the 2-methyl benzenesulfonamide
3-chloro-N-[3-(2-ethoxyethyl group)-1,2,4-thiadiazoles-5-yl]-the 2-methyl benzenesulfonamide
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl)-N, the N-diethyl acetamide
(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino-1,2,4-thiadiazoles-3-yl) methyl acetate
3-chloro-N-[3-(2-isopropoxy ethyl)-1,2,4-thiadiazoles-5-yl]-the 2-methyl benzenesulfonamide
3-chloro-N-[3-(2-methoxy ethyl)-1,2,4-thiadiazoles-5-yl]-the 2-methyl benzenesulfonamide
Methylsulfonic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethyl ester
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino-1,2,4-thiadiazoles-3-yl) ethanamide
3-chloro-N-{5-[2-(2-fluorine oxyethyl group) ethyl]-1,2,4-thiadiazoles-5-yl }-the 2-methyl benzenesulfonamide
3-chloro-2-methyl-N-{3-[2-(2,2, the 2-trifluoro ethoxy) ethyl]-1,2,4-thiadiazoles-5-yl } benzsulfamide
Acetate 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethyl ester
3-chloro-2-methyl-N-[3-(2-morpholine-4-base ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
N-[3-(2-bromotrifluoromethane)-1,2,4-thiadiazoles-5-yl]-3-chloro-2-methyl benzenesulfonamide
Morpholine-4-formic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethyl ester
Diethylamino formic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethyl ester
Propionic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethyl ester
2 Methylpropionic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethyl ester
2-furancarboxylic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethyl ester
Phenylformic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethyl ester
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl)-N-methoxyl group-N-methylacetamide
3-chloro-N-{3-[2-(diethylin) ethyl] amino-1,2,4-thiadiazoles-5-yl }-the 2-methyl benzenesulfonamide
Ethyl carbamic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethyl ester
N-[2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethyl]-the N-ethyl acetamide
3-chloro-2-methyl-N-[3-(2-oxo amyl group)-1,2,4-thiadiazoles-5-yl] benzsulfamide
N-{3-[2-(1,1-dioxy thiomorpholine-4-yl)-2-oxoethyl]-1,2,4-thiadiazoles-5-yl }-4-propylbenzene sulphonamide
2,4,6-three chloro-N-[3-(2-morpholine-4-base ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
2,4-two chloro-N-[3-(2-morpholine-4-base ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
3-chloro-2-methyl-N-{3-[2-(3-oxo morpholine-4-yl) ethyl]-1,2,4-thiadiazoles-5-yl } benzsulfamide
2,4-two chloro-6-methyl-N-[3-(2-morpholine-4-base ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
N-[3-(2-morpholine-4-base ethyl)-1,2,4-thiadiazoles-5-yl]-4-propylbenzene sulphonamide
2,4-two chloro-6-methyl-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
2,4,6-three chloro-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-1,1 '-xenyl-4-sulphonamide
N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-4-propylbenzene sulphonamide
N-[3-(2-oxo-2-thiomorpholine-4-base ethyl)-1,2,4-thiadiazoles-5-yl]-1,1 '-xenyl-4-sulphonamide
N-[3-(2-oxo-2-thiomorpholine-4-base ethyl)-1,2,4-thiadiazoles-5-yl]-4-propylbenzene sulphonamide
2,4-two chloro-6-methyl-N-[3-(2-oxo-2-thiomorpholine-4-base ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
N-[3-(2-oxo-2-piperidines-1-base ethyl)-1,2,4-thiadiazoles-5-yl]-1,1 '-xenyl-4-sulphonamide
N-[3-(2-oxo-2-piperidines-1-base ethyl)-1,2,4-thiadiazoles-5-yl]-4-propylbenzene sulphonamide
2,4-two chloro-6-methyl-N-[3-(2-oxo-2-piperidines-1-base ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
2,4,6-three chloro-N-[3-(2-oxo-2-piperidines-1-base ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
N-(3-phenyl-1,2,4-thiadiazoles-5-yl)-4-propylbenzene sulphonamide
(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) (oxygen) ethyl acetate
3-chloro-2-methyl-N-(3-phenyl-1,2,4-thiadiazoles-5-yl) benzsulfamide
3-chloro-N-[3-(4-fluoro-3-aminomethyl phenyl)-1,2,4-thiadiazoles-5-yl)-the 2-methyl benzenesulfonamide
2,4,6-three chloro-N-(3-phenyl-1,2,4-thiadiazoles-5-yl) benzsulfamide
N-(3-phenyl-1,2,4-thiadiazoles-5-yl)-1,1 '-xenyl-4-sulphonamide
2,4-two chloro-6-methyl-N-(3-phenyl-1,2,4-thiadiazoles-5-yl) benzsulfamide
2-{5-[(1,1 '-xenyl-4-base alkylsulfonyl) amino]-1,2,4-thiadiazoles-3-yl }-N-ethyl-N-methylacetamide
N-ethyl-N-methyl-2-(5-{[(4-propyl group phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethanamide
2-(5-{[(2,4-two chloro-6-aminomethyl phenyls) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl)-N-ethyl-N-methylacetamide
N-ethyl-N-methyl-2-(5-{[(2,4,6-trichlorophenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethanamide
2,4,6-three chloro-N-[3-(2-oxo-2-thiomorpholine-4-base ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
2-{5-[(1,1 '-xenyl-4-base alkylsulfonyl) amino]-1,2,4-thiadiazoles-3-yl }-N-sec.-propyl-N-methylacetamide
2-{5-[(1,1 '-xenyl-4-base alkylsulfonyl) amino]-1,3,4-thiadiazoles-2-yl }-N, the N-diethyl acetamide
N, N-diethyl-2-(5-{[(4-propyl group phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethanamide
2-(5-{[(2,4-two chloro-6-aminomethyl phenyls) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl)-N, the N-diethyl acetamide
N, N-diethyl-2-(5-{[(2,4,6-trichlorophenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethanamide
2-{5-[(1,1 '-xenyl-4-base alkylsulfonyl) amino]-1,2,4-thiadiazoles-3-yl }-N, N-di-isopropyl ethanamide
N, N-di-isopropyl 2-(5-{[(4-propyl group phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethanamide
2-(5-{[(2,4-two chloro-6-aminomethyl phenyls) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl)-N, N-di-isopropyl ethanamide
N, N-di-isopropyl-2-(5-{[(2,4,6-trichlorophenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethanamide
N-[4-(5-{[(4-propyl group phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) phenyl] ethanamide
4-propyl group-N-(3-pyridin-3-yl-1,2,4-thiadiazoles-5-yl) benzsulfamide
N-[3-(2-chloro-5-nitrophenyl)-1,2,4-thiadiazoles-5-yl]-4-propylbenzene sulphonamide
N-[3-(2-chloro-phenyl-)-1,2,4-thiadiazoles-5-yl]-4-propylbenzene sulphonamide
3-chloro-N-[3-(2-chloro-5-nitrophenyl)-1,2,4-thiadiazoles-5-yl]-the 2-methyl benzenesulfonamide
3-chloro-N-[3-(5-chlorothiophene-2-yl)-1,2,4-thiadiazoles-5-yl]-the 2-methyl benzenesulfonamide
3-chloro-N-[3-(2-chloro-phenyl-)-1,2,4-thiadiazoles-5-yl]-the 2-methyl benzenesulfonamide
N-[4-(5-{[(2,4,6-trichlorophenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) phenyl] ethanamide
2,4,6-three chloro-N-(3-pyridin-3-yl-1,2,4-thiadiazoles-5-yl) benzsulfamide
2,4,6-three chloro-N-[3-(2-chloro-5-nitrophenyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
2,4,6-three chloro-N-[3-(5-chlorothiophene-2-yl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
2,4,6-three chloro-N-[3-(2-chloro-phenyl-)-1,2,4-thiadiazoles-5-yl] benzsulfamide
N-[4-{5-[(1,1 '-xenyl-4-base alkylsulfonyl) amino]-1,2,4-thiadiazoles-3-yl } phenyl) ethanamide
N-(3-pyridin-3-yl-1,2,4-thiadiazoles-5-yl)-1,1 '-xenyl-4-sulphonamide
N-[3-(2-chloro-5-nitrophenyl)-1,2,4-thiadiazoles-5-yl]-1,1 '-xenyl-4-sulphonamide
N-[3-(2-chloro-phenyl-)-1,2,4-thiadiazoles-5-yl]-1,1 '-xenyl-4-sulphonamide
N-[4-{5-[(2,4-two chloro-6-aminomethyl phenyls) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) phenyl] ethanamide
2,4-two chloro-6-methyl-N-(3-pyridin-3-yl-1,2,4-thiadiazoles-5-yl) benzsulfamide
2,4-two chloro-N-[3-(2-chloro-5-nitrophenyl)-1,2,4-thiadiazoles-5-yl]-the 6-methyl benzenesulfonamide
2,4-two chloro-N-[3-(5-chlorothiophene-2-yl)-1,2,4-thiadiazoles-5-yl]-the 6-methyl benzenesulfonamide
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl)-N, the N-Valpromide
3-chloro-2-methyl-N-[3-(2-oxo-2-piperazine-1-base ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
2,4-two chloro-N-[3-(2,5-dimethyl-3-furyl)-1,2,4-thiadiazoles-5-yl]-the 6-methyl benzenesulfonamide
N-[3-(3-chlorothiophene-2-yl)-1,2,4-thiadiazoles-5-yl]-4-propylbenzene sulphonamide
3-chloro-N-[3-(3-chlorothiophene-2-yl)-1,2,4-thiadiazoles-5-yl]-the 2-methyl benzenesulfonamide
2,4,6-three chloro-N-[3-(3-chlorothiophene-2-yl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
2,4-two chloro-N-[3-chlorothiophene-2-yls)-1,2,4-thiadiazoles-5-yl]-the 6-methyl benzenesulfonamide
2,4-two chloro-N-[3-(2-chloro-phenyl-)-1,2,4-thiadiazoles-5-yl]-the 6-methyl benzenesulfonamide
4-bromo-2-methyl-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-2, two (trifluoromethyl) benzsulfamides of 4-
2-methyl-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-4-(trifluoromethoxy) benzsulfamide
N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-4-phenoxyphenylsulfonyhalides amine
4-chloro-2,6-dimethyl-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
2,4-two chloro-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
4-[(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethanoyl] piperazine-1-t-butyl formate
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl)-N,N-dimethylacetamide
3-chloro-2-methyl-N-{3-[2 (pyridin-3-yl oxygen base) ethyl]-1,2,4-thiadiazoles-5-yl } benzsulfamide
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl)-N-sec.-propyl-N-methylacetamide
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl)-N-ethyl-N-methylacetamide
3-chloro-2-methyl-N-[3-(2-oxo-2-thiomorpholine-4-base ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
3-chloro-2-methyl-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl)-N, N-di-isopropyl ethanamide
3-chloro-2-methyl-N-[3-(2-oxo-2-tetramethyleneimine-1-base ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
3-chloro-2-methyl-N-[3-(2-oxo-2-piperidines-1-base ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
3-chloro-2-methyl-N-[3-(morpholine-4-ylmethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
3-chloro-N-{3-[2-(1H-imidazoles-1-yl) ethyl]-1,2,4-thiadiazoles-5-yl }-the 2-methyl benzenesulfonamide
2,4,5-three chloro-N-[3-(3-chlorothiophene-2-yl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
2,3,4-three chloro-N-[3-(3-chlorothiophene-2-yl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
2,3,4-three chloro-N-[3-(2-chloro-phenyl-)-1,2,4-thiadiazoles-5-yl] benzsulfamide
N-[4-(5-{[(4-bromo-2,5-difluorophenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) phenyl] ethanamide
4-bromo-N-[3-(3-chlorothiophene-2-yl)-1,2,4-thiadiazoles-5-yl]-2,5-difluoro benzsulfamide
4,5-two chloro-N-[3-(2-chloro-phenyl-)-1,2,4-thiadiazoles-5-yl] thiophene-2-sulphonamide
N-[4-(5-{[(2,4,5-trichlorophenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) phenyl] ethanamide
4-bromo-5-chloro-N-[3-(3-chlorothiophene-2-yl)-1,2,4-thiadiazoles-5-yl] thiophene-2-sulphonamide
3-bromo-5-chloro-N-[3-(2-chloro-phenyl-)-1,2,4-thiadiazoles-5-yl] thiophene-2-sulphonamide
N-[4-(5-{[(2,6-dichlorophenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) phenyl] ethanamide
2,6-two chloro-N-[3-(3-chlorothiophene-2-yl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
N-[2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethyl] ethanamide
3-chloro-2-methyl-N-(3-{2-[(methyl sulphonyl) amino] ethyl }-1,2,4-thiadiazoles-5-yl) benzsulfamide
3-chloro-2-methyl-N-{3-[2-(3-oxo-1,4-oxygen azatropylidene-4-yl) ethyl]-1,2,4-thiadiazoles-5-yl } benzsulfamide
3-chloro-2-methyl-N-{3-[2-(2-oxo-pyrrolidine-1-yl) ethyl]-1,2,4-thiadiazoles-5-yl } benzsulfamide
2,3,4-three chloro-N-{3-[2,6-two chloro-4-(trifluoromethyl) phenyl]-1,2,4-thiadiazoles-5-yl } benzsulfamide
N-[3-(2-chloro-6-fluorophenyl)-1,2,4-thiadiazoles-5-yl]-4-propylbenzene sulphonamide
4-bromo-N-{3-[2,6-two chloro-4-(trifluoromethyl) phenyl]-1,2,4-thiadiazoles-5-yl }-2,5-difluoro benzsulfamide
4,5-two chloro-N-[3-(2-chloro-6-fluorophenyl)-1,2,4-thiadiazoles-5-yl] thiophene-2-sulphonamide
4-bromo-5-chloro-N-{3-[2,6-two chloro-4-(trifluoromethyl) phenyl]-1,2,4-thiadiazoles-5-yl } thiophene-2-sulphonamide
2,4-two chloro-N-[3-(2-chloro-6-fluorophenyl)-1,2,4-thiadiazoles-5-yl]-the 6-methyl benzenesulfonamide
4-bromo-N-[3-(2-chloro-6-fluorophenyl)-1,2,4-thiadiazoles-5-yl]-the 2-methyl benzenesulfonamide
3-chloro-2-methyl-N-(3-{2-[methyl (methylsulfonyl) amino] ethyl }-1,2,4-thiadiazoles-5-yl) benzsulfamide
N-[2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethyl]-N-methyl cyclopropane methane amide
3-chloro-2-methyl-N-{3-[2-(4-methyl-2-oxo piperazine-1-yl) ethyl]-1,2,4-thiadiazoles-5-yl } benzsulfamide
3-chloro-2-methyl-N-[3-(2-{[(trifluoromethyl) alkylsulfonyl] amino } ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
N-[4-(5-{[(4-bromo-5-chlorothiophene-2-yl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) phenyl] ethanamide
2,4-two chloro-N-{3-[2-(3-oxo morpholine-4-yl) ethyl]-1,2,4-thiadiazoles-5-yl } benzsulfamide
2,4-two chloro-6-methyl-N-{3-[2-(3-oxo morpholine-4-yl) ethyl]-1,2,4-thiadiazoles-5-yl } benzsulfamide
2,4,6-three chloro-N-{3-[2-(3-oxo morpholine-4-yl) ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
4-(2-furyl)-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
5 '-fluoro-2 '-methoxyl group-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-1,1 '-xenyl-4-sulphonamide
4-(5-thiotolene-2-yl)-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
3 '-ethanoyl-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-1,1 '-xenyl-4-sulphonamide
N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-4 '-(trifluoromethoxy)-1,1 '-xenyl-4-sulphonamide
3 ', 4 '-two chloro-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-1,1 '-xenyl-4-sulphonamide
4-(1,3-benzo dioxole-5-yl)-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
4-(5-chlorothiophene-2-yl)-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-4-pyridin-4-yl benzsulfamide
N-[4 '-({ [3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl] amino } alkylsulfonyl)-1,1 '-xenyl-3-yl] ethanamide
N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-4-thiene-3-yl-benzsulfamide
N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-4-thiophene-2-base benzsulfamide
4 '-(methylthio group)-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-1,1 '-xenyl-4-sulphonamide
N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-3 ', 5 '-two (trifluoromethyl)-1,1 '-xenyl-4-sulphonamide
4 '-chloro-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-1,1 '-xenyl-4-sulphonamide
N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-3 '-nitro-1,1 '-xenyl-4-sulphonamide
3-chloro-2-methyl-N-[3-(2-{ methyl [(trifluoromethyl) alkylsulfonyl] amino } ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
N-[2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethyl-1-methyl isophthalic acid H-imidazoles-4-sulphonamide
3-chloro-N-{3-[2-(2-hydroxyl-3-oxo morpholine-4-yl) ethyl]-1,2,4-thiadiazoles-5-yl }-the 2-methyl benzenesulfonamide
4,5-two chloro-N-{3-[2-(3-oxo morpholine-4-yl) ethyl]-1,2,4-thiadiazoles-5-yl } thiophene-2-sulphonamide
N-{3-[2-(3-oxo morpholine-4-yl) ethyl]-1,2,4-thiadiazoles-5-yl }-4-phenoxyphenylsulfonyhalides amine
3-fluoro-N-{3-[2-(3-oxo morpholine-4-yl) ethyl]-1,2,4-thiadiazoles-5-yl } benzsulfamide
N-{3-[2-(3-oxo morpholine-4-yl) ethyl]-1,2,4-thiadiazoles-5-yl }-5-pyridine-2-base thiophene-2-sulphonamide
N-{2-chloro-4-[({3-[2-(3-oxo morpholine-4-yl) ethyl]-1,2,4-thiadiazoles-5-yl } amino) alkylsulfonyl] phenyl } ethanamide
Another object of the present invention is the application of aforesaid compound in medicine.
Another object of the present invention is treatment or prevent diabetes, X syndrome, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertension, osteoporosis, dementia, dysthymia disorders, virus disease or inflammation illness and can not cause hypoglycemia and realize immunomodulatory, preferred pin to tuberculosis, leprosy and psoriasic method, described method need to comprise the following steps: this class treatment Mammals, comprise general formula (I) compound or its salt, hydrate or the solvate of people's (being accredited as needs) significant quantity:
Wherein
T is optional independently by [R] nThe aromatic ring or the hetero-aromatic ring that replace, wherein n is that integer and the R of 0-5 are hydrogen, aryl, heteroaryl, heterocycle, optional halogenated C 1-6-alkyl, optional halogenated C 1-6-alkoxyl group, C 1-6-alkyl sulphonyl, carboxyl, cyano group, nitro, halogen, optional single replacement or dibasic amine, optional single replacement or disubstituded amide, aryloxy, aryl sulfonyl, fragrant amino, wherein aryl, heteroaryl and aryloxy residue and heterocycle can be further optional independently of one another by C on one or more positions 1-6-acyl group, C 1-6-alkylthio, cyano group, nitro, hydrogen, halogen, optional halogenated C 1-6-alkyl, optional halogenated C 1-6-alkoxyl group, optional single replacement or disubstituded amide, (benzamido) methyl, carboxyl, 2-thienyl methylamino-or ({ [4-(2-oxyethyl group-2-oxoethyl)-1,3-thiazoles-2-yl] amino } carbonyl) replacement;
R 1Be hydrogen or C 1-6-alkyl;
A 1And A 2Be nitrogen-atoms or C-Z, condition is A 1And A 2Have different implications, wherein:
Z is selected from can be further optional independently of one another by hydrogen, C on one or more positions 1-6-alkyl, halo C 1-6-alkyl, halogen, C 1-6-alkoxyl group, nitro, C 1-6-alkoxy carbonyl, C 1-6Aromatic ring or hetero-aromatic ring that-alkyl sulphonyl, kharophen or aryloxy replace, wherein aryloxy can further optionally on one or more positions be replaced by hydrogen and halogen independently of one another; Or Z is X-Y-R 2, wherein:
X is CH 2Or CO;
Y is CH 2, CO or singly-bound;
R 2Be selected from:
C 1-6-alkyl, azido-, arylthio, heteroarylthio, halogen, methylol, 2-hydroxyethylamino methyl, mesyloxy methyl, 3-oxo-4-morpholinyl methylene radical (morpholinolinylmethylene), C 1-6-alkoxy carbonyl, 5-methyl isophthalic acid, 3,4-oxadiazole-2-base;
NR 3R 4, R wherein 3And R 4Be selected from hydrogen, C independently of one another 1-6-alkyl, optional halogenated C 1-6-alkyl sulphonyl, C 1-6-alkoxyl group, 2-methoxy ethyl, 2-hydroxyethyl, 1-methylimidazolyl alkylsulfonyl, C 1-6-acyl group, cyclohexyl methyl, cyclopropane carbonyl, aryl, optional halogenated aryl sulfonyl, furyl carbonyl, tetrahydrochysene-2-furyl methyl, N-ethoxycarbonyl piperidyl or the C that is replaced by one or more aryl, heterocycle or heteroaryl 1-6-alkyl; Or
NR 3R 4Common expression heterocycle is, they are imidazoles, piperidines, tetramethyleneimine, piperazine, morpholine, oxygen azatropylidene (oxazepine), oxazole, thiomorpholine, 1,1-dioxy thiomorpholine, 2-(3,4-dihydro-2 (1H) isoquinolyl), (1S, 4S)-and 2-oxa--5-azabicyclo [2.2.1] heptan-5-base, these heterocycles systems can choose wantonly by C 1-6-alkyl, C 1-6-acyl group, hydroxyl, oxygen, tert-butoxycarbonyl replace;
OCONR 3R 4, R wherein 3And R 4Be selected from hydrogen, C independently of one another 1-6-alkyl or form morpholinyl with the N-atom that they connected;
R 5O, wherein R 5Be hydrogen, optional halogenated C 1-6-alkyl, aryl, heteroaryl, C 1-6-acyl group, C 1-6-alkyl sulphonyl, aryl carbonyl, heteroaryl carbonyl, 2-methoxycarbonyl phenyl.
Another aspect of the present invention relates to the method that suppresses people 11-beta-hydroxysteroid dehydrogenase 1 type enzyme.This method comprise experimenter (for example Mammals, human or animal) (the being accredited as needs) significant quantity that needs any general formula described herein compound or comprise the step of the composition of any general formula compound of this paper.
The invention still further relates to the treatment of diseases method of 11-beta-hydroxysteroid dehydrogenase 1 type enzyme-mediation.The compound of any general formula described herein of the experimenter (for example Mammals, human or animal) that this method afford needs (being accredited as needs) significant quantity or comprise the step of the composition of any general formula compound of this paper.The disease of 11-beta-hydroxysteroid dehydrogenase 1 type enzyme-mediation is related disease or the process of symptom or any disease or the symptom of performance of 11-beta-hydroxysteroid dehydrogenase 1 type enzyme wherein.The disease of 11-beta-hydroxysteroid dehydrogenase 1 type enzyme-mediation including, but not limited to diabetes, X syndrome, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertension, osteoporosis, dementia, dysthymia disorders, virus disease, inflammation illness and immunomodulatory at disease.Immunomodulatory at the preferred embodiment of disease be tuberculosis, leprosy and psoriasis.When described disease was hyperglycemia, its methods of treatment can not cause hypoglycemia.
Method as herein described can also comprise the step of identifying the experimenter according to the needs of above-mentioned disease of treatment or illness.Evaluation can be to the judgement of experimenter or Occupational health situation (healthprofessional) and can be subjective (for example suggestion) or objective (for example can determine by test or diagnostic method).
These compounds can also be used for preparation prevention, control or treatment diabetes, X syndrome, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertension, osteoporosis, dementia, dysthymia disorders, virus disease or inflammation illness and can not cause hypoglycemia and realize immunoregulatory medicine.The immunomodulatory preferred embodiment is tuberculosis, leprosy and psoriasis.
Preferably:
T is selected from:
5-chloro-1,3-dimethyl-1H-pyrazoles-4-base; 4-chloro-2,3,1-Ben Bing oxadiazole base; 5-(dimethylamino)-1-naphthyl; 1-Methylimidazole-4-base; The 1-naphthyl; The 2-naphthyl; The 8-quinolyl;
By the thienyl of the one or more replacements in the following groups: (benzamido) methyl, bromine, chlorine, 3-isoxazolyl, 2-(methyl sulfane base)-4-pyrimidyl, 1-methyl-5-(trifluoromethyl) pyrazole-3-yl, phenyl sulfonyl, pyridyl;
By the phenyl of the one or more replacements in the following groups: kharophen, the 3-acetylamino phenyl, the 3-acetylphenyl, phenylamino, 1,3-benzo dioxole-5-base, the 2-benzofuryl, benzyl amino, 3, two (trifluoromethyl) phenyl of 5-, bromine, butoxy, carboxyl, chlorine, the 4-carboxyl phenyl, 3-chloro-2-cyano-benzene oxygen, the 4-chloro-phenyl-, 5-chloro-2-thienyl, cyano group, 3, the 4-dichlorophenyl, ({ [4-(2-oxyethyl group-2-oxoethyl)-1,3-thiazoles-2-yl] amino } carbonyl), fluorine, 5-fluoro-2-p-methoxy-phenyl, the 2-furyl, hydrogen, iodine, sec.-propyl, methylsulfonyl, methoxyl group, methyl, 4-methyl isophthalic acid-piperazinyl, 4-methyl isophthalic acid-piperidyl, 4-methyl sulfane base phenyl, 5-methyl-2-thienyl, the 4-morpholinyl, nitro, the 3-nitrophenyl, phenoxy group, phenyl, n-propyl, the 4-pyridyl, 3-pyridyl methylamino-, the 1-pyrrolidyl, the 2-thienyl, the 3-thienyl, 2-thienyl methylamino-, trifluoromethoxy, the 4-Trifluoromethoxyphen-l, trifluoromethyl; Or
R 1Be hydrogen or methyl;
A 1And A 2Be nitrogen-atoms or C-Z, condition is A 1And A 2Have different implications, wherein:
Z is selected from: 1-thionaphthene-3-base, 3-(2,5-dimethyl furan base), pyridyl;
The optional thienyl that is replaced by one or more chlorine, methyl sulphonyl;
Optional by the phenyl of the one or more replacements in ethoxy carbonyl, nitro, fluorine, methyl, methoxyl group, kharophen, chlorine, 4-chlorophenoxy, the trifluoromethyl;
Or Z is X-Y-R 2, wherein
X is CH 2Or CO;
Y is CH 2, CO or singly-bound;
R 2Be selected from:
N-propyl, azido-, bromine, chlorine, 2-pyridyl sulfane base, 3-oxo-4-morpholinyl methylene radical (morpholinolinylmethylene), ethoxy carbonyl, 5-methyl isophthalic acid, 3,4-oxadiazole-2-base, methylol, 2-hydroxyethylamino methyl, mesyloxy methyl;
NR 3R 4, R wherein 3And R 4Be selected from ethanoyl, diphenyl-methyl, 1 independently of one another, 3-benzo dioxole-5-ylmethyl, benzyl, 3-chloro-2-aminomethyl phenyl alkylsulfonyl, cyclohexyl, cyclohexyl methyl, cyclopropane carbonyl, ethyl, 2-furyl carbonyl, 2-furyl methyl, hydrogen, 2-hydroxyethyl, 2-(1H-indol-3-yl) ethyl, sec.-propyl, methoxyl group, 2-methoxy ethyl, methyl, 4-(1-methylimidazolyl) alkylsulfonyl, methyl sulphonyl, phenyl, (1S)-styroyl, n-propyl, tetrahydrochysene-2-furyl methyl, trifluoromethyl sulfonyl, N-ethoxycarbonyl piperidyl; Or
NR 3R 4Common expression 4-ethanoyl piperazinyl, 4-tert-butoxycarbonyl piperazinyl, 2-(3,4-dihydro-2 (1H) isoquinolyl), (2R, 6S)-2, the 6-dimethylated morpholinyl, (2R)-2,4-dimethyl-1-piperazinyl, 2-hydroxyl-3-oxo morpholinyl, imidazolyl, 2-methyl-3-oxo morpholinyl, 4-methyl-2-oxo piperazinyl, 4-methylpiperazine base, morpholinyl, (1S, 4S)-2-oxa--5-aza-bicyclo [2.2.1] heptan-5-base, 2-oxoimidazolinium base, 3-oxo morpholinyl, 3-oxo-1,4-oxygen azatropylidene base (oxazepinyl), 2-Yang oxazolines base, piperazinyl, piperidyl, pyrrolidyl, pyrrolidone-base, thio-morpholinyl, 1,1-dioxy-thio-morpholinyl;
OCONR 3R 4, R wherein 3And R 4Be selected from ethyl, hydrogen independently of one another or form morpholinyl with the N-atom that they connected;
R 5O, wherein R 5Be ethanoyl, benzoyl, benzyl, ethyl, 2-fluoro ethyl, 2-furyl carbonyl, hydrogen, isobutyryl, sec.-propyl, methyl, 2-methoxycarbonyl benzyl, methyl sulphonyl, phenyl, positive propionyl, 3-pyridyl, 2,2, the 2-trifluoroethyl;
The specific examples of The compounds of this invention is as above given compound and also comprises following compounds:
3-chloro-N-{5-[2-(diethylamino) ethyl]-1,3,4-thiadiazoles-2-yl }-the 2-methyl benzenesulfonamide
N-(5-phenyl-1,3,4-thiadiazoles-2-yl)-4-propylbenzene sulphonamide
3-chloro-2-methyl-N-(5-phenyl-1,3,4-thiadiazoles-2-yl) benzsulfamide
3-chloro-N-[5-(4-fluoro-3-aminomethyl phenyl)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
2,4,6-three chloro-N-(5-phenyl-1,3,4-thiadiazoles-2-yl) benzsulfamide
N-(5-phenyl-1,3,4-thiadiazoles-2-yl)-1,1 '-xenyl-4-sulphonamide
2,4-two chloro-6-methyl-N-(5-phenyl-1,3,4-thiadiazoles-2-yl) benzsulfamide
N-[4-(5-{[(4-propyl group phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
N-[5-(2-chloro-5-nitrophenyl)-1,3,4-thiadiazoles-2-yl]-4-propylbenzene sulphonamide
N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl]-4-propylbenzene sulphonamide
3-chloro-N-[5-(2-chloro-5-nitrophenyl)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
3-chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
N-(4-(5-{[(2,4,6-trichlorophenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
2,4,6-three chloro-N-[5-(2-chloro-5-nitrophenyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
2,4,6-three chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-(4-{5-[(1,1 '-xenyl-4-base alkylsulfonyl) amino]-1,3,4-thiadiazoles-2-yl } phenyl) ethanamide
N-[5-(2-chloro-5-nitrophenyl)-1,3,4-thiadiazoles-2-yl]-1,1 '-xenyl-4-sulphonamide
N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl]-1,1 '-xenyl-4-sulphonamide
N-[4-(5-{[(2,4-two chloro-6-aminomethyl phenyls) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
2,4-two chloro-N-[5-(2-chloro-5-nitrophenyl)-1,3,4-thiadiazoles-2-yl]-the 6-methyl benzenesulfonamide
2,4-two chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl]-the 6-methyl benzenesulfonamide
2,3,4-three chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-[4-(5-{[(4-bromo-2,5-difluorophenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
4,5-two chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl] thiophene-2-sulphonamide
N-[4-(5-{[(2,4,5-trichlorophenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
3-bromo-5-chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl] thiophene-2-sulphonamide
N-[4-(5-{[(2,6-dichlorophenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
2,3,4-three chloro-N-{5-[2,6-two chloro-4-(trifluoromethyl) phenyl]-1,3,4-thiadiazoles-2-yl } benzsulfamide
N-[5-(2-chloro-6-fluorophenyl)-1,3,4-thiadiazoles-2-yl]-4-propylbenzene sulphonamide
4-bromo-N-{5-[2,6-two chloro-4-(trifluoromethyl) phenyl]-1,3,4-thiadiazoles-2-yl }-2,5-difluoro benzsulfamide
4,5-two chloro-N-[5-(2-chloro-6-fluorophenyl)-1,3,4-thiadiazoles-2-yl] thiophene-2-sulphonamide
4-bromo-5-chloro-N-{5-[2,6-two chloro-4-(trifluoromethyl) phenyl]-1,3,4-thiadiazoles-2-yl } thiophene-2-sulphonamide
2,4-two chloro-N-[5-(2-chloro-6-fluorophenyl)-1,3,4-thiadiazoles-2-yl]-the 6-methyl benzenesulfonamide
4-bromo-N-[5-(2-chloro-6-fluorophenyl)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
N-[4-(5-{[(4-bromo-5-chlorothiophene-2-yl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide.
Another object of the present invention is to comprise the pharmaceutical composition that can accept carrier at least a as above-mentioned defined general formula (I) compound and the medicine.
The preparation method who also comprises general formula (I) compound in the scope of the invention.This method comprises and obtains any midbody compound as herein described, makes its and one or more reagent react and generate the step of general formula (I) compound, comprises any means of the special description of this paper.
From detailed description and claim, obviously can draw other features and advantages of the present invention.
Detailed Description Of The Invention
Compound of the present invention can be used for the indication of several 11-of relating to beta-hydroxysteroid dehydrogenase 1 type enzymes, therefore, compound of the present invention can be used for dementia (referring to WO97/07789), osteoporosis is (referring to Canalis E 1996, " mechanism of action of glucocorticosteroid in bone: the relation of the osteoporosis of bringing out with glucocorticosteroid " (Mechanisms of glucocorticoid action in bone:implications toglucocorticoid-induced osteoporosis)-" clinical endocrinology and metabolism magazine " (Journal of Clinical Endocrinology and Metabolism), 81,3441-3447) and can also be used for disease of immune system (referring to Franchimont etc. " glucocorticosteroid is to the immunoreactive inhibition of Th1: the dexamethasone selectivity suppresses Stat 4 phosphorylations of the T lymphocyte that IL-12-brings out " (" Inhibition of Th1 immune response byglucocorticoids:dexamethasone selectively inhibits IL-12-inducedStat 4 phosphorylation in T lymphocytes ")-" IMMUNOLOGY KEY WORDS INDEX (Thejournal of Immunology) 2000, February 15, the 164th volume (4), the 1768-74 page or leaf) and above-mentioned listed indication.
The various terms that explanation has in the above-mentioned definition of general formula (I) compound separately and uses with array mode.
Term in this specification sheets " aryl " is in order to comprise the aromatic ring (monocycle or dicyclo) that contains 6-10 ring carbon atom, and such as phenyl (Ph) and naphthyl, they can be chosen wantonly by C 1-6-alkyl replaces.The example of substituted aryl is benzyl and 2-aminomethyl phenyl.
Term in this specification sheets " heteroaryl " refers to and contains 5-14, preferred 5-10 annular atoms, the monocycle such as 5,6,7,8,9 or 10 annular atomses (monocycle or dicyclo), dicyclo or three cyclophane ring systems (only requiring a ring is aromatic nucleus), wherein one or more annular atomses are non-carbon atoms, such as nitrogen, sulphur, oxygen and the selenium part as ring system.The example of this class hetero-aromatic ring is the pyrroles, imidazoles, thiophene, furans, thiazole, isothiazole, thiadiazoles oxazole isoxazole oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazoles, triazole, tetrazolium, chroman, isochroman, quinoline, quinoxaline, isoquinoline 99.9,2, the 3-naphthyridine, cinnolines, quinazoline, indoles, isoindole, indoline, isoindoline, thionaphthene, cumarone, isobenzofuran benzoxazole, 2,1,3-Ben Bing oxadiazole, benzothiazole, 2,1, the 3-benzothiazole, 2,1, the 3-selenole, benzoglyoxaline, indazole, benzodioxan, 1, the 2-indane, 1,2,3, the 4-tetrahydroquinoline, 3,4-dihydro-2H-1, the 4-benzimidazole dihydrochloride, naphthyridine, 1, the 8-naphthyridine, acridine, azophenlyene (fenazine) and xanthene.
Term in this specification sheets " heterocycle " is in order to comprise unsaturated and part and complete saturated monocycle, dicyclo and three rings that contain 4-14, preferred 4-10 annular atoms, containing one or more heteroatomss (for example oxygen, sulphur or nitrogen) in described annular atoms is carbon as the part and the remaining annular atoms of described ring system, such as: for example above-mentioned heteroaryl and corresponding fractional saturation or saturated heterocycle fully.Typical saturated heterocyclic is azetidine, tetramethyleneimine, piperidines, piperazine, morpholine, thiomorpholine and 1,4-oxygen azatropylidene.
C on the application's general formula (I) compound 1-6-alkyl can be straight chain, side chain or ring-type, preferred C 1-4-alkyl.Typical alkyl comprises methyl, ethyl, n-propyl, sec.-propyl, normal-butyl, sec-butyl, the tertiary butyl, amyl group, isopentyl, hexyl, isohexyl and cyclohexyl.With regard to scope " C 1-6-alkyl " integral part, pay close attention to all its subbase groups, such as C 1-5-alkyl, C 1-4-alkyl, C 1-3-alkyl, C 1-2-alkyl, C 2-6-alkyl, C 2-5-alkyl, C 2-4-alkyl, C 2-3-alkyl, C 3-6-alkyl, C 4-5-alkyl etc.
C on the application's general formula (I) compound 1-6-alkoxyl group can be straight chain, side chain or ring-type, preferred C 1-4-alkoxyl group.Typical alkoxyl group comprises methoxyl group, oxyethyl group, propoxy-, isopropoxy, butoxy, sec-butoxy, tert.-butoxy, pentyloxy, isopentyloxy, hexyloxy and different hexyloxy.With regard to scope " C 1-6-alkoxyl group " integral part, pay close attention to all its subbase groups, such as C 1-5-alkoxyl group, C 1-4-alkoxyl group, C 1-3-alkoxyl group, C 1-2-alkoxyl group, C 2-6-alkoxyl group, C 2-5-alkoxyl group, C 2-4-alkoxyl group, C 2-3-alkoxyl group, C 3-6-alkoxyl group, C 4-5-alkoxyl group etc.
C on the application's general formula (I) compound 1-6-acyl group can be saturated or undersaturated and preferred C 1-4-acyl group.Typical acyl group comprises formyl radical, ethanoyl, propionyl, butyryl radicals, isobutyryl, pentanoyl, isovaleryl, crotonoyl (for example 3-crotonoyl), hexenoyl (for example 5-hexenoyl).With regard to scope " C 1-6-acyl group " integral part, pay close attention to all its subbase groups, such as C 1-5-acyl group, C 1-4-acyl group, C 1-3-acyl group, C 1-2-acyl group, C 2-6-acyl group, C 2-5-acyl group, C 2-4-acyl group, C 2-3-acyl group, C 3-6-acyl group, C 4-5-acyl group etc.
C on the application's general formula (I) compound 2-6-alkenyl can be straight chain, side chain or ring-type, preferred C 2-4-alkenyl.Typical alkenyl comprises vinyl, 1-propenyl, 2-propenyl, pseudoallyl, 1-butylene base, crotyl, 1-pentenyl, pentenyl, 1-hexenyl, 2-hexenyl and 1-cyclohexenyl.With regard to scope " C 2-6-alkenyl " integral part, pay close attention to all its subbase groups, such as C 2-5-alkenyl, C 2-4-alkenyl, C 2-3-alkenyl, C 3-6-alkenyl, C 4-5-alkenyl etc.
Term in this specification sheets " halogen " is in order to comprise fluorine, chlorine, bromine and iodine.
Term in this specification sheets " sulfane base " refers to thio group.
So-called " the single replacement or two replacements ", referring to described functional group in this manual can be independently by C 1-6-acyl group, C 2-6-alkenyl, C 1-6-(ring) alkyl, aryl, pyridylmethyl or the such heterocyclic substituted of azetidine, tetramethyleneimine, piperidines, piperazine, morpholine and thiomorpholine for example, these heterocycles can be chosen wantonly by C 1-6-alkyl replaces.So-called " optional single the replacement or two replacements " refers to described functional group in this manual and also can be replaced by hydrogen independently.
Substituent combination that the present invention estimates and version only are those substituting group and versions that stable compound is formed.Term used herein " stablize " refer to have be enough to produce and keep the enough time bars of compound integrity with the compound of the stability that is used for purpose described herein (for example to the experimenter treat administration with treatment disease, 11 β HSD1 suppress, the disease of 11 β HSD1-mediation).
Term in this specification sheets " prodrug form " refers to acceptable derivates on the pharmacology, such as ester or acid amides, this derivative is become described active medicine (referring to " pharmacological basis of therapeutical agent " (ThePharmacological basis of Therapeutics) of Goodman and Gilman the 8th edition by bio-transformation in vivo, McGraw-Hill, international version 1992, " bio-transformation of medicine " (" Biotransformation of Drugs), p.13-15).
" pharmaceutically acceptable " refers to the pharmaceutical composition that is used to prepare Generally Recognized as safe, nontoxicity and both lifeless matter activity, the effect that also needs invariably in this manual and comprises and be used for that veterinary drug is used and people's medicine is used.
" pharmaceutically acceptable salt " refers to aforesaid pharmaceutically acceptable and have the salt of required pharmacologically active in this manual.This class salt comprises the salt of the sour addition that forms with organic acid and mineral acid, and described organic acid and mineral acid are all if any hydrochloric acid, Hydrogen bromide, hydroiodic acid HI, sulfuric acid, phosphoric acid, acetate, oxyacetic acid, toxilic acid, propanedioic acid, oxalic acid, methylsulfonic acid, trifluoroacetic acid, fumaric acid, succsinic acid, tartrate, citric acid, phenylformic acid, xitix etc.Can with the salt that forms the alkali addition such as such organic bases such as sodium, ammonia, potassium, calcium, thanomin, diethanolamine, N-methylglucosamine, choline and mineral alkali.The present invention includes the pharmaceutically acceptable salt or the compound of any this paper general formula.
Pharmaceutical composition of the present invention contains pharmaceutically acceptable carrier and is dissolved or dispersed in wherein at least a compound that contains general formula (I) as the active antibacterial component.In preferred embodiments, when being therapeutic purpose during to the human patient administration, described therapeutic composition is not immunogenic, unless purpose just is the induction of immunity reaction.
Containing the drug combination preparation that is dissolved or dispersed in active ingredient is wherein fully understood in the art.In general, this based composition is made the moisture of sterile injectable or anhydrous liq solution or suspension, but, can also prepare the solid dosage that is suitable in liquid dissolving or suspendible before use.Can also be with said preparation emulsification.
Can will can accept on active ingredient and the medicine and the mixed with excipients compatible, and its consumption is applicable to methods of treatment as herein described with described active ingredient.Suitable vehicle for example is water, salt solution, glucose, glycerine, ethanol etc. and combination thereof.In addition, if desired, described composition can contain the auxiliary substance of the described active ingredient validity of a small amount of enhancing, such as wetting agent or emulsifying agent, pH buffer reagent etc.Can also contain adjuvant in the described composition.
Pharmaceutically acceptable carrier is well-known in the art.Exemplary of liquid carriers is not contain other material or contain such as the sodium phosphate under the physiological pH value, physiological saline or both, such as the aseptic aqueous solution of the such buffer reagent of phosphate-buffered saline except that active ingredient and water.In addition, aqueous carrier can contain more than one buffering salts and such as sodium-chlor and such salt, glucose, propylene glycol, polyoxyethylene glycol and other solute of Repone K.
Liquid composition can also contain liquid phase, can comprise water or not comprise water.The additional liquid phase of typical this class is glycerine, such as the such vegetables oil of oleum gossypii seminis, such as ethyl oleate such organosilane ester and water-oil-emulsion.
Comprise the pharmaceutically acceptable salt that can comprise aforesaid composition in the pharmaceutical composition of one of preferred embodiment of the invention of containing general formula (I) compound.Pharmaceutically acceptable salt comprises the salt (forming with the free amine group of polypeptide) of the sour addition that forms with the such mineral acid of all example hydrochloric acids or phosphoric acid or form with such organic acid acid such as acetate, tartrate, amygdalic acid etc.The salt that forms with free carboxy can also derive from such as the such mineral alkali of the oxyhydroxide of sodium, potassium, ammonium, calcium or iron with such as such organic basess such as Isopropylamine, Trimethylamine 99,2-ethylaminoethyl alcohol, Histidine, PROCAINE HCL, PHARMA GRADE.
Can be by oral, local, intraperitoneal, intraarticular, encephalic, in skin, intramuscular, intraocular, sheath, intravenously, the subcutaneous preparation that gives preferred embodiment.Other approach is known to those skilled in the art.
Composition for oral administration of the present invention can be the form of tablet, capsule, powder, particle, lozenge, liquid or gel preparation, such as oral, local or aseptic non-enteron aisle solution or suspension.The tablet and the capsule that are used for oral administration can be unit dosage forms and can contain usual excipients, such as: tackiness agent, for example syrup, gum arabic, gelatin, sorbyl alcohol, tragacanth gum or polyvinylpyrrolidone; Weighting agent, for example lactose, sugar, W-Gum, calcium phosphate, sorbyl alcohol or glycine; Compressing tablet lubricant, for example Magnesium Stearate, talcum, polyoxyethylene glycol or silica gel; Disintegrating agent, for example yam starch; Or acceptable wetting agent, such as sodium lauryl sulphate.Can give tablet coating according to well-known method in the general medicinal practice.Oral liquid can be the form of for example water or oil suspension, solution, emulsion, syrup or elixir maybe can make use before water or other appropriate carrier dissolved dry product again.This class I liquid I preparation can contain typical additives, such as: suspension agent, for example sorbyl alcohol, syrup, methylcellulose gum, glucose syrup, gelatin hydrogenation edible fat; Emulsifying agent, for example Yelkin TTS, dehydrating sorbitol monooleate or Sudan Gum-arabic; Nonaqueous carrier (can comprise edible oil), for example Oleum Cocois of Prunus amygdalus oil, fractional separation; The grease class is such as glycerine, propylene glycol or ethanol; Sanitas, for example methyl p-hydroxybenzoate or propylparaben or Sorbic Acid; And if desired, can also contain seasonings commonly used or tinting material.
" significant quantity " refers to the compound amount that the experimenter who is treated is produced therapeutic action.Therapeutic action can be objective (is the indication that produces of experimenter or feel effect) of (can by some test or marker determination) or subjectivity.Pharmaceutical composition of the present invention can contain general consumption and be at least the compound that contains general formula (I) that accounts for total therapeutic composition weight 0.1 weight percent.Weight percent is the ratio in general composition weight meter.Therefore, for example, 0.1 weight percent is to contain the compound that 0.1 gram contains general formula (I) in per 100 gram total compositions.To Mammals, preferred human suitable every day oral dosage can change in the wide region that do not coexist with patient's situation.But, the dosage that contains general formula (I) compound is about the 0.1-300mg/kg body weight and may suits.
Composition of the present invention can also as the veterinary drug use and they can contain acceptable vehicle or carrier on the veterinary drug thus.Can in methods of treatment, give these compounds and composition thus to animal, for example cat, dog or horse.
Can with mark pattern, for example isotope-labeled The compounds of this invention is as diagnostic reagent.
The present invention relates to the preparation method of any compound of this paper general formula, this method comprises the step of any one or the multiple compound reaction that makes general formula described herein, comprises any means as herein described.Can be by ordinary method or with the similar method of ordinary method and especially prepare the compound of above-mentioned general formula (I) according to following method or with the similar method of following method.In addition, use following reagent and method to study external pharmacological characteristics.
Chemical substance used in the route of synthesis as herein described can comprise: for example solvent, reagent, catalyzer and protecting group and deprotection base reagent.Aforesaid method can also comprise interpolation or remove the step of suitable protecting group so that finally synthetic described compound before and after the specifically described step of this paper.In addition, can implement different synthesis steps so that obtain required compound according to selectable order or order.The synthetic chemistry conversion and the protecting group method (protection and deprotection) that are used for synthetic compound used therefor are as known in the art and comprise those methods described in for example following document: R.Larock, " comprehensive organic transformation " (Comprehensive Organic Transformations), VCH Publishers (1989); T.W.Greene and P.GM.Wuts, " protecting group in the organic synthesis " (Protective Groups in Organic Synthesis) the 3rd edition, John Wiley and Sons (1999); L.Fieser and M.Fieser, " organic synthesis Fieser and FieserShi reagent " (Fieser and Fieser ' s Reagents for Organic Synthesis), JohnWiley and Sons (1994); With " organic synthesis reagent encyclopedia " (Encyclopedia of Reagents for Organic Synthesis) that L.Paquette edits, John Wiley and Sons (1995) and and later release.
Above-mentioned used open source literature is incorporated herein by reference.So-called " comprising " refer to " including, but not limited to ".Therefore, can there be other NM material, additive or carrier.
Referring now to the following example the present invention is described.Should not regard these embodiment as limiting the scope of the invention, and only should use with interpretive mode.
Embodiment
Experimental technique
Scintillation proximity assay
[1,2 (n)- 3H]-cortisone is purchased the Biotech from Amersham Pharmacia.Anti-hydrocortisone monoclonal mouse antibody clone 6D6.7 available from Immunotech and bag by the flicker of monoclonal anti mouse antibodies get close to mensuration (SPA) pearl from Amersham PharmaciaBiotech.The NADPH tetra-na salt is provided by Sigma from Calbiochem and Robison ester (G-6-P).Expressing human 11-beta-hydroxysteroid dehydrogenase 1 type enzyme in Pichia pastoris (pichia pastoris) (11-β-HSD1).18-β-Gan Caotingsuan (GA) is available from Sigma.The described compound of serial dilution on Tecan Genesis RSP 150.Test compounds is dissolved in DMSO (1mM) and uses the 50mMTris-HCl of the pH7.2 that contains 1mM EDTA to dilute.
On WallacQuadra, carry out flat board propagation.Mensuration and described pearl bonded product on Packard Top Count microtest plate liquid scintillation counter [ 3H]-amount of hydrocortisone.
At 96 hole microtitration flat board (Packard, Optiplate) carry out 11-β-HSD1 enzyme test on, total pore volume is 220 μ L and Tris-HCl and the 1mMEDTA that contains 30mM pH7.2, and promptly the substrate mixture of serial dilution form (9-0.15 μ M) contains tritiate cortisone/NADPH (175nM/181 μ M), G-6-P (1mM) and inhibitor.By adding people 11-β-HSD 1Start reaction, the microsome (the final consumption of used enzyme changes) that becomes Pichia pastoris cell homogenize thing or prepare between 0.057-0.11mg/mL by Pichia pastoris.After the mixing, at room temperature with dull and stereotyped jolting 30-45 minute.Make this reaction terminating with 10 μ L 1mMGA stop baths.Add monoclonal mouse antibody (10 μ L, 4 μ M) then, add the SPA pearl (explanation according to manufacturers suspends) of 100 μ L subsequently.By not using 11-β-HSD 1Set up suitable reference substance and obtain non-specific binding (NSB) value.
Flat board with insulation on plastics film covering and the vibrator at room temperature 30 minutes, is after this counted.With microtest plate liquid flashing counter measuring and described pearl bonded [ 3H]-amount of hydrocortisone.
Calculate the K of inhibitor by using activity basic value (Activity Base) iValue.According to IC 50Calculating K iValue is also used Cheng Prushoff equation calculating K mValue (but wherein retroactive inhibition meets the Michaelis-Menten equation): K i=IC 50(1+[S]/K m) [Cheng, Y.C.; Prushoff, W.H. " biological chemistry and pharmacology " (Biochem.Pharmacol.) 1973,22,3099-3108].In a kind of assay method, measure IC by experiment 50, wherein the cortisone minimizing that is updated to hydrocortisone depends on the inhibition potential of every kind of material.The compounds of this invention is to the K of 11-β-HSD1 enzyme iValue generally is about the about 10 μ M of 10nM-.
The preparation of compound
General method:
In order to be prepared type net phase (straight phase) HPLC purifying, in the Gi1Son system, use Phenomenex post (250 * 21.1mm, 10 μ m), with alcoholic acid chloroformic solution wash-out (gradient 0-10%, 10 minutes), flow velocity is 20mL/ minute.Use silica gel 60 (230-400 order), Merck carries out silica gel column chromatography.On the Gallenkamp instrument, measure fusing point.Use Vario EL instrument record ultimate analysis value.Use Hypersil Elite post (150 * 4.6mm, 3 μ) to carry out HPLC in Waters 600E system and analyze, flow velocity is 3mL/ minute, monitors at the 254nm place.At 100 * 21.2mm, carry out anti-phase preparation HPLC on the 5 μ Hypersil Elite posts, gradient elution with 5% aqueous solution (0.2%TFA damping fluid) of 95% aqueous solution-95%ACN of 5%ACN, time is in 10 minutes, flow velocity is 20mL/ minute, uses the UV detector that is set in the 254nm place.Use the silica gel F-254 plate (0.25mm is thick) of precoating to carry out tlc.On the desk-top LCMS spectrometer of Micromass, obtain the electrospray mass spectrum.The crude product compound that uses pre-silica gel SPE post (10g silica gel) purifying of filling to obtain by the flash column chromatography method, in Isco Foxy200 Combiflash system, and gradient progressively increases to 100% ethyl acetate from the hexane solution of 16.67% ethyl acetate.
The abbreviation table
The ACN=acetonitrile
The DCM=methylene dichloride
DIEA=N, the N-diisopropylethylamine
The DMAP=4-Dimethylamino pyridine
The DME=glycol dimethyl ether
The DMF=dimethyl formamide
The DMSO=methyl-sulphoxide
EDCI=1-(3-dimethylamino-propyl)-3-ethyl carbocyclic ring diimmonium salt hydrochlorate
The EDTA=ethylenediamine tetraacetic acid (EDTA)
HCOOH=formic acid
HOAT=1-hydroxyl-7-azepine benzotriazole
The HOBT=1-hydroxy benzotriazole hydrate
The MTBE=t-butyl methyl ether
The TEA=triethylamine
The TFA=trifluoroacetic acid
The THF=tetrahydrofuran (THF)
The sulphonamide coupling:
Method A:
The heterogeneous ring compound that has exocyclic amino group of 1Eq (promptly 1,2,4-thiadiazoles or 1,3,4-thiadiazoles derivative) is dissolved in pyridine (0.5M solution).Adding SULPHURYL CHLORIDE (1.2eq) also stirs this reaction mixture 15 hours at ambient temperature with in the nitrogen environment.With this reaction mixture impouring HCl aqueous solution (1M).If the product precipitation then is collected in it on filter membrane and also washs and make its recrystallization from ethanol with the HCl aqueous solution (1M).With regard to obtaining oil condition, extract crude product and use standard step to handle and purifying with DCM.
Method B:
With the heterogeneous ring compound that has exocyclic amino group of 1Eq (promptly 1,2,4-thiadiazoles or 1,3,4-thiadiazoles derivative) (1eq), triethylamine (2eq) and DMAP (1eq) is dissolved in DMF (1M) and the resulting solution of DCM (0.225M) is allocated reaction flask into.SULPHURYL CHLORIDE (1.2eq) is dissolved in DCM (0.33M) and adding.This reaction mixture is kept at room temperature spending the night.Then this mixture is joined in the sherwood oil (10 times of reaction volumes).Place in refrigerator after several hours, supernatant decanted liquid also is dissolved in DMSO-methyl alcohol-acetate (300 μ L+500 μ L+50 μ L) with (part) resistates and by preparation type LCMS (acetonitrile-water gradient) purifying.Collect the purest fraction and freeze-drying.On the other hand, use the extraction operation to separate crude product and use the standard step purifying.
Saponification:
Method C:
The ester of 1Eq is suspended in 95% ethanol (0.1M) also with KOH (aqueous solution, 6eq) processing.Add entry till obtain settled solution.This reaction mixture was stirred 2-3 hour at ambient temperature.Under reduced pressure, remove and desolvate and crude product is water-soluble again.Add dense HCl to pH2, thereby obtain precipitation, it is collected on the filter membrane also with cold water washing and drying.
The acid amides coupling:
Method D:
Carboxylicesters is dissolved in (0.05M) a large amount of excessive amine, obtains 40 or 70% aqueous solution.This reaction mixture stirred at ambient temperature spend the night.Under reduced pressure,, use the DCM eluant solution of methyl alcohol (0 → 6%) except that desolvating and passing through silica gel flash column chromatography purifying crude product.
Method E:
Carboxylic acid is suspended among the DCM (0.05M) amine (1.2eq) that adds EDCI (1.1eq), triethylamine (3eq), DMAP (0.5eq) subsequently and select.When beginning no longer to dissolve, raw material adds DMF.This reaction mixture stirred at ambient temperature spend the night.Wash organic phase, also evaporate in a vacuum with the HCl aqueous solution (1M) with dried over sodium sulfate, filtration.By silica gel flash column chromatography purifying crude product acid amides, use the DCM solution or the eluent ethyl acetate of methyl alcohol (1 → 3 → 6%).
Method F:
Carboxylic acid is suspended among the DCM (0.1M) and in nitrogen (g) compression ring border is cooled to 0 ℃.Add EDCI (1eq), HOAT (1eq) or HOBT (1eq), add TEA (2.2eq) subsequently.After 10 minutes, the amine that brings Selection In (1.2eq) also is warmed to envrionment temperature with this reaction mixture.After 5 hours, DCM handles and purifying mutually and described in method E with the HCl aqueous solution (1M) washing.
Method G:
At N 2In-compression ring the border aluminum chloride (1eq) is suspended among the DCM (0.1M) also at ambient temperature with amine (4eq) processing of selecting.After 10 minutes, add alkyl ester (1eq) and with this reaction mixture be stirred to raw material consumption intact till (TLC).Make reaction terminating and complete with the saturated sodium bicarbonate aqueous solution or the HCl aqueous solution (1M), obtain crude product,, use DCM/ carbinol mixture wash-out then by the hurried chromatography purification crude product of silica gel with ethyl acetate extraction.
Acidylate:
Method J:
Be dissolved in the chloride of acid that adds 1.1eq in the resulting solution of dried pyridine (0.3M) to alcohol under 0 ℃.With this reaction mixture at room temperature stir 6 hours, concentrate, evaporate, be dissolved in again DCM, go forward side by side with the HCl aqueous solution (0.5M) washing, with dried over sodium sulfate and exercise usefulness sherwood oil and ethyl acetate silica gel chromatography as eluent with acetonitrile.
Amino formate:
Method K:
Be dissolved in the 4-chloroformate nitrophenyl ester (the dried pyridine solution of 0.5M) that adds 1.5eq in the resulting solution of dried pyridine (0.3M) to alcohol under 0 ℃.After this reaction mixture at room temperature stirred 12 hours, at 0 ℃ of primary amine or secondary amine that adds 5eq down.With this solution at room temperature stir 3 hours, concentrate, with acetonitrile evaporate, be dissolved in again DCM, with the HCl aqueous solution (0.5M) and saturated sodium bicarbonate aqueous solution washing, with dried over sodium sulfate enforcement usefulness DCM and methyl alcohol the silica gel chromatography of going forward side by side as eluent.
The SULPHURYL CHLORIDE class
Prepare the non-aryl sulfonyl chloride class that is purchased (for example, referring to Hoffinan, R.V. (1981) " organic synthesis " is 60:121 (Org.Synth.)) according to the document step by anils.
The preparation of starting compound
The preparation method of thiadiazolyl group (rudimentary) alkane acid derivative is described in the following document: Teraji, Tsutomu; Sakane, Kazuo; Goto, Jiro. (FujisawaPharmaceutical Co., Ltd., Japan) in.Brit.UKPat.Appl. (1981), 13pp.CODEN:BAXXDU GB2068361 A 19810812 applications: GB 79-4460319791231.CAN 96:142862 AN 1982:142862.
In addition, according to " tetrahedron communication " (Tet.Lett.) 1993,34 (40), (5-amino-1,2,4-thiadiazoles-3-yl) methyl acetate of the N-protected of preparation described in the 6423-6426.The preparation method of general formula (IV) compound has been described in the document:
Wherein:
R '=H, X=H 2, and R=Me; Or
R '=OMe, X=O, NOH or NOMe, and R=Me, Et, Bn or Ph.
After the protecting group of removing on the exocyclic amino group, can described in above-mentioned sulphonamide coupling, make products therefrom participate in reaction.
As " bioorganic pesticide thing chemistry communication " (Bioorg.Med.Chem.Lett.) 1996,6 (13), compound (5-amino-1,3, the 4-thiadiazoles-2-yl) methyl acetate of the logical formula V of preparation described in the 1487-1490:
Figure A0282028000981
Can described in above-mentioned sulphonamide coupling, make the compound of general formula (VII) participate in reaction.
Above-mentionedly described various embodiments of the present invention, but those skilled in the art can carry out further local modification within the scope of the present invention.Amplitude of the present invention and scope should not limited by above-mentioned any typical embodiments, and only determine according to following claim and equivalency range thereof.

Claims (25)

1. compound or its salt, hydrate or the solvate of general formula (I):
Figure A028202800002C1
Wherein:
T is optional independently by [R] nThe aromatic ring or the hetero-aromatic ring that replace, wherein n is that integer and the R of 0-5 are hydrogen, aryl, heteroaryl, heterocycle, optional halogenated C 1-6-alkyl, optional halogenated C 1-6-alkoxyl group, C 1-6-alkyl sulphonyl, carboxyl, cyano group, nitro, halogen, single replacement or dibasic amine, optional single replacement or disubstituded amide, aryloxy, aryl sulfonyl, virtue amino, wherein aryl, heteroaryl and aryloxy residue and heterocycle are further optional independently of one another by C on one or more positions 1-6-acyl group, C 1-6-alkylthio, cyano group, nitro, hydrogen, halogen, optional halogenated C 1-6-alkyl, optional halogenated C 1-6-alkoxyl group, optional single replacement or disubstituded amide, (benzamido) methyl, carboxyl, 2-thienyl methylamino-or ({ [4-(2-oxyethyl group-2-oxoethyl)-1,3-thiazoles-2-yl] amino } carbonyl) replacement;
R 1Be hydrogen or C 1-6-alkyl;
A 1And A 2Be nitrogen-atoms or C-Z, condition is A 1And A 2Have different implications, wherein:
Z is selected from further optional independently of one another by hydrogen, C on one or more positions 1-6-alkyl, halogenated C 1-6-alkyl, halogen, C 1-6-alkoxyl group, nitro, C 1-6-alkoxy carbonyl, C 1-6Aromatic ring or hetero-aromatic ring that-alkyl sulphonyl, kharophen or aryloxy replace, wherein aryloxy is further optional on one or more positions is replaced by hydrogen and halogen independently of one another; Or Z is X-Y-R 2, wherein:
X is CH 2Or CO;
Y is CH 2, CO or singly-bound;
R 2Be selected from:
C 1-6-alkyl, azido-, arylthio, heteroarylthio, halogen, methylol, 2-hydroxyethylamino methyl, mesyloxy methyl, 3-oxo-4-morpholinyl methylene radical, C 1-6-alkoxy carbonyl, 5-methyl isophthalic acid, 3,4-oxadiazole-2-base;
NR 3R 4, R wherein 3And R 4Be selected from hydrogen, C independently of one another 1-6-alkyl, optional halogenated C 1-6-alkyl sulphonyl, C 1-6-alkoxyl group, 2-methoxy ethyl, 2-hydroxyethyl, 1-methylimidazolyl alkylsulfonyl, C 1-6-acyl group, cyclohexyl methyl, cyclopropane carbonyl, aryl, optional halogenated aryl sulfonyl, furyl carbonyl, tetrahydrochysene-2-furyl methyl, N-ethoxycarbonyl piperidyl or the C that is replaced by one or more aryl, heterocycle or heteroaryl 1-6-alkyl; Or
NR 3R 4Common expression heterocycle is, they are imidazoles, piperidines, tetramethyleneimine, piperazine, morpholine, oxygen azatropylidene, oxazole, thiomorpholine, 1,1-dioxy thiomorpholine, 2-(3,4-dihydro-2 (1H) isoquinolyl) or (1S, 4S)-and 2-oxa--5-azabicyclo [2.2.1] heptan-5-base, these heterocycles systems are optional by C 1-6-alkyl, C 1-6-acyl group, hydroxyl, oxygen, tert-butoxycarbonyl replace;
OCONR 3R 4, R wherein 3And R 4Be selected from hydrogen, C independently of one another 1-6-alkyl or form morpholinyl with the N-atom that they connected;
R 5O, wherein R 5Be hydrogen, optional halogenated C 1-6-alkyl, aryl, heteroaryl, C 1-6-acyl group, C 1-6-alkyl sulphonyl, aryl carbonyl, heteroaryl carbonyl, 2-methoxycarbonyl phenyl;
Condition is to work as:
A 1Be C-Z and A 2When being nitrogen-atoms, then T be not the phenyl that only on 4, replaced near the nitrogenous substituting group of phenyl ring by nitrogen-atoms, not be only on 2 by methyl substituted phenyl, not be only on 4 by methyl substituted phenyl and be not the phenyl that only on 4, is replaced by ethyl;
A 1Be nitrogen-atoms and A 2When being C-Z, then Z is not 2-furyl, 5-nitro-2-furyl, 2-thienyl, the optional phenyl that replaces, the benzyl of para-orientation;
A 1Be nitrogen-atoms and A 2Be that C-Z, X are CH 2, when Y is singly-bound, R then 2Not C 1-6-alkyl, methoxyl group, oxyethyl group, benzothiazole-2-base sulfenyl and NR 3R 4, R wherein 3And R 4Be selected from methyl, ethyl, n-propyl, normal-butyl;
A 1Be nitrogen-atoms and A 2Be that C-Z, X are CH 2, Y is CH 2The time, R then 2Not C 1-6-alkyl and NR 3R 4, R wherein 3And R 4Be selected from methyl, ethyl, n-propyl, normal-butyl.
2. the described compound of claim 1, wherein
T is selected from:
5-chloro-1,3-dimethyl-1H-pyrazoles-4-base; 4-chloro-2,3,1-Ben Bing oxadiazole base; 5-(dimethylamino)-1-naphthyl; 1-Methylimidazole-4-base; The 1-naphthyl; The 2-naphthyl; The 8-quinolyl;
By the thienyl of the one or more replacements in the following groups: (benzamido) methyl, bromine, chlorine, 3-isoxazolyl, 2-(methyl sulfane base)-4-pyrimidyl, 1-methyl-5-(trifluoromethyl) pyrazole-3-yl, phenyl sulfonyl, pyridyl;
By the phenyl of the one or more replacements in the following groups: kharophen, the 3-acetylamino phenyl, the 3-acetylphenyl, phenylamino, 1,3-benzo dioxole-5-base, the 2-benzofuryl, benzyl amino, 3, two (trifluoromethyl) phenyl of 5-, bromine, butoxy, carboxyl, chlorine, the 4-carboxyl phenyl, 3-chloro-2-cyano-benzene oxygen, the 4-chloro-phenyl-, 5-chloro-2-thienyl, cyano group, 3, the 4-dichlorophenyl, ({ [4-(2-oxyethyl group-2-oxoethyl)-1,3-thiazoles-2-yl] amino } carbonyl), fluorine, 5-fluoro-2-p-methoxy-phenyl, the 2-furyl, hydrogen, iodine, sec.-propyl, methylsulfonyl, methoxyl group, methyl, 4-methyl isophthalic acid-piperazinyl, 4-methyl isophthalic acid-piperidyl, 4-methyl sulfane base phenyl, 5-methyl-2-thienyl, the 4-morpholinyl, nitro, the 3-nitrophenyl, phenoxy group, phenyl, n-propyl, the 4-pyridyl, 3-pyridyl methylamino-, the 1-pyrrolidyl, the 2-thienyl, the 3-thienyl, 2-thienyl methylamino-, trifluoromethoxy, the 4-Trifluoromethoxyphen-l, trifluoromethyl; Or
R 1Be hydrogen or methyl;
A 1And A 2Be nitrogen-atoms or C-Z, condition is A 1And A 2Have different implications, wherein:
Z is selected from: 1-thionaphthene-3-base, 3-(2,5-dimethyl furan base), pyridyl; The optional thienyl that is replaced by one or more chlorine, methyl sulphonyl; Optional by the phenyl of the one or more replacements in ethoxy carbonyl, nitro, fluorine, methyl, methoxyl group, kharophen, chlorine, 4-chlorophenoxy, the trifluoromethyl; Or Z is X-Y-R 2, wherein
X is CH 2Or CO;
Y is CH 2, CO or singly-bound;
R 2Be selected from:
N-propyl, azido-, bromine, chlorine, 2-pyridyl sulfane base, 3-oxo-4-morpholinyl methylene radical, ethoxy carbonyl, 5-methyl isophthalic acid, 3,4-oxadiazole-2-base, methylol, 2-hydroxyethylamino methyl, mesyloxy methyl;
NR 3R 4, R wherein 3And R 4Be selected from ethanoyl, diphenyl-methyl, 1 independently of one another, 3-benzo dioxole-5-ylmethyl, benzyl, 3-chloro-2-aminomethyl phenyl alkylsulfonyl, cyclohexyl, cyclohexyl methyl, cyclopropane carbonyl, ethyl, 2-furyl carbonyl, 2-furyl methyl, hydrogen, 2-hydroxyethyl, 2-(1H-indol-3-yl) ethyl, sec.-propyl, methoxyl group, 2-methoxy ethyl, methyl, 4-(1-methylimidazolyl) alkylsulfonyl, methyl sulphonyl, phenyl, (1S)-styroyl, n-propyl, tetrahydrochysene-2-furyl methyl, trifluoromethyl sulfonyl, N-ethoxycarbonyl piperidyl; Or
NR 3R 4Common expression 4-ethanoyl piperazinyl, 4-tert-butoxycarbonyl piperazinyl, 2-(3,4-dihydro-2 (1H) isoquinolyl), (2R, 6S)-2, the 6-dimethylated morpholinyl, (2R)-2,4-dimethyl-1-piperazinyl, 2-hydroxyl-3-oxo morpholinyl, imidazolyl, 2-methyl-3-oxo morpholinyl, 4-methyl-2-oxo piperazinyl, 4-methylpiperazine base, morpholinyl, (1S, 4S)-2-oxa--5-aza-bicyclo [2.2.1] heptan-5-base, 2-oxoimidazolinium base, 3-oxo morpholinyl, 3-oxo-1,4-oxygen azatropylidene base, 2-Yang oxazolines base, piperazinyl, piperidyl, pyrrolidyl, pyrrolidone-base, thio-morpholinyl, 1,1-dioxy-thio-morpholinyl;
OCONR 3R 4, R wherein 3And R 4Be selected from ethyl, hydrogen independently of one another or form morpholinyl with the N-atom that they connected;
R 5O, wherein R 5Be ethanoyl, benzoyl, benzyl, ethyl, 2-fluoro ethyl, 2-furyl carbonyl, hydrogen, isobutyryl, sec.-propyl, methyl, 2-methoxycarbonyl benzyl, methyl sulphonyl, phenyl, positive propionyl, 3-pyridyl, 2,2, the 2-trifluoroethyl;
Condition is to work as;
A 1Be C-Z and A 2When being nitrogen-atoms, then T be not only at the phenyl that is replaced by nitro, 4-morpholinyl, 1-pyrrolidyl, kharophen, phenylamino, benzyl amino, 3-pyridyl methylamino-, 4-methyl isophthalic acid-piperazinyl, 4-methyl isophthalic acid-piperidyl or 2-thienyl methylamino-on 4, not be only on 2 by methyl substituted phenyl and be not only on 4 by methyl substituted phenyl;
A 1Be nitrogen-atoms and A 2When being C-Z, then Z is not a 2-thienyl and optional by the phenyl of the one or more replacements in ethoxy carbonyl, nitro, fluorine, methyl, methoxyl group, kharophen, chlorine, 4-chlorophenoxy, the trifluoromethyl;
A 1Be nitrogen-atoms and A 2Be that C-Z, X are CH 2, when Y is singly-bound, R then 2Not n-propyl, methoxyl group, oxyethyl group and NR 3R 4, R wherein 3And R 4Be selected from methyl, ethyl, n-propyl;
A 1Be nitrogen-atoms and A 2Be that C-Z, X are CH 2, Y is CH 2The time, R then 2Not n-propyl and NR 3R 4, R wherein 3And R 4Be selected from methyl, ethyl, n-propyl.
3. the described compound of claim 1-2 is selected from the group that following compounds is formed:
(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethyl acetate
(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) acetate
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino-1,3,4-thiadiazoles-2-yl)-the N-methylacetamide
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl)-the N-ethyl acetamide
2,5-two chloro-N-[5-(3-chlorothiophene-2-yl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) isopropyl acetate
3-chloro-N-[5-(2-hydroxyethyl)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
3-chloro-N-[5-(2-ethoxyethyl group)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl)-N, the N-diethyl acetamide
(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) methyl acetate
3-chloro-N-[5-(2-isopropoxy ethyl)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
3-chloro-N-[5-(2-methoxy ethyl)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
Methylsulfonic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethyl ester
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethanamide
3-chloro-N-{5-[2-(2-fluorine oxyethyl group) ethyl]-1,3,4-thiadiazoles-2-yl }-the 2-methyl benzenesulfonamide
3-chloro-2-methyl-N-{5-[2-(2,2, the 2-trifluoro ethoxy) ethyl]-1,3,4-thiadiazoles-2-yl } benzsulfamide
Acetate 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethyl ester
3-chloro-2-methyl-N-[5-(2-morpholine-4-base ethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-[5-(2-bromotrifluoromethane)-1,3,4-thiadiazoles-2-yl]-3-chloro-2-methyl benzenesulfonamide
Morpholine-4-formic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethyl ester
Diethylamino formic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethyl ester
Propionic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethyl ester
2 Methylpropionic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino-1,3,4-thiadiazoles-2-yl) ethyl ester
2-furancarboxylic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethyl ester
Phenylformic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethyl ester
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl)-N-methoxyl group-N-methylacetamide
Ethyl carbamic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethyl ester
N-[2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethyl]-the N-ethyl acetamide
3-chloro-2-methyl-N-[5-(2-oxo amyl group)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-{5-[2-(1,1-dioxy thiomorpholine-4-yl)-2-oxoethyl]-1,3,4-thiadiazoles-2-yl }-4-propylbenzene sulphonamide
2,4,6-three chloro-N-[5-(2-morpholine-4-base ethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
2,4-two chloro-N-[5-(2-morpholine-4-base ethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
3-chloro-2-methyl-N-{5-[2-(2-oxo morpholine-4-yl) ethyl]-1,3,4-thiadiazoles-2-yl } benzsulfamide
2,4-two chloro-6-methyl-N-[5-(2-morpholine-4-base ethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-[5-(2-morpholine-4-base ethyl)-1,3,4-thiadiazoles-2-yl]-4-propylbenzene sulphonamide
2,4-two chloro-6-methyl-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
2,4,6-three chloro-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-1,1 '-xenyl-4-sulphonamide
N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-4-propylbenzene sulphonamide
N-[5-(2-oxo-2-thiomorpholine-4-base ethyl)-1,3,4-thiadiazoles-2-yl]-1,1 '-xenyl-4-sulphonamide
N-[5-(2-oxo-2-thiomorpholine-4-base ethyl)-1,3,4-thiadiazoles-2-yl]-4-propylbenzene sulphonamide
2,4-two chloro-6-methyl-N-[5-(2-oxo-2-thiomorpholine-4-base ethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-[5-(2-oxo-2-piperidines-1-base ethyl)-1,3,4-thiadiazoles-2-yl]-1,1 '-xenyl-4-sulphonamide
N-[5-(2-oxo-2-piperidines-1-base ethyl)-1,3,4-thiadiazoles-2-yl]-4-propylbenzene sulphonamide
2,4-two chloro-6-methyl-N-[5-(2-oxo-2-piperidines-1-base ethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
2,4,6-three chloro-N-[5-(2-oxo-2-piperidines-1-base ethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) (oxygen) ethyl acetate
2-{5-[(1,1 '-xenyl-4-base alkylsulfonyl) amino]-1,3,4-thiadiazoles-2-yl }-N-ethyl-N-methylacetamide
N-ethyl-N-methyl-2-(5-{[(4-propyl group phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethanamide
2-(5-{[(2,4-two chloro-6-aminomethyl phenyls) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl)-N-ethyl-N-methylacetamide
N-ethyl-N-methyl-2-(5-{[(2,4,6-trichlorophenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethanamide
2,4,6-three chloro-N-[5-(2-oxo-2-thiomorpholine-4-base ethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
2-{5-[(1,1 '-xenyl-4-base alkylsulfonyl) amino]-1,3,4-thiadiazoles-2-yl }-N-sec.-propyl-N-methylacetamide
2-{5-[(1,1 '-xenyl-4-base alkylsulfonyl) amino]-1,3,4-thiadiazoles-2-yl }-N, the N-diethyl acetamide
N, N-diethyl-2-(5-{[(4-propyl group phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethanamide
2-(5-{[(2,4-two chloro-6-aminomethyl phenyls) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl)-N, the N-diethyl acetamide
N, N-diethyl-2-(5-{[(2,4,6-trichlorophenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethanamide
2-{5-[(1,1 '-xenyl-4-base alkylsulfonyl) amino]-1,3,4-thiadiazoles-2-yl }-N, N-di-isopropyl ethanamide
N, N-di-isopropyl-2-(5-{[(4-propyl group phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethanamide
2-(5-{[(2,4-two chloro-6-aminomethyl phenyls) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl)-N, N-di-isopropyl ethanamide
N, N-di-isopropyl-2-(5-{[(2,4,6-trichlorophenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethanamide
4-propyl group-N-(5-pyridin-3-yl-1,3,4-thiadiazoles-2-yl) benzsulfamide
3-chloro-N-[5-(5-chlorothiophene-2-yl)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
2,4,6-three chloro-N-(5-pyridin-3-yl-1,3,4-thiadiazoles-2-yl) benzsulfamide
2,4,6-three chloro-N-[5-(5-chlorothiophene-2-yl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-(5-pyridin-3-yl-1,3,4-thiadiazoles-2-yl)-1,1 '-xenyl-4-sulphonamide
2,4-two chloro-6-methyl-N-(5-pyridin-3-yl-1,3,4-thiadiazoles-2-yl) benzsulfamide
2,4-two chloro-N-[5-(5-chlorothiophene-2-yl)-1,3,4-thiadiazoles-2-yl]-the 6-methyl benzenesulfonamide
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl)-N, the N-Valpromide
3-chloro-2-methyl-N-[5-(2-oxo-2-piperazine-1-base ethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
2,4-two chloro-N-[5-(2,5-dimethyl-2-furyl)-1,3,4-thiadiazoles-2-yl]-the 6-methyl benzenesulfonamide
N-[5-(3-chlorothiophene-2-yl)-1,3,4-thiadiazoles-2-yl]-4-propylbenzene sulphonamide
3-chloro-N-[5-(3-chlorothiophene-2-yl)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
2,4,6-three chloro-N-[5-(3-chlorothiophene-2-yl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
2,4-two chloro-N-[5-(3-chlorothiophene-2-yl)-1,3,4-thiadiazoles-2-yl]-the 6-methyl benzenesulfonamide
4-bromo-2-methyl-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-2, two (trifluoromethyl) benzsulfamides of 4-
2-methyl-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-4-(trifluoromethoxy) benzsulfamide
N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-4-phenoxyphenylsulfonyhalides amine
4-chloro-2,6-dimethyl-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
2,4-two chloro-N-[5-(2-morpholine 4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
4-[(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethanoyl] piperazine-1-t-butyl formate
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl)-N,N-dimethylacetamide
3-chloro-2-methyl-N-{5-[2-(pyridin-3-yl oxygen base) ethyl]-1,3,4-thiadiazoles-2-yl } benzsulfamide
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl)-N-sec.-propyl-N-methylacetamide
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl)-N-ethyl-N-methylacetamide
3-chloro-2-methyl-N-[5-(2-oxo-2-thiomorpholine-4-base ethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
3-chloro-2-methyl-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl)-N, N-di-isopropyl ethanamide
3-chloro-2-methyl-N-[5-[2-oxo-2-tetramethyleneimine-1-base ethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
3-chloro-2-methyl-N-[5-(2-oxo-2-piperidines-1-base ethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
3-chloro-2-methyl-N-[5-(morpholine-4-ylmethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
3-chloro-N-{5-[2-(1H-imidazoles-1-yl) ethyl]-1,3,4-thiadiazoles-2-yl }-the 2-methyl benzenesulfonamide
2,4,5-three chloro-N-[5-(3-chlorothiophene-2-yl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
2,3,4-three chloro-N-[5-(3-chlorothiophene-2-yl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
4-bromo-N-[5-(3-chlorothiophene-2-yl)-1,3,4-thiadiazoles-2-yl]-2,5-difluoro benzsulfamide
4-bromo-5-chloro-N-[5-(3-chlorothiophene-2-yl)-1,3,4-thiadiazoles-2-yl] thiophene-2-sulphonamide
2,6-two chloro-N-[5-(3-chlorothiophene-2-yl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-[2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethyl] ethanamide
3-chloro-2-methyl-N-(5-{2-[(methyl sulphonyl) amino] ethyl }-1,3,4-thiadiazoles-2-yl) benzsulfamide
3-chloro-2-methyl-N-{5-[2-(3-oxo-1,4-azepine ring-4-in heptan yl) ethyl]-1,3,4-thiadiazoles-2-yl } benzsulfamide
3-chloro-2-methyl-N-{5-[2-(2-oxo-pyrrolidine-1-yl) ethyl]-1,3,4-thiadiazoles-2-yl } benzsulfamide
3-chloro-2-methyl-N-(5-{2-[methyl (methyl sulphonyl) amino] ethyl }-1,3,4-thiadiazoles-2-yl) benzsulfamide
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethyl]-N-methyl cyclopropane methane amide
3-chloro-2-methyl-N-{5-[2-(4-methyl-2-oxo piperazine-1-yl) ethyl]-1,3,4-thiadiazoles-2-yl } benzsulfamide
3-chloro-2-methyl-N-[5-(2-{[(trifluoromethyl) alkylsulfonyl] amino } ethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
2,4-two chloro-N-{5-[2-(3-oxo morpholine-4-yl) ethyl]-1,3,4-thiadiazoles-2-yl } benzsulfamide
2,4-two chloro-6-methyl-N-{5-[2-(3-oxo morpholine-4-yl) ethyl]-1,3,4-thiadiazoles-2-yl } benzsulfamide
2,4,6-three chloro-N-{5-[2-(3-oxo morpholine-4-yl) ethyl]-1,3,4-thiadiazoles-2-yl } benzsulfamide
4-(2-furyl)-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
5 '-fluoro-2 '-methoxyl group-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-1,1 '-xenyl-4-sulphonamide
4-(5-thiotolene-2-yl)-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
3 '-ethanoyl-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-1,1 '-xenyl-4-sulphonamide
N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-4 '-(trifluoromethoxy)-1,1 '-xenyl-4-sulphonamide
3 ', 4 '-two chloro-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-1,1 '-xenyl-4-sulphonamide
4-(1,3-benzo dioxole-5-yl)-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
4-(5-chlorothiophene-2-yl)-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-4-pyridin-4-yl benzsulfamide
N-[4 '-({ [5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl] amino } alkylsulfonyl)-1,1 '-xenyl-3-yl] ethanamide
N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-4-thiene-3-yl-benzsulfamide
N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-4-thiophene-2-base benzsulfamide
4 '-(methylthio group)-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-1,1 '-xenyl-4-sulphonamide
N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-3 ', 5 '-two (trifluoromethyl)-1,1 '-xenyl-4-sulphonamide
4 '-chloro-N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-1,1 '-xenyl-4-sulphonamide
N-[5-(2-morpholine-4-base-2-oxoethyl)-1,3,4-thiadiazoles-2-yl]-3 '-nitro-1,1 '-xenyl-4-sulphonamide
3-chloro-2-methyl-N-[5-(2-{ methyl [(trifluoromethyl) alkylsulfonyl] amino } ethyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-[2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) ethyl]-1-methyl isophthalic acid H-imidazoles-4-sulphonamide
3-chloro-N-{5-[2-(2-hydroxyl-3-oxo morpholine-4-yl) ethyl]-1,3,4-thiadiazoles-2-yl }-the 2-methyl benzenesulfonamide
4,5-two chloro-N-{5-[2-(3-oxo morpholine-4-yl) ethyl]-1,3,4-thiadiazoles-2-yl } thiophene-2-sulphonamide
N-{5-[2-(3-oxo morpholine-4-yl) ethyl]-1,3,4-thiadiazoles-2-yl }-4-phenoxyphenylsulfonyhalides amine
3-fluoro-N-{5-[2-(3-oxo morpholine-4-yl) ethyl]-1,3,4-thiadiazoles-2-yl } benzsulfamide
N-{5-[2-(3-oxo morpholine-4-yl) ethyl]-1,3,4-thiadiazoles-2-yl }-5-pyridine-2-base thiophene-2-sulphonamide
N-{2-chloro-4-[({5-[2-(3-oxo morpholine-4-yl) ethyl]-1,3,4-thiadiazoles-2-yl } amino) alkylsulfonyl] phenyl } ethanamide
(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethyl acetate
(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) acetate
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl)-the N-methylacetamide
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl)-the N-ethyl acetamide
2,5-two chloro-N-[3-(3-chlorothiophene-2-yl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) isopropyl acetate
3-chloro-N-[3-(2-hydroxyethyl)-1,2,4-thiadiazoles-5-yl]-the 2-methyl benzenesulfonamide
3-chloro-N-[3-(2-ethoxyethyl group)-1,2,4-thiadiazoles-5-yl]-the 2-methyl benzenesulfonamide
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl)-N, the N-diethyl acetamide
(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) methyl acetate
3-chloro-N-[3-(2-isopropoxy ethyl)-1,2,4-thiadiazoles-5-yl]-the 2-methyl benzenesulfonamide
3-chloro-N-[3-(2-methoxy ethyl)-1,2,4-thiadiazoles-5-yl]-the 2-methyl benzenesulfonamide
Methylsulfonic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethyl ester
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethanamide
3-chloro-N-{3-[2-(2-fluorine oxyethyl group) ethyl]-1,2,4-thiadiazoles-5-yl }-the 2-methyl benzenesulfonamide
3-chloro-2-methyl-N-{3-[2-(2,2, the 2-trifluoro ethoxy) ethyl]-1,2,4-thiadiazoles-5-yl } benzsulfamide
Acetate 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethyl ester
3-chloro-2-methyl-N-[3-(2-morpholine-4-base ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
N-[3-(2-bromotrifluoromethane)-1,2,4-thiadiazoles-5-yl]-3-chloro-2-methyl benzenesulfonamide
Morpholine-4-formic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethyl ester
Diethylamino formic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethyl ester
Propionic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethyl ester
2 Methylpropionic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethyl ester
2-furancarboxylic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethyl ester
Phenylformic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethyl ester
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl)-N-methoxyl group-N-methylacetamide
3-chloro-N-{3-[2-(diethylin) ethyl]-1,2,4-thiadiazoles-5-yl }-the 2-methyl benzenesulfonamide
Ethyl carbamic acid 2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethyl ester
N-[2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethyl]-the N-ethyl acetamide
3-chloro-2-methyl-N-[3-(2-oxo amyl group)-1,2,4-thiadiazoles-5-yl] benzsulfamide
N-{3-[2-(1,1-dioxy thiomorpholine-4-yl)-2-oxoethyl]-1,2,4-thiadiazoles-5-yl }-4-propylbenzene sulphonamide
2,4,6-three chloro-N-[3-(2-morpholine-4-base ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
2,4-two chloro-N-[3-(2-morpholine-4-base ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
3-chloro-2-methyl-N-{3-[2-(3-oxo morpholine-4-yl) ethyl]-1,2,4-thiadiazoles-5-yl } benzsulfamide
2,4-two chloro-6-methyl-N-[3-(2-morpholine-4-base ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
N-[3-(2-morpholine-4-base ethyl)-1,2,4-thiadiazoles-5-yl]-4-propylbenzene sulphonamide
2,4-two chloro-6-methyl-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
2,4,6-three chloro-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-1,1 '-xenyl-4-sulphonamide
N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-4-propylbenzene sulphonamide
N-[3-(2-oxygen-2-thiomorpholine-4-base ethyl)-1,2,4-thiadiazoles-5-yl]-1,1 '-xenyl-4-sulphonamide
N-[3-(2-oxo-2-thiomorpholine-4-base ethyl)-1,2,4-thiadiazoles-5-yl]-4-propylbenzene sulphonamide
2,4-two chloro-6-methyl-N-[3-(2-oxo-2-thiomorpholine-4-base ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
N-[3-(2-oxo-2-piperidines-1-base ethyl)-1,2,4-thiadiazoles-5-yl]-1,1 '-xenyl-4-sulphonamide
N-[3-(2-oxo-2-piperidines-1-base ethyl)-1,2,4-thiadiazoles-5-yl]-4-propylbenzene sulphonamide
2,4-two chloro-6-methyl-N-[3-(2-oxo-2-piperidines-1-base ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
2,4,6-three chloro-N-[3-(2-oxo-2-piperidines-1-base ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
N-(3-phenyl-1,2,4-thiadiazoles-5-yl)-4-propylbenzene sulphonamide
(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) (oxygen) ethyl acetate
3-chloro-2-methyl-N-(3-phenyl-1,2,4-thiadiazoles-5-yl) benzsulfamide
3-chloro-N-[3-(4-fluoro-3-aminomethyl phenyl)-1,2,4-thiadiazoles-5-yl]-the 2-methyl benzenesulfonamide
2,4,6-three chloro-N-(3-phenyl-1,2,4-thiadiazoles-5-yl) benzsulfamide
N-(3-phenyl-1,2,4-thiadiazoles-5-yl)-1,1 '-xenyl-4-sulphonamide
2,4-two chloro-6-methyl-N-(3-phenyl-1,2,4-thiadiazoles-5-yl) benzsulfamide
2-{5-[(1,1 '-xenyl-4-base alkylsulfonyl) amino]-1,2,4-thiadiazoles-3-yl }-N-ethyl-N-methylacetamide
N-ethyl-N-methyl-2-(5-{ (4-propyl group phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethanamide
2-(5-{[(2,4-two chloro-6-aminomethyl phenyls) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl)-N-ethyl-N-methylacetamide
N-ethyl-N-methyl-2-(5-{[(2,4,6-trifluorophenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethanamide
2,4,6-three chloro-N-[3-(2-oxo-2-thiomorpholine-4-base ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
2-{5-[(1,1 '-xenyl-4-base alkylsulfonyl) amino]-1,2,4-thiadiazoles-3-yl }-N-sec.-propyl-N-methylacetamide
2-{5-[(1,1 '-xenyl-4-base alkylsulfonyl) amino]-1,2,4-thiadiazoles-3-yl }-N, the N-diethyl acetamide
N, N-diethyl-2-(5-{[(4-propyl group phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethanamide
2-(5-{[(2,4-two chloro-6-aminomethyl phenyls) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl }-N, the N-diethyl acetamide
N, N-diethyl-2-(5-{[(2,4,6-trifluorophenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethanamide
2-{5-[(1,1 '-xenyl-4-base alkylsulfonyl) amino]-1,2,4-thiadiazoles-3-yl }-N, N-di-isopropyl ethanamide
N, N-di-isopropyl-2-{5-[(4-propyl group phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethanamide
2-(5-{[(2,4-two chloro-6-aminomethyl phenyls) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl)-N, N-di-isopropyl ethanamide
N, N-di-isopropyl-2-(5-{[(2,4,6-trichlorophenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethanamide
N-[4-(5-{[(4-propyl group phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) phenyl] ethanamide
4-propyl group-N-(3-pyridin-3-yl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
N-[3-(2-chloro-5-nitrophenyl)-1,2,4-thiadiazoles-5-yl]-4-propylbenzene sulphonamide
N-[3-(2-chloro-phenyl-)-1,2,4-thiadiazoles-5-yl]-4-propylbenzene sulphonamide
3-chloro-N-[3-(2-chloro-5-nitrophenyl)-1,2,4-thiadiazoles-5-yl]-the 2-methyl benzenesulfonamide
3-chloro-N-[3-(5-chlorothiophene-2-yl)-1,2,4-thiadiazoles-5-yl]-the 2-methyl benzenesulfonamide
3-chloro-N-[3-(2-chloro-phenyl-)-1,2,4-thiadiazoles-5-yl]-the 2-methyl benzenesulfonamide
N-[4-(5-{[(2,4,6-trifluorophenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) phenyl] ethanamide
2,4,6-three chloro-N-[3-pyridin-3-yls-1,2,4-thiadiazoles-5-yl) benzsulfamide
2,4,6-three chloro-N-[3-(2-chloro-5-nitrophenyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
2,4,6-three chloro-N-[3-(5-chlorothiophene-2-yl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
2,4,6-three chloro-N-[3-(2-chloro-phenyl-)-1,2,4-thiadiazoles-5-yl] benzsulfamide
N-(4-{5-[(1,1 '-xenyl-4-base alkylsulfonyl) amino]-1,2,4-thiadiazoles-3-yl } phenyl) ethanamide
N-(3-pyridin-3-yl-1,2,4-thiadiazoles-5-yl)-1,1 '-xenyl-4-sulphonamide
N-[3-(2-chloro-5-nitrophenyl)-1,2,4-thiadiazoles-5-yl]-1,1 '-xenyl-4-sulphonamide
N-[3-(2-chloro-phenyl-)-1,2,4-thiadiazoles-5-yl]-1,1 '-xenyl-4-sulphonamide
N-(4-{5-[(2,4-two chloro-6-aminomethyl phenyls) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) phenyl] ethanamide
2,4-two chloro-6-methyl-N-(3-pyridin-3-yl-1,2,4-thiadiazoles-5-yl) benzsulfamide
2,4-two chloro-N-[3-(2-chloro-5-nitrophenyl)-1,2,4-thiadiazoles-5-yl]-the 6-methyl benzenesulfonamide
2,4-two chloro-N-[3-(5-chlorothiophene-2-yl)-1,2,4-thiadiazoles-5-yl]-the 6-methyl benzenesulfonamide
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl)-N, the N-Valpromide
3-chloro-2-methyl-N-[3-(2-oxo-2-piperazine-1-base ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
2,4-two chloro-N-[3-(2,5-dimethyl-3-furyl)-1,2,4-thiadiazoles-5-yl]-the 6-methyl benzenesulfonamide
N-[3-(3-chlorothiophene-2-yl)-1,2,4-thiadiazoles-5-yl]-4-propylbenzene sulphonamide
3-chloro-N-[3-(3-chlorothiophene-2-yl)-1,2,4-thiadiazoles-5-yl]-the 2-methyl benzenesulfonamide
2,4,6-three chloro-N-[3-(3-chlorothiophene-2-yl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
2,4-two chloro-N-[3-chlorothiophene-2-yls)-1,2,4-thiadiazoles-5-yl]-the 6-methyl benzenesulfonamide
2,4-two chloro-N-[3-(2-chloro-phenyl-)-1,2,4-thiadiazoles-5-yl]-the 6-methyl benzenesulfonamide
4-bromo-2-methyl-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-2, two (trifluoromethyl) benzsulfamides of 4-
2-methyl-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-4-(trifluoromethoxy) benzsulfamide
N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-4-phenoxyphenylsulfonyhalides amine
4-chloro-2,6-dimethyl-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
2,4-two chloro-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
4-[(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino-1,2,4-thiadiazoles-3-yl) ethanoyl] piperazine-1-t-butyl formate
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl)-N,N-dimethylacetamide
3-chloro-2-methyl-N-{3-[2-(pyridin-3-yl oxygen base) ethyl]-1,2,4-thiadiazoles-5-yl } benzsulfamide
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl)-N-sec.-propyl-N-methylacetamide
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl)-N-ethyl-N-methylacetamide
3-chloro-2-methyl-N-[3-(2-oxo-2-thiomorpholine-4-base ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
3-chloro-2-methyl-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl)-N, N-di-isopropyl ethanamide
3-chloro-2-methyl-N-[3-(2-oxo-2-tetramethyleneimine-1-base ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
3-chloro-2-methyl-N-[3-(2-oxo-2-tetramethyleneimine-1-base ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
3-chloro-2-methyl-N-[3-(morpholine-4-ylmethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
3-chloro-N-{3-[2-(1H-imidazoles-1-yl) ethyl]-1,2,4-thiadiazoles-5-yl }-the 2-methyl benzenesulfonamide
2,4,5-three chloro-N-[3-(3-chlorothiophene-2-yl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
2,3,4-three chloro-N-[3-(3-chlorothiophene-2-yl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
2,3,4-three chloro-N-[3-(2-chloro-phenyl-)-1,2,4-thiadiazoles-5-yl] benzsulfamide
N-[4-(5-{[(4-bromo-2,5-difluorophenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) phenyl] ethanamide
4-bromo-N-[3-(3-chlorothiophene-2-yl)-1,2,4-thiadiazoles-5-yl]-2,5-difluoro benzsulfamide
4,5-two chloro-N-[3-(2-chloro-phenyl-)-1,2,4-thiadiazoles-5-yl] thiophene-2-sulphonamide
N-[4-(5-{[(2,4,5-trichlorophenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) phenyl] ethanamide
4-bromo-5-chloro-N-[3-(3-chlorothiophene-2-yl)-1,2,4-thiadiazoles-5-yl] thiophene-2-sulphonamide
3-bromo-5-chloro-N-[3-(2-chloro-phenyl-)-1,2,4-thiadiazoles-5-yl] thiophene-2-sulphonamide
N-[4-(5-{[(2,6-dichlorophenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) phenyl] ethanamide
2,6-two chloro-N-[3-(3-chlorothiophene-2-yl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
N-[2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethyl] ethanamide
3-chloro-2-methyl-N-(3-{2-[(methyl sulphonyl) amino] ethyl }-1,2,4-thiadiazoles-5-yl) benzsulfamide
3-chloro-2-methyl-N-{3-[2-(3-oxo-1,4-azepine ring-4-in heptan yl) ethyl]-1,2,4-thiadiazoles-5-yl } benzsulfamide
3-chloro-2-methyl-N-{3-[2-(2-oxo-pyrrolidine-1-yl) ethyl]-1,2,4-thiadiazoles-5-yl } benzsulfamide
2,3,4-three chloro-N-{3-[2,6-two chloro-4-(trifluoromethyl) phenyl]-1,2,4-thiadiazoles-5-yl } benzsulfamide
N-[3-(2-chloro-6-fluorophenyl)-1,2,4-thiadiazoles-5-yl]-4-propylbenzene sulphonamide
4-bromo-N-{3-[2,6-two chloro-4-(trifluoromethyl) phenyl]-1,2,4-thiadiazoles-5-yl }-2,5-difluoro benzsulfamide
4,5-two chloro-N-[3-(2-chloro-6-fluorophenyl)-1,2,4-thiadiazoles-5-yl] thiophene-2-sulphonamide
4-bromo-5-chloro-N-{3-[2,6-two chloro-4-(trifluoromethyl) phenyl]-1,2,4-thiadiazoles-5-yl } thiophene-2-sulphonamide
2,4-two chloro-N-[3-(2-chloro-6-fluorophenyl)-1,2,4-thiadiazoles-5-yl]-the 6-methyl benzenesulfonamide
4-bromo-N-[3-(2-chloro-6-fluorophenyl)-1,2,4-thiadiazoles-5-yl]-the 2-methyl benzenesulfonamide
3-chloro-2-methyl-N-(3-{2-[methyl (methyl sulphonyl) amino] ethyl }-1,2,4-thiadiazoles-5-yl) benzsulfamide
N-[2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethyl]-N-methyl cyclopropane methane amide
3-chloro-2-methyl-N-{3-[2-(4-methyl-2-oxo piperazine-1-yl) ethyl]-1,2,4-thiadiazoles-5-yl } benzsulfamide
3-chloro-2-methyl-N-[3-(2-{[(trifluoromethyl) alkylsulfonyl] amino } ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
N-[4-(5-{[(4-bromo-5-chlorothiophene-2-yl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) phenyl] ethanamide
2,4-two chloro-N-{3-[2-(3-oxo morpholine-4-yl) ethyl]-1,2,4-thiadiazoles-5-yl } benzsulfamide
2,4-two chloro-6-methyl-N-{3-[2-(3-oxo morpholine-4-yl) ethyl]-1,2,4-thiadiazoles-5-yl } benzsulfamide
2,4,6-three chloro-N-{3-[2-(3-oxo morpholine-4-yl) ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
4-(2-furyl)-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
5 '-fluoro-2 '-methoxyl group-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-1,1 '-xenyl-4-sulphonamide
4-(5-thiotolene-2-yl)-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
3 '-ethanoyl-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-1,1 '-xenyl-4-sulphonamide
N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-4 '-(trifluoromethoxy)-1,1 '-xenyl-4-sulphonamide
3 ', 4 '-two chloro-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-1,1 '-xenyl-4-sulphonamide
4-(1,3-benzo dioxole-5-yl)-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
4-(5-chlorothiophene-2-yl)-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-4-pyridin-4-yl benzsulfamide
N-[4 '-([3-(2-morpholine-4-base-2-oxoethyl-1,2,4-thiadiazoles-5-yl] amino } alkylsulfonyl)-1,1 '-xenyl-3-yl] ethanamide
N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-4-thiene-3-yl-benzsulfamide
N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-4-thiophene-2-base benzsulfamide
4 '-(methylthio group)-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-1,1 '-xenyl-4-sulphonamide
N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-3 ', 5 '-two (trifluoromethyl)-1,1 '-xenyl-4-sulphonamide
4 '-chloro-N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-1,1 '-xenyl-4-sulphonamide
N-[3-(2-morpholine-4-base-2-oxoethyl)-1,2,4-thiadiazoles-5-yl]-3 '-nitro-1,1 '-xenyl-4-sulphonamide
3-chloro-2-methyl-N-[3-(2-{ methyl [(trifluoromethyl) alkylsulfonyl] amino } ethyl)-1,2,4-thiadiazoles-5-yl] benzsulfamide
N-[2-(5-{[(3-chloro-2-aminomethyl phenyl) alkylsulfonyl] amino }-1,2,4-thiadiazoles-3-yl) ethyl]-1-methyl isophthalic acid H-imidazoles-4-sulphonamide
3-chloro-N-{3-[2-(2-hydroxyl-3-oxo morpholine-4-yl) ethyl]-1,2,4-thiadiazoles-5-yl)-2-sulfonyloxy methyl amine
4,5-two chloro-N-{3-[2-(3-oxo morpholine-4-yl) ethyl]-1,2,4-thiadiazoles-5-yl } thiophene-2-sulphonamide
N-{3-[2-(3-oxo morpholine-4-yl) ethyl]-1,2,4-thiadiazoles-5-yl }-4-phenoxyphenylsulfonyhalides amine
3-fluoro-N-{3-[2-(3-oxo morpholine-4-yl) ethyl]-1,2,4-thiadiazoles-5-yl } benzsulfamide
N-{3-[2-(3-oxo morpholine-4-yl) ethyl]-1,2,4-thiadiazoles-5-yl }-5-pyridine-2-base thiophene-2-sulphonamide
N-{2-chloro-4-[({3-[2-(3-oxo morpholine-4-yl) ethyl]-1,2,4-thiadiazoles-5-yl } amino) alkylsulfonyl] phenyl } ethanamide.
4. the compound of claim 1-3 with general formula (II):
Wherein, T, R 1With Z in the claim 1-2 definition.
5. the compound of claim 1-3 with general formula (III):
Wherein, T, R 1With Z in the claim 1-2 definition.
6. any one compound among the claim 1-5 is used for medicinal application.
7. treatment or prevent diabetes, X syndrome, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertension, osteoporosis, dementia, dysthymia disorders, virus disease or inflammation illness and can not cause hypoglycemia and realize immunoregulatory method, described method comprises the step of general formula (I) compound or its salt, hydrate or the solvate of the Mammals significant quantity that needs this class treatment, and the structural formula of its formula of (I) compound is as follows:
Figure A028202800024C2
Wherein
T is optional independently by [R] nThe aromatic ring or the hetero-aromatic ring that replace, wherein n is that integer and the R of 0-5 are hydrogen, aryl, heteroaryl, heterocycle, optional halogenated C 1-6-alkyl, optional halogenated C 1-6-alkoxyl group, C 1-6-alkyl sulphonyl, carboxyl, cyano group, nitro, halogen, optional single replacement or dibasic amine, optional single replacement or disubstituded amide, aryloxy, aryl sulfonyl, fragrant amino, wherein aryl, heteroaryl and aryloxy residue and heterocycle are further optional independently of one another by C on one or more positions 1-6-acyl group, C 1-6-alkylthio, cyano group, nitro, hydrogen, halogen, optional halogenated C 1-6-alkyl, optional halogenated C 1-6-alkoxyl group, optional single replacement or disubstituded amide, (benzamido) methyl, carboxyl, 2-thienyl methylamino-or ({ [4-(2-oxyethyl group-2-oxoethyl)-1,3-thiazoles-2-yl] amino } carbonyl) replacement;
R 1Be hydrogen or C 1-6-alkyl;
A 1And A 2Be nitrogen-atoms or C-Z, condition is A 1And A 2Have different implications, wherein:
Z is selected from further optional independently of one another by hydrogen, C on one or more positions 1-6-alkyl, halogenated C 1-6-alkyl, halogen, C 1-6-alkoxyl group, nitro, C 1-6-alkoxy carbonyl, C 1-6Aromatic ring or hetero-aromatic ring that-alkyl sulphonyl, kharophen or aryloxy replace, wherein aryloxy is further optional on one or more positions is replaced by hydrogen and halogen independently of one another; Or Z is X-Y-R 2, wherein:
X is CH 2Or CO;
Y is CH 2, CO or singly-bound;
R 2Be selected from:
C 1-6-alkyl, azido-, arylthio, heteroarylthio, halogen, methylol, 2-hydroxyethylamino methyl, mesyloxy methyl, 3-oxo-4-morpholinyl methylene radical, C 1-6-alkoxy carbonyl, 5-methyl isophthalic acid, 3,4-oxadiazole-2-base;
NR 3R 4, R wherein 3And R 4Be selected from hydrogen, C independently of one another 1-6-alkyl, optional halogenated C 1-6-alkyl sulphonyl, C 1-6-alkoxyl group, 2-methoxy ethyl, 2-hydroxyethyl, 1-methylimidazolyl alkylsulfonyl, C 1-6-acyl group, cyclohexyl methyl, cyclopropane carbonyl, aryl, optional halogenated aryl sulfonyl, furyl carbonyl, tetrahydrochysene-2-furyl methyl, N-ethoxycarbonyl piperidyl or the C that is replaced by one or more aryl, heterocycle or heteroaryl 1-6-alkyl; Or
NR 3R 4Common expression heterocycle is, they are imidazoles, piperidines, tetramethyleneimine, piperazine, morpholine, oxygen azatropylidene, oxazole, thiomorpholine, 1,1-dioxy thiomorpholine, 2-(3,4-dihydro-2 (1H) isoquinolyl) or (1S, 4S)-and 2-oxa--5-azabicyclo [2.2.1] heptan-5-base, these heterocycles systems are optional by C 1-6-alkyl, C 1-6-acyl group, hydroxyl, oxygen, tert-butoxycarbonyl replace;
OCONR 3R 4, R wherein 3And R 4Be selected from hydrogen, C independently of one another 1-6-alkyl or form morpholinyl with the N-atom that they connected;
R 5O, wherein R 5Be hydrogen, optional halogenated C 1-6-alkyl, aryl, heteroaryl, C 1-6-acyl group, C 1-6-alkyl sulphonyl, aryl carbonyl, heteroaryl carbonyl, 2-methoxycarbonyl phenyl.
8. the described method of claim 7, wherein immunomodulatory is selected from tuberculosis, leprosy and psoriasis.
9. the described method of claim 7-8, wherein
T is selected from:
5-chloro-1,3-dimethyl-1H-pyrazoles-4-base; 4-chloro-2,3,1-Ben Bing oxadiazole base; 5-(dimethylamino)-1-naphthyl; 1-Methylimidazole-4-base; The 1-naphthyl; The 2-naphthyl; The 8-quinolyl;
By the thienyl of the one or more replacements in the following groups: (benzamido) methyl, bromine, chlorine, 3-isoxazolyl, 2-(methyl sulfane base)-4-pyrimidyl, 1-methyl-5-(trifluoromethyl) pyrazole-3-yl, phenyl sulfonyl, pyridyl;
By the phenyl of the one or more replacements in the following groups: kharophen, the 3-acetylamino phenyl, the 3-acetylphenyl, phenylamino, 1,3-benzo dioxole-5-base, the 2-benzofuryl, benzyl amino, 3, two (trifluoromethyl) phenyl of 5-, bromine, butoxy, carboxyl, chlorine, the 4-carboxyl phenyl, 3-chloro-2-cyano-benzene oxygen, the 4-chloro-phenyl-, 5-chloro-2-thienyl, cyano group, 3, the 4-dichlorophenyl, ({ [4-(2-oxyethyl group-2-oxoethyl)-1,3-thiazoles-2-yl] amino } carbonyl), fluorine, 5-fluoro-2-p-methoxy-phenyl, the 2-furyl, hydrogen, iodine, sec.-propyl, methylsulfonyl, methoxyl group, methyl, 4-methyl isophthalic acid-piperazinyl, 4-methyl isophthalic acid-piperidyl, 4-methyl sulfane base phenyl, 5-methyl-2-thienyl, the 4-morpholinyl, nitro, the 3-nitrophenyl, phenoxy group, phenyl, n-propyl, the 4-pyridyl, 3-pyridyl methylamino-, the 1-pyrrolidyl, the 2-thienyl, the 3-thienyl, 2-thienyl methylamino-, trifluoromethoxy, the 4-Trifluoromethoxyphen-l, trifluoromethyl; Or
R 1Be hydrogen or methyl;
A 1And A 2Be nitrogen-atoms or C-Z, condition is A 1And A 2Have different implications, wherein:
Z is selected from:
1-thionaphthene-3-base, 3-(2,5-dimethyl furan base), pyridyl;
The optional thienyl that is replaced by one or more chlorine, methyl sulphonyl;
Optional by the phenyl of the one or more replacements in ethoxy carbonyl, nitro, fluorine, methyl, methoxyl group, kharophen, chlorine, 4-chlorophenoxy, the trifluoromethyl;
Or Z is X-Y-R 2, wherein
X is CH 2Or CO;
Y is CH 2, CO or singly-bound;
R 2Be selected from:
N-propyl, azido-, bromine, chlorine, 2-pyridyl sulfane base, 3-oxo-4-morpholinyl methylene radical, ethoxy carbonyl, 5-methyl isophthalic acid, 3,4-oxadiazole-2-base, methylol, 2-hydroxyethylamino methyl, mesyloxy methyl;
NR 3R 4, R wherein 3And R 4Be selected from ethanoyl, diphenyl-methyl, 1 independently of one another, 3-benzo dioxole-5-ylmethyl, benzyl, 3-chloro-2-aminomethyl phenyl alkylsulfonyl, cyclohexyl, cyclohexyl methyl, cyclopropane carbonyl, ethyl, 2-furyl carbonyl, 2-furyl methyl, hydrogen, 2-hydroxyethyl, 2-(1H-indol-3-yl) ethyl, sec.-propyl, methoxyl group, 2-methoxy ethyl, methyl, 4-(1-methylimidazolyl) alkylsulfonyl, methyl sulphonyl, phenyl, (1S)-styroyl, n-propyl, tetrahydrochysene-2-furyl methyl, trifluoromethyl sulfonyl, N-ethoxycarbonyl piperidyl; Or
NR 3R 4Common expression 4-ethanoyl piperazinyl, 4-tert-butoxycarbonyl piperazinyl, 2-(3,4-dihydro-2 (1H) isoquinolyl), (2R, 6S)-2, the 6-dimethylated morpholinyl, (2R)-2,4-dimethyl-1-piperazinyl, 2-hydroxyl-3-oxo morpholinyl, imidazolyl, 2-methyl-3-oxo morpholinyl, 4-methyl-2-oxo piperazinyl, 4-methylpiperazine base, morpholinyl, (1S, 4S)-2-oxa--5-aza-bicyclo [2.2.1] heptan-5-base, 2-oxoimidazolinium base, 3-oxo morpholinyl, 3-oxo-1,4-oxygen azatropylidene base, 2-Yang oxazolines base, piperazinyl, piperidyl, pyrrolidyl, pyrrolidone-base, thio-morpholinyl, 1,1-dioxy-thio-morpholinyl;
OCONR 3R 4, R wherein 3And R 4Be selected from ethyl, hydrogen independently of one another or form morpholinyl with the N-atom that they connected;
R 5O, wherein R 5Be ethanoyl, benzoyl, benzyl, ethyl, 2-fluoro ethyl, 2-furyl carbonyl, hydrogen, isobutyryl, sec.-propyl, methyl, 2-methoxycarbonyl benzyl, methyl sulphonyl, phenyl, positive propionyl, 3-pyridyl, 2,2, the 2-trifluoroethyl.
10. the described method of claim 7-9, wherein said compound is selected from compound and the following compounds described in claim 3:
3-chloro-N-{5-[2-(diethylamino) ethyl]-1,3,4-thiadiazoles-2-yl }-the 2-methyl benzenesulfonamide
N-(5-phenyl-1,3,4-thiadiazoles-2-yl)-4-propylbenzene sulphonamide
3-chloro-2-methyl-N-(5-phenyl-1,3,4-thiadiazoles-2-yl) benzsulfamide
3-chloro-N-[5-(4-fluoro-3-aminomethyl phenyl)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
2,4,6-three chloro-N-(5-phenyl-1,3,4-thiadiazoles-2-yl) benzsulfamide
N-(5-phenyl-1,3,4-thiadiazoles-2-yl)-1,1 '-xenyl-4-sulphonamide
2,4-two chloro-6-methyl-N-(5-phenyl-1,3,4-thiadiazoles-2-yl) benzsulfamide
N-[4-(5-{[(4-propyl group phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
N-[5-(2-chloro-5-nitrophenyl)-1,3,4-thiadiazoles-2-yl]-4-propylbenzene sulphonamide
N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl]-4-propylbenzene sulphonamide
3-chloro-N-[5-(2-chloro-5-nitrophenyl)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
3-chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
N-[4-(5-{[(2,4,6-trichlorophenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
2,4,6-three chloro-N-[5-(2-chloro-5-nitrophenyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
2,4,6-three chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-(4-{5-[(1,1 '-xenyl-4-base alkylsulfonyl) amino]-1,3,4-thiadiazoles-2-yl } phenyl) the ethanamide scope
N-[5-(2-chloro-5-nitrophenyl)-1,3,4-thiadiazoles-2-yl]-1,1 '-xenyl-4-sulphonamide
N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl]-1,1 '-xenyl-4-sulphonamide
N-[4-(5-{[(2,4-two chloro-6-aminomethyl phenyls) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
2,4-two chloro-N-[5-(2-chloro-5-nitrophenyl)-1,3,4-thiadiazoles-2-yl]-the 6-methyl benzenesulfonamide
2,4-two chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl]-the 6-methyl benzenesulfonamide
2,3,4-three chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-[4-(5-{[(4-bromo-2,5-difluorophenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
4,5-two chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl] thiophene-2-sulphonamide
N-[4-(5-{[(2,4,5-trichlorophenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
3-bromo-5-chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl] thiophene-2-sulphonamide
N-[4-(5-{[(2,6-dichlorophenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
2,3,4-three chloro-N-{5-[2,6-two chloro-4-(trifluoromethyl) phenyl]-1,3,4-thiadiazoles-2-yl } benzsulfamide
N-[5-(2-chloro-6-fluorophenyl)-1,3,4-thiadiazoles-2-yl]-4-propylbenzene sulphonamide
4-bromo-N-{5-[2,6-two chloro-4-(trifluoromethyl) phenyl]-1,3,4-thiadiazoles-2-yl }-2,5-difluoro benzsulfamide
4,5-two chloro-N-[5-(2-chloro-6-fluorophenyl)-1,3,4-thiadiazoles-2-yl] thiophene-2-sulphonamide
4-bromo-5-chloro-N-{5-[2,6-two chloro-4-(trifluoromethyl) phenyl]-1,3,4-thiadiazoles-2-yl } thiophene-2-sulphonamide
2,4-two chloro-N-[5-(2-chloro-6-fluorophenyl)-1,3,4-thiadiazoles-2-yl]-the 6-methyl benzenesulfonamide
4-bromo-N-[5-(2-chloro-6-fluorophenyl)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
N-[4-(5-{[(4-bromo-5-chlorothiophene-2-yl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide.
11. suppress the method for people 11-beta-hydroxysteroid dehydrogenase 1 type enzyme, the step of general formula (I) compound or its salt, hydrate or the solvate of experimenter's significant quantity that this method bag needs, the structural formula of its formula of (I) compound is as follows:
Figure A028202800029C1
Wherein
T is optional independently by [R] nThe aromatic ring or the hetero-aromatic ring that replace, wherein n is that integer and the R of 0-5 are hydrogen, aryl, heteroaryl, heterocycle, optional halogenated C 1-6-alkyl, optional halogenated C 1-6-alkoxyl group, C 1-6-alkyl sulphonyl, carboxyl, cyano group, nitro, halogen, optional single replacement or dibasic amine, optional single replacement or disubstituded amide, aryloxy, aryl sulfonyl, fragrant amino, wherein aryl, heteroaryl and aryloxy residue and heterocycle are further optional independently of one another by C on one or more positions 1-6-acyl group, C 1-6-alkylthio, cyano group, nitro, hydrogen, halogen, optional halogenated C 1-6-alkyl, optional halogenated C 1-6-alkoxyl group, optional single replacement or disubstituded amide, (benzamido) methyl, carboxyl, 2-thienyl methylamino-or ({ [4-(2-oxyethyl group-2-oxoethyl)-1,3-thiazoles-2-yl] amino } carbonyl) replacement;
R 1Be hydrogen or C 1-6-alkyl;
A 1And A 2Be nitrogen-atoms or C-Z, condition is A 1And A 2Have different implications, wherein:
Z is selected from further optional independently of one another by hydrogen, C on one or more positions 1-6-alkyl, halo C 1-6-alkyl, halogen, C 1-6-alkoxyl group, nitro, C 1-6-alkoxy carbonyl, C 1-6Aromatic ring or hetero-aromatic ring that-alkyl sulphonyl, kharophen or aryloxy replace, wherein aryloxy is further optional on one or more positions is replaced by hydrogen and halogen independently of one another; Or Z is X-Y-R 2, wherein:
X is CH 2Or CO;
Y is CH 2, CO or singly-bound;
R 2Be selected from:
C 1-6-alkyl, azido-, arylthio, heteroarylthio, halogen, methylol, 2-hydroxyethylamino methyl, mesyloxy methyl, 3-oxo-4-morpholinyl methylene radical, C 1-6-alkoxy carbonyl, 5-methyl isophthalic acid, 3,4-oxadiazole-2-base;
NR 3R 4, R wherein 3And R 4Be selected from hydrogen, C independently of one another 1-6-alkyl, optional halo C 1-6-alkyl sulphonyl, C 1-6-alkoxyl group, 2-methoxy ethyl, 2-hydroxyethyl, 1-methylimidazolyl alkylsulfonyl, C 1-6-acyl group, cyclohexyl methyl, cyclopropane carbonyl, aryl, optional halogenated aryl sulfonyl, furyl carbonyl, tetrahydrochysene-2-furyl methyl, N-ethoxycarbonyl piperidyl or the C that is replaced by one or more aryl, heterocycle or heteroaryl 1-6-alkyl; Or
NR 3R 4Common expression heterocycle is, they are imidazoles, piperidines, tetramethyleneimine, piperazine, morpholine, oxygen azatropylidene, oxazole, thiomorpholine, 1,1-dioxy thiomorpholine, 2-(3,4-dihydro-2 (1H) isoquinolyl) or (1S, 4S)-and 2-oxa--5-azabicyclo [2.2.1] heptan-5-base, these heterocycles systems are optional by C 1-6-alkyl, C 1-6-acyl group, hydroxyl, oxygen, tert-butoxycarbonyl replace;
OCONR 3R 4, R wherein 3And R 4Be selected from hydrogen, C independently of one another 1-6-alkyl or form morpholinyl with the N-atom that they connected;
R 5O, wherein R 5Be hydrogen, optional halogenated C 1-6-alkyl, aryl, heteroaryl, C 1-6-acyl group, C 1-6-alkyl sulphonyl, aryl carbonyl, heteroaryl carbonyl, 2-methoxycarbonyl phenyl.
12. the described method of claim 11, wherein
T is selected from:
5-chloro-1,3-dimethyl-1H-pyrazoles-4-base; 4-chloro-2,3,1-Ben Bing oxadiazole base; 5-(dimethylamino)-1-naphthyl; 1-Methylimidazole-4-base; The 1-naphthyl; The 2-naphthyl; The 8-quinolyl;
By the thienyl of the one or more replacements in the following groups: (benzamido) methyl, bromine, chlorine, 3-isoxazolyl, 2-(methyl sulfane base)-4-pyrimidyl, 1-methyl-5-(trifluoromethyl) pyrazole-3-yl, phenyl sulfonyl, pyridyl;
By the phenyl of the one or more replacements in the following groups: kharophen, the 3-acetylamino phenyl, the 3-acetylphenyl, phenylamino, 1,3-benzo dioxole-5-base, the 2-benzofuryl, benzyl amino, 3, two (trifluoromethyl) phenyl of 5-, bromine, butoxy, carboxyl, chlorine, the 4-carboxyl phenyl, 3-chloro-2-cyano-benzene oxygen, the 4-chloro-phenyl-, 5-chloro-2-thienyl, cyano group, 3, the 4-dichlorophenyl, ({ [4-(2-oxyethyl group-2-oxoethyl)-1,3-thiazoles-2-yl] amino } carbonyl), fluorine, 5-fluoro-2-p-methoxy-phenyl, the 2-furyl, hydrogen, iodine, sec.-propyl, methylsulfonyl, methoxyl group, methyl, 4-methyl isophthalic acid-piperazinyl, 4-methyl isophthalic acid-piperidyl, 4-methyl sulfane base phenyl, 5-methyl-2-thienyl, the 4-morpholinyl, nitro, the 3-nitrophenyl, phenoxy group, phenyl, n-propyl, the 4-pyridyl, 3-pyridyl methylamino-, the 1-pyrrolidyl, the 2-thienyl, the 3-thienyl, 2-thienyl methylamino-, trifluoromethoxy, the 4-Trifluoromethoxyphen-l, trifluoromethyl; Or
R 1Be hydrogen or methyl;
A 1And A 2Be nitrogen-atoms or C-Z, condition is A 1And A 2Have different implications, wherein:
Z is selected from:
1-thionaphthene-3-base, 3-(2,5-dimethyl furan base), pyridyl;
The optional thienyl that is replaced by one or more chlorine, methyl sulphonyl;
Optional by the phenyl of the one or more replacements in ethoxy carbonyl, nitro, fluorine, methyl, methoxyl group, kharophen, chlorine, 4-chlorophenoxy, the trifluoromethyl;
Or Z is X-Y-R 2, wherein
X is CH 2Or CO;
Y is CH 2, CO or singly-bound;
R 2Be selected from:
N-propyl, azido-, bromine, chlorine, 2-pyridyl sulfane base, 3-oxo-4-morpholinyl methylene radical, ethoxy carbonyl, 5-methyl isophthalic acid, 3,4-oxadiazole-2-base, methylol, 2-hydroxyethylamino methyl, mesyloxy methyl;
NR 3R 4, R wherein 3And R 4Be selected from ethanoyl, diphenyl-methyl, 1 independently of one another, 3-benzo dioxole-5-ylmethyl, benzyl, 3-chloro-2-aminomethyl phenyl alkylsulfonyl, cyclohexyl, cyclohexyl methyl, cyclopropane carbonyl, ethyl, 2-furyl carbonyl, 2-furyl methyl, hydrogen, 2-hydroxyethyl, 2-(1H-indol-3-yl) ethyl, sec.-propyl, methoxyl group, 2-methoxy ethyl, methyl, 4-(1-methylimidazolyl) alkylsulfonyl, methyl sulphonyl, phenyl, (1S)-styroyl, n-propyl, tetrahydrochysene-2-furyl methyl, trifluoromethyl sulfonyl, N-ethoxycarbonyl piperidyl; Or
NR 3R 4Common expression 4-ethanoyl piperazinyl, 4-tert-butoxycarbonyl piperazinyl, 2-(3,4-dihydro-2 (1H) isoquinolyl), (2R, 6S)-2, the 6-dimethylated morpholinyl, (2R)-2,4-dimethyl-1-piperazinyl, 2-hydroxyl-3-oxo morpholinyl, imidazolyl, 2-methyl-3-oxo morpholinyl, 4-methyl-2-oxo piperazinyl, 4-methylpiperazine base, morpholinyl, (1S, 4S)-2-oxa--5-aza-bicyclo [2.2.1] heptan-5-base, 2-oxoimidazolinium base, 3-oxo morpholinyl, 3-oxo-1,4-oxygen azatropylidene base, 2-Yang oxazolines base, piperazinyl, piperidyl, pyrrolidyl, pyrrolidone-base, thio-morpholinyl, 1,1-dioxy-thio-morpholinyl;
OCONR 3R 4, R wherein 3And R 4Be selected from ethyl, hydrogen independently of one another or form morpholinyl with the N-atom that they connected;
R 5O, wherein R 5Be ethanoyl, benzoyl, benzyl, ethyl, 2-fluoro ethyl, 2-furyl carbonyl, hydrogen, isobutyryl, sec.-propyl, methyl, 2-methoxycarbonyl benzyl, methyl sulphonyl, phenyl, positive propionyl, 3-pyridyl, 2,2, the 2-trifluoroethyl.
13. the described method of claim 11-12, wherein said compound are selected from compound and following compounds described in claim 3:
3-chloro-N-{5-[2-(diethylin) ethyl]-1,3,4-thiadiazoles-2-yl }-the 2-methyl benzenesulfonamide
N-(5-phenyl-1,3,4-thiadiazoles-2-yl)-4-propylbenzene sulphonamide
3-chloro-2-methyl-N-(5-phenyl-1,3,4-thiadiazoles-2-yl) benzsulfamide
3-chloro-N-[5-(4-fluoro-3-aminomethyl phenyl)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
2,4,6-three chloro-N-(5-phenyl-1,3,4-thiadiazoles-2-yl) benzsulfamide
N-(5-phenyl-1,3,4-thiadiazoles-2-yl)-1,1 '-xenyl-4-sulphonamide
2,4-two chloro-6-methyl-N-(5-phenyl-1,3,4-thiadiazoles-2-yl) benzsulfamide
N-[4-(5-{[(4-propyl group phenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
N-[5-(2-chloro-5-nitrophenyl)-1,3,4-thiadiazoles-2-yl]-4-propylbenzene sulphonamide
N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl]-4-propylbenzene sulphonamide
3-chloro-N-[5-(2-chloro-5-nitrophenyl)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
3-chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
N-[4-(5-{[(2,4,6-trichlorophenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
2,4,6-three chloro-N-[5-(2-chloro-5-nitrophenyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
2,4,6-three chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-(4-{[5-[(1,1 '-xenyl-4-base alkylsulfonyl) amino]-1,3,4-thiadiazoles-2-yl } phenyl) ethanamide
N-[5-(2-chloro-5-nitrophenyl)-1,3,4-thiadiazoles-2-yl]-1,1 '-xenyl-4-sulphonamide
N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl]-1,1 '-xenyl-4-sulphonamide
N-[4-(5-{[(2,4-two chloro-6-aminomethyl phenyls) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
2,4-two chloro-N-[5-(2-chloro-5-nitrophenyl)-1,3,4-thiadiazoles-2-yl]-the 6-methyl benzenesulfonamide
2,4-two chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl]-the 6-methyl benzenesulfonamide
2,3,4-three chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-[4-(5-{[(4-bromo-2,5-difluorophenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
4,5-two chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl] thiophene-2-sulphonamide
N-[4-(5-{[(2,4,5-trichlorophenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
3-bromo-5-chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl] thiophene-2-sulphonamide
N-[4-(5-{[(2,6-dichlorophenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
2,3,4-three chloro-N-{5-[2,6-two chloro-4-(trifluoromethyl) phenyl]-1,3,4-thiadiazoles-2-yl } benzsulfamide
N-[5-(2-chloro-6-fluorophenyl)-1,3,4-thiadiazoles-2-yl]-4-propylbenzene sulphonamide
4-bromo-N-{5-[2,6-two chloro-4-(trifluoromethyl) phenyl]-1,3,4-thiadiazoles-2-yl }-2,5-difluoro benzsulfamide
4,5-two chloro-N-[5-(2-chloro-6-fluorophenyl)-1,3,4-thiadiazoles-2-yl] thiophene-2-sulphonamide
4-bromo-5-chloro-N-{5-[2,6-two chloro-4-(trifluoromethyl) phenyl]-1,3,4-thiadiazoles-2-yl } thiophene-2-sulphonamide
2,4-two chloro-N-[5-(2-chloro-6-fluorophenyl)-1,3,4-thiadiazoles-2-yl]-the 6-methyl benzenesulfonamide
4-bromo-N-[5-(2-chloro-6-fluorophenyl)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
N-[4-(5-{[(4-bromo-5-chlorothiophene-2-yl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide.
14. the described method of claim 11-13, wherein said experimenter is the people.
15.11-the treatment of diseases method of beta-hydroxysteroid dehydrogenase 1 type enzyme mediation, this method comprises the step of general formula (I) compound or its salt, hydrate or the solvate of the experimenter's significant quantity that needs, and the structural formula of its formula of (I) compound is as follows:
Figure A028202800035C1
Wherein
T is optional independently by [R] nThe aromatic ring or the hetero-aromatic ring that replace, wherein n is that integer and the R of 0-5 are hydrogen, aryl, heteroaryl, heterocycle, optional halogenated C 1-6-alkyl, optional halogenated C 1-6-alkoxyl group, C 1-6-alkyl sulphonyl, carboxyl, cyano group, nitro, halogen, optional single replacement or dibasic amine, optional single replacement or disubstituded amide, aryloxy, aryl sulfonyl, fragrant amino, wherein aryl, heteroaryl and aryloxy residue and heterocycle are further optional independently of one another by C on one or more positions 1-6-acyl group, C 1-6-alkylthio, cyano group, nitro, hydrogen, halogen, optional halogenated C 1-6-alkyl, optional halogenated C 1-6-alkoxyl group, optional single replacement or disubstituded amide, (benzamido) methyl, carboxyl, 2-thienyl methylamino-or ({ [4-(2-oxyethyl group-2-oxoethyl)-1,3-thiazoles-2-yl] amino } carbonyl) replacement;
R 1Be hydrogen or C 1-6-alkyl;
A 1And A 2Be nitrogen-atoms or C-Z, condition is A 1And A 2Have different implications, wherein:
Z is selected from further optional independently of one another by hydrogen, C on one or more positions 1-6-alkyl, halo C 1-6-alkyl, halogen, C 1-6-alkoxyl group, nitro, C 1-6-alkoxy carbonyl, C 1-6Aromatic ring or hetero-aromatic ring that-alkyl sulphonyl, kharophen or aryloxy replace, wherein aryloxy is further optional on one or more positions is replaced by hydrogen and halogen independently of one another; Or Z is X-Y-R 2, wherein:
X is CH 2Or CO;
Y is CH 2, CO or singly-bound;
R 2Be selected from:
C 1-6-alkyl, azido-, arylthio, heteroarylthio, halogen, methylol, 2-hydroxyethylamino methyl, mesyloxy methyl, 3-oxo-4-morpholinyl methylene radical, C 1-6-alkoxy carbonyl, 5-methyl isophthalic acid, 3,4-oxadiazole-2-base;
NR 3R 4, R wherein 3And R 4Be selected from hydrogen, C independently of one another 1-6-alkyl, optional halogenated C 1-6-alkyl sulphonyl, C 1-6-alkoxyl group, 2-methoxy ethyl, 2-hydroxyethyl, 1-methylimidazolyl alkylsulfonyl, C 1-6-acyl group, cyclohexyl methyl, cyclopropane carbonyl, aryl, optional halogenated aryl sulfonyl, furyl carbonyl, tetrahydrochysene-2-furyl methyl, N-ethoxycarbonyl piperidyl or the C that is replaced by one or more aryl, heterocycle or heteroaryl 1-6-alkyl; Or
NR 3R 4Common expression heterocycle is, they are imidazoles, piperidines, tetramethyleneimine, piperazine, morpholine, oxygen azatropylidene, oxazole, thiomorpholine, 1,1-dioxy thiomorpholine, 2-(3,4-dihydro-2 (1H) isoquinolyl) or (1S, 4S)-and 2-oxa--5-azabicyclo [2.2.1] heptan-5-base, these heterocycles systems are optional by C 1-6-alkyl, C 1-6-acyl group, hydroxyl, oxygen, tert-butoxycarbonyl replace;
OCONR 3R 4, R wherein 3And R 4Be selected from hydrogen, C independently of one another 1-6-alkyl or form morpholinyl with the N-atom that they connected;
R 5O, wherein R 5Be hydrogen, optional halogenated C 1-6-alkyl, aryl, heteroaryl, C 1-6-acyl group, C 1-6-alkyl sulphonyl, aryl carbonyl, heteroaryl carbonyl, 2-methoxycarbonyl phenyl.
16. the described method of claim 15, wherein said disease is selected from diabetes, X syndrome, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertension, osteoporosis, dementia, dysthymia disorders, virus disease, inflammation illness and immunomodulatory, wherein can not cause hypoglycemia to hyperglycemic treatment.
17. the described method of claim 15-16, wherein immunomodulatory is selected from tuberculosis, leprosy and psoriasis.
18. the described method of claim 15-17, wherein
T is selected from:
5-chloro-1,3-dimethyl-1H-pyrazoles-4-base; 4-chloro-2,3,1-Ben Bing oxadiazole base; 5-(dimethylamino)-1-naphthyl; 1-Methylimidazole-4-base; The 1-naphthyl; The 2-naphthyl; The 8-quinolyl;
By the thienyl of the one or more replacements in the following groups: (benzamido) methyl, bromine, chlorine, 3-isoxazolyl, 2-(methyl sulfane base)-4-pyrimidyl, 1-methyl-5-(trifluoromethyl) pyrazole-3-yl, phenyl sulfonyl, pyridyl;
By the phenyl of the one or more replacements in the following groups: kharophen, the 3-acetylamino phenyl, the 3-acetylphenyl, phenylamino, 1,3-benzo dioxole-5-base, the 2-benzofuryl, benzyl amino, 3, two (trifluoromethyl) phenyl of 5-, bromine, butoxy, carboxyl, chlorine, the 4-carboxyl phenyl, 3-chloro-2-cyano-benzene oxygen, the 4-chloro-phenyl-, 5-chloro-2-thienyl, cyano group, 3, the 4-dichlorophenyl, ({ [4-(2-oxyethyl group-2-oxoethyl)-1,3-thiazoles-2-yl] amino } carbonyl), fluorine, 5-fluoro-2-p-methoxy-phenyl, the 2-furyl, hydrogen, iodine, sec.-propyl, methylsulfonyl, methoxyl group, methyl, 4-methyl isophthalic acid-piperazinyl, 4-methyl isophthalic acid-piperidyl, 4-methyl sulfane base phenyl, 5-methyl-2-thienyl, the 4-morpholinyl, nitro, the 3-nitrophenyl, phenoxy group, phenyl, n-propyl, the 4-pyridyl, 3-pyridyl methylamino-, the 1-pyrrolidyl, the 2-thienyl, the 3-thienyl, 2-thienyl methylamino-, trifluoromethoxy, the 4-Trifluoromethoxyphen-l, trifluoromethyl; Or
R 1Be hydrogen or methyl;
A 1And A 2Be nitrogen-atoms or C-Z, condition is A 1And A 2Have different implications, wherein:
Z is selected from:
1-thionaphthene-3-base, 3-(2,5-dimethyl furan base), pyridyl;
The optional thienyl that is replaced by one or more chlorine, methyl sulphonyl;
Optional by the phenyl of the one or more replacements in ethoxy carbonyl, nitro, fluorine, methyl, methoxyl group, kharophen, chlorine, 4-chlorophenoxy, the trifluoromethyl;
Or Z is X-Y-R 2, wherein
X is CH 2Or CO;
Y is CH 2, CO or singly-bound;
R 2Be selected from:
N-propyl, azido-, bromine, chlorine, 2-pyridyl sulfane base, 3-oxo-4-morpholinyl methylene radical, ethoxy carbonyl, 5-methyl isophthalic acid, 3,4-oxadiazole-2-base, methylol, 2-hydroxyethylamino methyl, mesyloxy methyl;
NR 3R 4, R wherein 3And R 4Be selected from ethanoyl, diphenyl-methyl, 1 independently of one another, 3-benzo dioxole-5-ylmethyl, benzyl, 3-chloro-2-aminomethyl phenyl alkylsulfonyl, cyclohexyl, cyclohexyl methyl, cyclopropane carbonyl, ethyl, 2-furyl carbonyl, 2-furyl methyl, hydrogen, 2-hydroxyethyl, 2-(1H-indol-3-yl) ethyl, sec.-propyl, methoxyl group, 2-methoxy ethyl, methyl, 4-(1-methylimidazolyl) alkylsulfonyl, methyl sulphonyl, phenyl, (1S)-styroyl, n-propyl, tetrahydrochysene-2-furyl methyl, trifluoromethyl sulfonyl, N-ethoxycarbonyl piperidyl; Or
NR 3R 4Common expression 4-ethanoyl piperazinyl, 4-tert-butoxycarbonyl piperazinyl, 2-(3,4-dihydro-2 (1H) isoquinolyl), (2R, 6S)-2, the 6-dimethylated morpholinyl, (2R)-2,4-dimethyl-1-piperazinyl, 2-hydroxyl-3-oxo morpholinyl, imidazolyl, 2-methyl-3-oxo morpholinyl, 4-methyl-2-oxo piperazinyl, 4-methylpiperazine base, morpholinyl, (1S, 4S)-2-oxa--5-aza-bicyclo [2.2.1] heptan-5-base, 2-oxoimidazolinium base, 3-oxo morpholinyl, 3-oxo-1,4-oxygen azatropylidene base, 2-Yang oxazolines base, piperazinyl, piperidyl, pyrrolidyl, pyrrolidone-base, thio-morpholinyl, 1,1-dioxy-thio-morpholinyl;
OCONR 3R 4, R wherein 3And R 4Be selected from ethyl, hydrogen independently of one another or form morpholinyl with the N-atom that they connected;
R 5O, wherein R 5Be ethanoyl, benzoyl, benzyl, ethyl, 2-fluoro ethyl, 2-furyl carbonyl, hydrogen, isobutyryl, sec.-propyl, methyl, 2-methoxycarbonyl benzyl, methyl sulphonyl, phenyl, positive propionyl, 3-pyridyl, 2,2, the 2-trifluoroethyl.
19. the described method of claim 15-18, wherein said compound are selected from compound and following compounds described in claim 3:
3-chloro-N-{5-[2-(diethylin) ethyl]-1,3,4-thiadiazoles-2-yl }-the 2-methyl benzenesulfonamide
N-(5-phenyl-1,3,4-thiadiazoles-2-yl)-4-propylbenzene sulphonamide
3-chloro-2-methyl-N-(5-phenyl-1,3,4-thiadiazoles-2-yl) benzsulfamide
3-chloro-N-[5-(4-fluoro-3-aminomethyl phenyl)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
2,4,6-three chloro-N-(5-phenyl-1,3,4-thiadiazoles-2-yl) benzsulfamide
N-(5-phenyl-1,3,4-thiadiazoles-2-yl)-1,1 '-xenyl-4-sulphonamide
2,4-two chloro-6-methyl-N-(5-phenyl-1,3,4-thiadiazoles-2-yl) benzsulfamide
N-[4-(5-{[(4-propyl group phenyl) alkylsulfonyl] amino 1-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
N-[5-(2-chloro-5-nitrophenyl)-1,3,4-thiadiazoles-2-yl]-4-propylbenzene sulphonamide
N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl]-4-propylbenzene sulphonamide
3-chloro-N-[5-(2-chloro-5-nitrophenyl)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
3-chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
N-[4-(5-{[(2,4,6-trichlorophenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
2,4,6-three chloro-N-[5-(2-chloro-5-nitrophenyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
2,4,6-three chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-(4-{5-[(1,1 '-xenyl-4-base alkylsulfonyl) amino]-1,3,4-thiadiazoles-2-yl } phenyl) ethanamide
N-[5-(2-chloro-5-nitrophenyl)-1,3,4-thiadiazoles-2-yl]-1,1 '-xenyl-4-sulphonamide
N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl]-1,1 '-xenyl-4-sulphonamide
N-[4-(5-{[(2,4-two chloro-6-aminomethyl phenyls) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
2,4-two chloro-N-[5-(2-chloro-5-nitrophenyl)-1,3,4-thiadiazoles-2-yl]-the 6-methyl benzenesulfonamide
2,4-two chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl]-the 6-methyl benzenesulfonamide
2,3,4-three chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-[4-(5-{[(4-bromo-2,5-difluorophenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
4,5-two chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl] thiophene-2-sulphonamide
N-[4-(5-{[(2,4,5-trichlorophenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
3-bromo-5-chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl] thiophene-2-sulphonamide
N-[4-(5-{[(2,6-dichlorophenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
2,3,4-three chloro-N-{5-[2,6-two chloro-4-(trifluoromethyl) phenyl]-1,3,4-thiadiazoles-2-yl } benzsulfamide
N-[5-(2-chloro-6-fluorophenyl)-1,3,4-thiadiazoles-2-yl]-4-propylbenzene sulphonamide
4-bromo-N-{5-[2,6-two chloro-4-(trifluoromethyl) phenyl]-1,3,4-thiadiazoles-2-yl }-2,5-difluoro benzsulfamide
4,5-two chloro-N-[5-(2-chloro-6-fluorophenyl)-1,3,4-thiadiazoles-2-yl] thiophene-2-sulphonamide
4-bromo-5-chloro-N-{5-[2,6-two chloro-4-(trifluoromethyl) phenyl]-1,3,4-thiadiazoles-2-yl } thiophene-2-sulphonamide
2,4-two chloro-N-[5-(2-chloro-6-fluorophenyl)-1,3,4-thiadiazoles-2-yl]-the 6-methyl benzenesulfonamide
4-bromo-N-[5-(2-chloro-6-fluorophenyl)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
N-[4-(5-{[(4-bromo-5-chlorothiophene-2-yl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide.
20. the described method of claim 15-19, wherein said experimenter is the people.
21. general formula (I) compound or its salt, hydrate or solvate are used for preventing, control or treat diabetes, X syndrome, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertension, osteoporosis, dementia, dysthymia disorders, virus disease or inflammation illness in preparation and can cause hypoglycemia and realize the application of immunoregulatory medicine, the structural formula of its formula of (I) compound is as follows:
Figure A028202800040C1
Wherein
T is optional independently by [R] nThe aromatic ring or the hetero-aromatic ring that replace, wherein n is that integer and the R of 0-5 are hydrogen, aryl, heteroaryl, heterocycle, optional halogenated C 1-6-alkyl, optional halogenated C 1-6-alkoxyl group, C 1-6-alkyl sulphonyl, carboxyl, cyano group, nitro, halogen, optional single replacement or dibasic amine, optional single replacement or disubstituded amide, aryloxy, aryl sulfonyl, fragrant amino, wherein aryl, heteroaryl and aryloxy residue and heterocycle are further optional independently of one another by C on one or more positions 1-6-acyl group, C 1-6-alkylthio, cyano group, nitro, hydrogen, halogen, optional halogenated C 1-6-alkyl, optional halogenated C 1-6-alkoxyl group, optional single replacement or disubstituded amide, (benzamido) methyl, carboxyl, 2-thienyl methylamino-or ({ [4-(2-oxyethyl group-2-oxoethyl)-1,3-thiazoles-2-yl] amino } carbonyl) replacement;
R 1Be hydrogen or C 1-6-alkyl;
A 1And A 2Be nitrogen-atoms or C-Z, condition is A 1And A 2Have different implications, wherein:
Z is selected from further optional independently of one another by hydrogen, C on one or more positions 1-6-alkyl, halo C 1-6-alkyl, halogen, C 1-6-alkoxyl group, nitro, C 1-6-alkoxy carbonyl, C 1-6Aromatic ring or hetero-aromatic ring that-alkyl sulphonyl, kharophen or aryloxy replace, wherein aryloxy is further optional on one or more positions is replaced by hydrogen and halogen independently of one another; Or Z is X-Y-R 2, wherein:
X is CH 2Or CO;
Y is CH 2, CO or singly-bound;
R 2Be selected from:
C 1-6-alkyl, azido-, arylthio, heteroarylthio, halogen, methylol, 2-hydroxyethylamino methyl, mesyloxy methyl, 3-oxo-4-morpholinyl methylene radical, C 1-6-alkoxy carbonyl, 5-methyl isophthalic acid, 3,4-oxadiazole-2-base;
NR 3R 4, R wherein 3And R 4Be selected from hydrogen, C independently of one another 1-6-alkyl, optional halo C 1-6-alkyl sulphonyl, C 1-6-alkoxyl group, 2-methoxy ethyl, 2-hydroxyethyl, 1-methylimidazolyl alkylsulfonyl, C 1-6-acyl group, cyclohexyl methyl, cyclopropane carbonyl, aryl, optional halogenated aryl sulfonyl, furyl carbonyl, tetrahydrochysene-2-furyl methyl, N-ethoxycarbonyl piperidyl or the C that is replaced by one or more aryl, heterocycle or heteroaryl 1-6-alkyl; Or
NR 3R 4Common expression heterocycle is, they are imidazoles, piperidines, tetramethyleneimine, piperazine, morpholine, oxygen azatropylidene, oxazole, thiomorpholine, 1,1-dioxy thiomorpholine, 2-(3,4-dihydro-2 (1H) isoquinolyl) or (1S, 4S)-and 2-oxa--5-azabicyclo [2.2.1] heptan-5-base, these heterocycles systems are optional by C 1-6-alkyl, C 1-6-acyl group, hydroxyl, oxygen, tert-butoxycarbonyl replace;
OCONR 3R 4, R wherein 3And R 4Be selected from hydrogen, C independently of one another 1-6-alkyl or form morpholinyl with the N-atom that they connected;
R 5O, wherein R 5Be hydrogen, optional halogenated C 1-6-alkyl, aryl, heteroaryl, C 1-6-acyl group, C 1-6-alkyl sulphonyl, aryl carbonyl, heteroaryl carbonyl, 2-methoxycarbonyl phenyl.
22. the described application of claim 21, wherein immunomodulatory is selected from tuberculosis, leprosy and psoriasis.
23. the described application of claim 21-22, wherein
T is selected from:
5-chloro-1,3-dimethyl-1H-pyrazoles-4-base; 4-chloro-2,3,1-Ben Bing oxadiazole base; 5-(dimethylamino)-1-naphthyl; 1-Methylimidazole-4-base; The 1-naphthyl; The 2-naphthyl; The 8-quinolyl;
By the thienyl of the one or more replacements in the following groups: (benzamido) methyl, bromine, chlorine, 3-isoxazolyl, 2-(methyl sulfane base)-4-pyrimidyl, 1-methyl-5-(trifluoromethyl) pyrazole-3-yl, phenyl sulfonyl, pyridyl;
By the phenyl of the one or more replacements in the following groups: kharophen, the 3-acetylamino phenyl, the 3-acetylphenyl, phenylamino, 1,3-benzo dioxole-5-base, the 2-benzofuryl, benzyl amino, 3, two (trifluoromethyl) phenyl of 5-, bromine, butoxy, carboxyl, chlorine, the 4-carboxyl phenyl, 3-chloro-2-cyano-benzene oxygen, the 4-chloro-phenyl-, 5-chloro-2-thienyl, cyano group, 3, the 4-dichlorophenyl, ({ [4-(2-oxyethyl group-2-oxoethyl)-1,3-thiazoles-2-yl] amino } carbonyl), fluorine, 5-fluoro-2-p-methoxy-phenyl, the 2-furyl, hydrogen, iodine, sec.-propyl, methylsulfonyl, methoxyl group, methyl, 4-methyl isophthalic acid-piperazinyl, 4-methyl isophthalic acid-piperidyl, 4-methyl sulfane base phenyl, 5-methyl-2-thienyl, the 4-morpholinyl, nitro, the 3-nitrophenyl, phenoxy group, phenyl, n-propyl, the 4-pyridyl, 3-pyridyl methylamino-, the 1-pyrrolidyl, the 2-thienyl, the 3-thienyl, 2-thienyl methylamino-, trifluoromethoxy, the 4-Trifluoromethoxyphen-l, trifluoromethyl; Or
R 1Be hydrogen or methyl;
A 1And A 2Be nitrogen-atoms or C-Z, condition is A 1And A 2Have different implications, wherein:
Z is selected from: 1-thionaphthene-3-base, 3-(2,5-dimethyl furan base), pyridyl;
The optional thienyl that is replaced by one or more chlorine, methyl sulphonyl;
Optional by the phenyl of the one or more replacements in ethoxy carbonyl, nitro, fluorine, methyl, methoxyl group, kharophen, chlorine, 4-chlorophenoxy, the trifluoromethyl;
Or Z is X-Y-R 2, wherein
X is CH 2Or CO;
Y is CH 2, CO or singly-bound;
R 2Be selected from:
N-propyl, azido-, bromine, chlorine, 2-pyridyl sulfane base, 3-oxo-4-morpholinyl methylene radical, ethoxy carbonyl, 5-methyl isophthalic acid, 3,4-oxadiazole-2-base, methylol, 2-hydroxyethylamino methyl, mesyloxy methyl;
NR 3R 4, R wherein 3And R 4Be selected from ethanoyl, diphenyl-methyl, 1 independently of one another, 3-benzo dioxole-5-ylmethyl, benzyl, 3-chloro-2-aminomethyl phenyl alkylsulfonyl, cyclohexyl, cyclohexyl methyl, cyclopropane carbonyl, ethyl, 2-furyl carbonyl, 2-furyl methyl, hydrogen, 2-hydroxyethyl, 2-(1H-indol-3-yl) ethyl, sec.-propyl, methoxyl group, 2-methoxy ethyl, methyl, 4-(1-methylimidazolyl) alkylsulfonyl, methyl sulphonyl, phenyl, (1S)-styroyl, n-propyl, tetrahydrochysene-2-furyl methyl, trifluoromethyl sulfonyl, N-ethoxycarbonyl piperidyl; Or
NR 3R 4Common expression 4-ethanoyl piperazinyl, 4-tert-butoxycarbonyl piperazinyl, 2-(3,4-dihydro-2 (1H) isoquinolyl), (2R, 6S)-2, the 6-dimethylated morpholinyl, (2R)-2,4-dimethyl-1-piperazinyl, 2-hydroxyl-3-oxo morpholinyl, imidazolyl, 2-methyl-3-oxo morpholinyl, 4-methyl-2-oxo piperazinyl, 4-methylpiperazine base, morpholinyl, (1S, 4S)-2-oxa--5-aza-bicyclo [2.2.1] heptan-5-base, 2-oxoimidazolinium base, 3-oxo morpholinyl, 3-oxo-1,4-oxygen azatropylidene base, 2-Yang oxazolines base, piperazinyl, piperidyl, pyrrolidyl, pyrrolidone-base, thio-morpholinyl, 1,1-dioxy-thio-morpholinyl;
OCONR 3R 4, R wherein 3And R 4Be selected from ethyl, hydrogen independently of one another or form morpholinyl with the N-atom that they connected;
R 5O, wherein R 5Be ethanoyl, benzoyl, benzyl, ethyl, 2-fluoro ethyl, 2-furyl carbonyl, hydrogen, isobutyryl, sec.-propyl, methyl, 2-methoxycarbonyl benzyl, methyl sulphonyl, phenyl, positive propionyl, 3-pyridyl, 2,2, the 2-trifluoroethyl.
24. the described application of claim 21-23, wherein said compound are selected from compound and following compounds described in claim 3:
3-chloro-N-{5-[2-(diethylin) ethyl]-1,3,4-thiadiazoles-2-yl }-the 2-methyl benzenesulfonamide
N-(5-phenyl-1,3,4-thiadiazoles-2-yl)-4-propylbenzene sulphonamide
3-chloro-2-methyl-N-(5-phenyl-1,3,4-thiadiazoles-2-yl) benzsulfamide
3-chloro-N-[5-(4-fluoro-3-aminomethyl phenyl)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
2,4,6-three chloro-N-(5-phenyl-1,3,4-thiadiazoles-2-yl) benzsulfamide
N-(5-phenyl-1,3,4-thiadiazoles-2-yl)-1,1 '-xenyl-4-sulphonamide
2,4-two chloro-6-methyl-N-(5-phenyl-1,3,4-thiadiazoles-2-yl) benzsulfamide
N-[4-(5-{[(4-propyl group phenyl) alkylsulfonyl] amino 1-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
N-[5-(2-chloro-5-nitrophenyl)-1,3,4-thiadiazoles-2-yl]-4-propylbenzene sulphonamide
N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl]-4-propylbenzene sulphonamide
3-chloro-N-[5-(2-chloro-5-nitrophenyl)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
3-chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
N-[4-(5-{[(2,4,6-trichlorophenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
2,4,6-three chloro-N-[5-(2-chloro-5-nitrophenyl)-1,3,4-thiadiazoles-2-yl] benzsulfamide
2,4,6-three chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-(4-{5-[(1,1 '-xenyl-4-base alkylsulfonyl) amino]-1,3,4-thiadiazoles-2-yl } phenyl) ethanamide
N-[5-(2-chloro-5-nitrophenyl)-1,3,4-thiadiazoles-2-yl]-1,1 '-xenyl-4-sulphonamide
N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl]-1,1 '-xenyl-4-sulphonamide
N-[4-(5-{[(2,4-two chloro-6-aminomethyl phenyls) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
2,4-two chloro-N-[5-(2-chloro-5-nitrophenyl)-1,3,4-thiadiazoles-2-yl]-the 6-methyl benzenesulfonamide
2,4-two chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl]-the 6-methyl benzenesulfonamide
2,3,4-three chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl] benzsulfamide
N-[4-(5-{[(4-bromo-2,5-difluorophenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
4,5-two chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl] thiophene-2-sulphonamide
N-[4-(5-{[(2,4,5-trichlorophenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
3-bromo-5-chloro-N-[5-(2-chloro-phenyl-)-1,3,4-thiadiazoles-2-yl] thiophene-2-sulphonamide
N-[4-(5-{[(2,6-dichlorophenyl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide
2,3,4-three chloro-N-{5-[2,6-two chloro-4-(trifluoromethyl) phenyl]-1,3,4-thiadiazoles-2-yl } benzsulfamide
N-[5-(2-chloro-6-fluorophenyl)-1,3,4-thiadiazoles-2-yl]-4-propylbenzene sulphonamide
4-bromo-N-{5-[2,6-two chloro-4-(trifluoromethyl) phenyl]-1,3,4-thiadiazoles-2-yl }-2,5-difluoro benzsulfamide
4,5-two chloro-N-[5-(2-chloro-6-fluorophenyl)-1,3,4-thiadiazoles-2-yl] thiophene-2-sulphonamide
4-bromo-5-chloro-N-{5-[2,6-two chloro-4-(trifluoromethyl) phenyl]-1,3,4-thiadiazoles-2-yl } thiophene-2-sulphonamide
2,4-chloro-N-[5-(2-chloro-6-fluorophenyl)-1,3,4-thiadiazoles-2-yl]-the 6-methyl benzenesulfonamide
4-bromo-N-[5-(2-chloro-6-fluorophenyl)-1,3,4-thiadiazoles-2-yl]-the 2-methyl benzenesulfonamide
N-[4-(5-{[(4-bromo-5-chlorothiophene-2-yl) alkylsulfonyl] amino }-1,3,4-thiadiazoles-2-yl) phenyl] ethanamide.
25. pharmaceutical composition comprises the compound and the pharmaceutically acceptable carrier of any defined general formula (I) among at least a claim 1-3.
CNA028202805A 2001-11-22 2002-11-22 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 Pending CN1649855A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
SE0103913 2001-11-22
SE01039130 2001-11-22
SE0104051 2001-11-30
SE01040518 2001-11-30
US34846802P 2002-01-14 2002-01-14
US60/348,468 2002-01-14

Publications (1)

Publication Number Publication Date
CN1649855A true CN1649855A (en) 2005-08-03

Family

ID=27354771

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028202805A Pending CN1649855A (en) 2001-11-22 2002-11-22 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1

Country Status (12)

Country Link
EP (1) EP1461327A1 (en)
JP (1) JP2005509676A (en)
KR (1) KR20050044578A (en)
CN (1) CN1649855A (en)
AU (1) AU2002353717B2 (en)
BR (1) BR0214342A (en)
CA (1) CA2466491A1 (en)
IL (1) IL160630A0 (en)
MX (1) MXPA04004842A (en)
NO (1) NO20042161L (en)
PL (1) PL370447A1 (en)
WO (1) WO2003044000A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103119034A (en) * 2010-04-16 2013-05-22 拜耳知识产权有限责任公司 Novel heterocyclic compounds as pest control agents

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200400708A1 (en) 2001-11-22 2004-10-28 Биовитрум Аб INHIBITORS 11-BETA-HYDROXYSTEROID DEGYDROGENASE TYPE 1
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Triazole Derivatives As Inhibitors Of 11-Beta -Hydroxysteriod Dehydrogenase-1
US7173030B2 (en) 2003-05-21 2007-02-06 Biovitrum Ab Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
EP1631558A1 (en) * 2003-05-21 2006-03-08 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i
WO2004113310A1 (en) * 2003-06-25 2004-12-29 Biovitrum Ab Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing
WO2005027882A1 (en) 2003-09-22 2005-03-31 Bionetworks Gmbh Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
CA2540843A1 (en) * 2003-10-23 2005-05-12 Sterix Limited Phenyl carboxamide and sulfonamide derivatives for use as 11-beta-hydroxysteroid dehydrogenase
GB0324792D0 (en) 2003-10-23 2003-11-26 Sterix Ltd Compound
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
GB0408771D0 (en) * 2004-04-20 2004-05-26 Sterix Ltd Compound
US8686011B2 (en) 2004-05-24 2014-04-01 Amgen Inc. Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
ATE417837T1 (en) 2004-05-24 2009-01-15 Amgen Inc INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1
MX2007003913A (en) * 2004-10-04 2007-05-21 Hoffmann La Roche Alkil-pyridines as 11-beta inhibitors for diabetes.
EP1659113A1 (en) * 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
EP1666467A1 (en) * 2004-11-08 2006-06-07 Evotec AG 11Beta-HSD1 Inhibitors
JP5140577B2 (en) 2005-03-31 2013-02-06 タケダ カリフォルニア インコーポレイテッド Hydroxysteroid dehydrogenase inhibitor
MX2007012212A (en) 2005-04-05 2007-12-07 Hoffmann La Roche Pyrazoles.
US8952176B2 (en) * 2005-06-07 2015-02-10 Shionogi & Co., Ltd. Heterocyclic compound having type I 11 β hydroxysteroid dehydrogenase inhibitory activity
US7622492B2 (en) 2005-08-31 2009-11-24 Hoffmann-La Roche Inc. Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase
AU2006304283B2 (en) * 2005-10-12 2012-01-19 Vertex Pharmaceuticals Incorporated Biphenyl derivatives as modulators of voltage gated ion channels
US8541592B2 (en) 2005-11-22 2013-09-24 Amgen Inc. Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1
AU2007207055B2 (en) 2006-01-18 2011-06-02 F. Hoffmann-La Roche Ag Thiazoles as 11 beta-HSD1 inhibitors
AR059355A1 (en) 2006-02-07 2008-03-26 Wyeth Corp 11-BETA HSD1 INHIBITORS
PE20110235A1 (en) 2006-05-04 2011-04-14 Boehringer Ingelheim Int PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE
MX2009001043A (en) 2006-08-08 2009-02-06 Sanofi Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use.
EP2054056A4 (en) * 2006-08-16 2010-08-25 J David Gladstone Inst A Testa Small molecule inhibitors of kynurenine-3-monooxygenase
EP2054397B1 (en) 2006-08-16 2015-10-07 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Small molecule inhibitors of kynurenine-3-monooxygenase
DE102007005045B4 (en) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazine derivatives, process for their preparation and their use as medicines
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
AR072707A1 (en) 2008-07-09 2010-09-15 Sanofi Aventis HETEROCICLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, DRUGS THAT UNDERSTAND THESE COMPOUNDS AND THE USE OF THEM
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8785608B2 (en) 2009-08-26 2014-07-22 Sanofi Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012120058A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683703B1 (en) 2011-03-08 2015-05-27 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683698B1 (en) 2011-03-08 2017-10-04 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120050A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TW201512171A (en) 2013-04-19 2015-04-01 Pfizer Ltd Chemical compounds
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
US11492346B2 (en) 2019-06-18 2022-11-08 Pfizer Inc. Benzisoxazole sulfonamide derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB822947A (en) * 1957-01-25 1959-11-04 Smith & Nephew Improvements in and relating to sulphonamides
GB839316A (en) * 1957-12-10 1960-06-29 Bayer Ag 5-arylsulphonamido-3-substituted 1,2,4-thiadiazole derivatives
GB858189A (en) * 1958-09-12 1961-01-11 Bayer Ag 5-arylsulphonamido-3-substituted-1,2,4-thiadiazole derivatives
US3332942A (en) * 1962-11-02 1967-07-25 White Lab Inc Substituted thiadiazoles
GB1053085A (en) * 1964-03-26
GB9512697D0 (en) * 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
BR9810991A (en) * 1997-07-11 2000-08-08 Smithkline Beecham Plc New compounds
IT1317735B1 (en) * 2000-01-26 2003-07-15 Nicox Sa SALTS OF ANTIMICROBIAL AGENTS.
SE0001899D0 (en) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103119034A (en) * 2010-04-16 2013-05-22 拜耳知识产权有限责任公司 Novel heterocyclic compounds as pest control agents
CN103119034B (en) * 2010-04-16 2016-08-03 拜耳知识产权有限责任公司 Heterocyclic compound as pest control agent

Also Published As

Publication number Publication date
BR0214342A (en) 2004-09-14
KR20050044578A (en) 2005-05-12
AU2002353717A1 (en) 2003-06-10
AU2002353717B2 (en) 2006-08-03
MXPA04004842A (en) 2004-08-02
PL370447A1 (en) 2005-05-30
IL160630A0 (en) 2004-07-25
EP1461327A1 (en) 2004-09-29
WO2003044000A1 (en) 2003-05-30
JP2005509676A (en) 2005-04-14
NO20042161L (en) 2004-08-17
CA2466491A1 (en) 2003-05-30

Similar Documents

Publication Publication Date Title
CN1649855A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
CN1633428A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
CN1564816A (en) 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
CN1249039C (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type I
CN1144791C (en) Triazole compounds and use thereof as dopamine-D3-ligands
CN1293076C (en) Activator for peroxisome proliferator-activated receptor delta
CN1267430C (en) Triazole compounds with dopamine -D3-receptor affinity
CN1063442C (en) Aminothiazole derivatives, drug containing the same and intermediate in the production of the compounds
CN1178936C (en) Sulfonyl-pyrrolidine derivatives useful for treatment of neurological disorders
CN1075070C (en) Substituted A2a-and diazacycloheptane and cyclooctane compounds and their use
CN1615300A (en) Benzimidazole derivatives and their use as GNRH antagonists
CN1753670A (en) Novel derivatives of benzimidazole and imidazo-pyridine and their use as medicaments
CN1608061A (en) Therapeutic isoquinoline compounds
CN1816549A (en) Inhibitors of phosphatidylinositol 3-kinase
CN1768058A (en) Imidazopyridine derivatives as melanocortin receptor agonists.
CN1043936A (en) Thiazolium compounds and preparation method thereof
CN1886397A (en) 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (gsk-3)
CN1353704A (en) Substituted pyrazole compounds
CN1516695A (en) Arylsulfonamides as antiviral agents
CN1152879C (en) Naphthyridine derivatives
CN1022185C (en) Process for preparing analgesic carboxylic acid amide derivatives
CN1639158A (en) Thiazole derivatives as NPY receptor antagonists
CN1167692C (en) Aminothiazole derivatives and their use as CRF receptor ligands
CN1809538A (en) Cis-2,4,5-triaryl-imidazolines
CN1129000A (en) New compound and its prepn.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1079523

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1079523

Country of ref document: HK